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Executive Summary 
Introduction 
Health Problem 
Prostate cancer (PCa) is the most common non-skin cancer in men in Europe 
[1]. In early stage, prostate cancer is localised and organ-confined [2]. Depend-
ing on the risk of progression, the cancerous lesion increases in volume and 
produces more PSA over time. Localised prostate cancer is often indolent, and 
has no impact on health; even without treatment. Locally relapsed/recurrent 
prostate cancer occurs when the cancer is still present or comes back after 
failed primary therapy [3] (A0002). Incidence rates reported by the Interna-
tional Agency for Research on Cancer (IARC) in 2014 varied between 35 and 
132 per 100,000 men in European countries [4] (A0023).  
The target population of this assessment is low-risk and intermediate-risk lo-
calised and locally recurrent/relapsed PCa patients without any regional lymph 
nodes (Nx-N0) and without any distant metastases (Mx-M0). Low-risk is de-
fined as prostate-specific antigen (PSA) <10 ng/mL, Gleason Score (GS) <7 
and cT1a-T2a. Intermediate-risk is defined as PSA 10-20 ng/mL, or GS 7 or 
cT2b [1] (A0007).  
Description of the Technology 
High-intensity focused ultrasound (HIFU) uses ultrasound (US) waves to 
cause tissue damage. The energy of the US waves are absorbed by the target 
tissue and converted to heat (exceeding 60 °C), causing coagulative necrosis. 
Inertial cavitation is caused by alternating cycles of compression and rarefac-
tion [1, 5].  
To administer HIFU, a probe is inserted into the rectum (or urethra) while 
the patient is anaesthetised. This probe enables real-time visualisation of pros-
tatic tissue and also delivers HIFU energy to destroy the desired target paren-
chyma [5].  
Two major systems of HIFU exist, based on the type of imaging guidance 
during the treatment.  
1. HIFU with TRUS imaging guidance is the traditional approach. TRUS-
guided HIFU is used to ablate the whole prostate gland or a relatively 
large region [6-9]. 
2. The novel approach is the HIFU system with MRI guidance. It is possi-
ble to localise the lesions within the prostate with MRI, hence the fo-
cal treatment (FT) of the prostate is also possible [6] (B0001). 
Based on the ablation strategy approach we differentiate whole gland ablation 
and FT. There is no consensus definition of FT, but for the time being any 
approach to preserve parts of the prostate tissue (hemiablation, hockey stick 
ablation, and targeted focal ablation) is considered FT [10] (B0001).  
The CE mark for the HIFU technology has been awarded for the primary 
treatment of patients with primary localised PCa or for salvage therapy of lo-
cally recurrent PCa following failed prior therapy [11] (B0002). 
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It is claimed that HIFU treatment has significantly lower side-effect profile 
(erectile and urinary dysfunction) [12], and reduces toxicity compared to oth-
er ablation techniques and adjacent blood vessels may be less vulnerable to 
damage compared with surgical risks [13] (B0002).  
The comparators  
Active surveillance (AS) and watchful waiting (WW) are deferred treatment 
strategies for men with localised PCa who are not candidates for definitive 
treatment. These conservative management strategies aim to reduce over-
treatment [1] (B0002). 
Radical prostatectomy (RP) is a definitive treatment strategy in which the 
prostate gland between the urethra and bladder is removed, along with the 
resection of both seminal vesicles and sufficient surrounding tissue to obtain 
negative margins. The goal of the procedure is to eradicate the disease, while 
preserving continence and if possible, potency [1] (B0001). 
Radiation therapy (RT) is another definitive treatment strategy in which a 
therapeutic dose of radiation is delivered to the tumour (either as external 
beam, brachytherapy or a combination of both) while minimizing the radia-
tion to normal tissue [14] (B0001).  
 
Methods 
We updated the LBI-HTA systematic review from 2010 [15], hence the sys-
tematic literature search was performed from January 2010 to December 2017 
in four databases (Cochrane Library, Centre for Research and Dissemination, 
Embase, Medline), complemented by handsearch in the reference list of rel-
evant studies. In addition, clinical trials databases were searched to identify 
ongoing studies on HIFU for prostate cancer treatment. 
Risk of bias on study level was assessed with the IHE-20-checklist [16] of the 
single-arm studies, and with ROBINS-I [17] that of the non-randomised con-
trolled study (non-RCT). The quality of the body of evidence was assessed 
using GRADE (Grading of Recommendations, Assessment, Development and 
Evaluation) [18].  
The inclusion criteria for assessing the clinical effectiveness of HIFU, was ex-
clusively restricted to studies with a comparison group (RCTs, non-RCTs). 
The inclusion criteria for assessing safety additionally considered prospective 
studies without a control group (single-arm studies, case series, and registry 
studies) with at least 50 patients. 
 
Results 
Available evidence 
Clinical effectiveness  
The systematic literature search identified one controlled study (matched-
pair analysis) that met our inclusion criteria. The study compared whole gland 
primary HIFU with brachytherapy, a type of radiotherapy for the treatment 
of localised PCa, including 70 patients in each treatment arm [19].  
We could not identify any controlled trials comparing either primary or sal-
vage HIFU with other treatments, (see comparators above). 
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Safety 
In the systematic literature search we identified four prospective single-arm 
studies [20-23] in addition to the one non-RCT [19] regarding primary HIFU 
and one prospective single-arm study regarding salvage HIFU [24], which met 
our inclusion criteria to assess safety. The single-arm primary HIFU studies 
applied hemiablation, the matched-pair analysis and the study on salvage 
HIFU applied whole gland ablation of the prostate.  
Clinical effectiveness 
Primary HIFU 
To assess the effect of HIFU on mortality, overall survival and PCa specific 
survival were considered. After five years, overall survival and PCa specific 
survival in the HIFU-group compared to brachytherapy was not significant-
ly different (88 vs. 97.5%, HR 0.24, CI 0.01-1.34 and 89% vs. 92%, HR 0.67, 
CI 0.32-1.29) [19]. 
To describe the effect of HIFU on the progression (or recurrence) of local-
ised and locally recurrent PCa biochemical recurrence-free survival (a surro-
gate outcome and not to be mistaken for “local disease recurrence”) was con-
sidered. This outcome was significantly lower for patients in the HIFU-group 
than for patients in the control group: 53.1 vs. 68.5% according to the Phoe-
nix and 51.3 vs. 60.9% according to the Stuttgart definitions (HR 0.41, CI 
0.19-0.81 for Phoenix, HR 0.39, CI 0.19-0.74 for Stuttgart, p<0.05 for both) 
[19]1. Additional outcomes that are suitable to describe the progression of PCa 
were not reported in the included study (the critical outcome local disease re-
currence, or others, like need for salvage/systemic therapy, ablation failure, 
distant disease recurrence/metastases or disease progression/pathological 
progression) [19]. 
Salvage HIFU 
No evidence was found to assess the effectiveness of salvage HIFU in com-
parison to any of the comparators.  
Safety 
Primary HIFU 
To assess the safety of HIFU intervention-specific mortality, functional out-
comes (urinary and sexual functions) and adverse events were considered.  
No intervention-related deaths occurred in any of the studies.  
Urinary dysfunction was reported in all studies. In the matched-pair analyses, 
urinary incontinence occurred in 7.2% of patients in the HIFU group and 
3.8% in the brachytherapy group (p=0.44). De novo urinary incontinence 
occurred in three single-arm studies: three patients in one study [23](6%) 
and two patients in each of the other two studies [21, 22] (2% resp. 3.9%) 
from pre-HIFU continent patients presented persistent incontinence at 12 
months follow-up. One study reported that none of the patients had inconti-
nence [20] at 12 months follow-up. Two single-arm studies [20, 21] found no 
significant change in urinary function based on the mean IPSS score from 
                                                             
1 Phoenix criteria: PSA nadir +2ng/mL; Stuttgart criteria: PSA nadir +1.2 ng/mL).  
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baseline to 3 resp. 12 months follow-up, and one study [22] reported a signif-
icant improvement in the IPSS score from baseline to 12 months follow-up 
(95% CI: 1.6; 4.4).  
Erectile dysfunction was reported as worsening in the IIEF score or as the 
number of de novo impotent patients. In the matched-pair analysis 5 pre-
HIFU potent patients (11.6%) became impotent (no comparison was possi-
ble as it was reported only for the HIFU-group). Two studies identified 20-
22% de novo erectile dysfunction in pre-intervention potent patients, where-
as one study [20] reported that nearly 48% of previously potent patients be-
came impotent post-intervention (none of the studies reported the time point 
when this was measured). Two single-arm studies [20, 21] showed a signifi-
cant negative impact on erectile function 3-12 months after HIFU assessed 
with the IIEF score (p<0.001). 
The most frequent adverse events in all studies were grade 1 and 2 events 
(urinary tract infection, storage and voiding LUTS). When comparing the se-
verity of adverse events in the matched-pair analysis, the rate of grade 3 com-
plications was higher in HIFU patients than in patients treated with brachy-
therapy (35% vs. 13%). Especially acute urinary retention and stricture oc-
curred more often in the HIFU-cohort than in the brachytherapy-cohort (more 
than 20% vs. less than 6% each), however, information on statistical signifi-
cance was not provided [19].Compared to the matched-pair analysis, which 
applied whole-gland ablation [19], the rate of storage and voiding LUTS [22, 
23] (grade 1), acute urinary retention [20, 22, 23] and stricture [21-23] (grade 3 
complications) was considerably lower in the single-arm studies, which ap-
plied hemiablation. Rectal fistula (grade 3 complication) occurred only in the 
matched-pair analysis [19]. Grade 4 complications have not occurred in any 
of the primary HIFU studies.  
Salvage HIFU 
The study on salvage HIFU [24] could not show a significant effect on the 
IPSS score 6 months post-intervention (p=0.06), but reported a significant 
negative effect on the sexual function based on the IIEF-5 scores 6 months 
post-intervention (p<0.001). Grade 3 complications were observed with a rate 
of 62%. Three grade 4 complications were also observed.  
Upcoming evidence 
A search for ongoing studies identified two RCTs and three non-RCTs of 
which one was terminated due to lack of inclusions, two had unknown sta-
tus, however according to the registry data completion date was planned for 
2008 and 2014, respectively. Results for both trials are still pending. One 
RCT is currently in the planning phase of recruitment, and one non-RCT is 
expected to be completed in November 2019. 
 
Discussion 
The overall quality of evidence on HIFU as primary treatment for clinically 
localised low-risk and intermediate-risk prostate cancer as well as on HIFU 
as salvage treatment for locally recurrent prostate cancer is very low. Studies 
are lacking sufficiently high patient numbers, comparators and sufficiently 
long periods (at least ten years) of follow-up. The small case numbers con-
siderably limit the generalizability of the findings. Furthermore, only two 
studies reported on outcomes with a follow-up of five years. All outcomes es-
timates on the efficacy of primary HIFU compared to brachytherapy are based 
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on only one comparative study, which consisted of two matched single-arm 
studies. The safety outcome estimates of primary HIFU are based on single-
arm studies in addition to the comparative study. Regarding salvage HIFU 
all outcomes estimates are based on one single-arm study. Direct prospective 
comparison between deferred treatment modalities (AS, WW) and RP or RT 
for salvage treatment is completely lacking. An additional limitation that hin-
ders the generalizability of the findings is that the matched-pair analysis ap-
plied whole gland ablation, whereas the single-arm studies applied hemiabla-
tion of the prostate. Whole gland ablation is associated with a worse side-
effect profile (more frequent toxicities, incontinence and erectile problems) 
compared to hemiablation [25, 26].  
Limitations of the present assessment are the lack of stratification to differ-
ent imaging guidance of HIFU, and additional interventions (TURP, ADT) 
as these information was often lacking. Moreover, we included the compara-
tive study [19], in which in the first period patients were treated with a pre-
vious version of device that is not commercially available anymore. It can be 
expected that the used device, the type of guidance and any concomitant treat-
ments will have a considerable effect on the effectiveness and safety of HIFU. 
Another limitation is the abstinence of indirect comparisons, which was not 
feasible within the timeframe of the rapid assessment.  
Evidence gaps  
To date there are no published RCTs comparing effectiveness and safety out-
comes of HIFU (either as whole gland or hemiablation) and any radical treat-
ment modalities or any deferred treatment modalities. MRI-guided HIFU 
ablation is such a new approach that the first pivotal studies have been com-
pleted just lately and their effectiveness and safety is currently being inves-
tigated.  
 
Conclusion 
The current evidence is not sufficient to prove that primary HIFU, as well as 
salvage HIFU is more effective and safe or as effective, but safer than the com-
parators AS, WW, RP or RT. Thus, the inclusion in the hospital benefit cat-
alogue is currently not recommended. 
There is a need for prospective RCTs with a higher number of patients and 
longer follow-up in order to be able to determine if HIFU is a suitable alter-
native to deferred treatment and/or radical therapies. 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Prostatakrebs ist eine der häufigsten Krebsarten bei Männern in Europa. Im 
Frühstadium ist der Krebs noch lokal begrenzt. Lokal begrenzter Prostata-
krebs ist meist indolent und hat keinen großen Einfluss auf die Gesundheit. 
Eine Behandlung ist hier nicht zwingend notwendig. In Abhängigkeit vom 
Risiko der Progression vergrößert sich der Tumor und mehr prostataspezifi-
schee Antigene (PSA) werden produziert; eine Behandlung kann hier notwen-
dig werden. Rezidivierender Prostatakrebs tritt auf, wenn der Krebs noch vor-
handen ist oder nach erfolgloser Primärtherapie wieder auftritt. Die Neuer-
krankungsrate von Prostatakrebs in europäischen Ländern liegt zwischen 35 
und 132 pro 100.000 Männer. 
Der vorliegende Bericht beschränkte sich auf Patienten mit lokal begrenztem 
Prostatakrebs und geringem oder mittlerem (intermediären) Risiko sowie auf 
Patienten mit rezidivierendem Prostatakrebs ohne Befall von Lymphknoten 
(Nx-NO) und ohne Metastasen (Mx-MO). Geringes Risiko ist definiert als: 
PSA <10 ng/ml, Gleason Score <7 und cT1a-T2a. Intermediäres Risiko ist 
definiert als: PSA von 10-20 ng/ml oder Gleason Score von 7 oder T2b. 
Beschreibung der Technologie 
Hochintensiver fokussierter Ultraschall (HIFU) macht sich die Nutzung von 
Ultraschallwellen zu Nutze, um Gewebe zu zerstören. Die Energie der Ultra-
schallwellen wird hierbei vom Gewebe absorbiert und in Hitze umgewandelt 
(mehr als 60°C), dabei entsteht eine sogenannte Koagulationsnekrose. Die Ul-
traschallwellen erzeugen immer im Wechsel eine Kompression (Überdruck) 
und eine Expansion (Unterdruck). 
Bei HIFU wird, unter Anästhesie, der Schallkopf durch das Rektum (oder 
auch durch die Harnröhre) eingeführt. Somit kann die Bildgebung in Echtzeit 
erfolgen und gleichzeitig können die Ultraschallwellen das Gewebe zerstören. 
HIFU kann technisch in zwei Kategorien unterteilt werden: 
1. HIFU mit Ultraschall-Visualisierung ist der “traditionelle” Ansatz. Diese 
Variante wird für die Ablation der gesamten oder großer Teile der Pros-
tata angewendet.  
2. Der neuere Ansatz ist HIFU mit Visualisierung über Magnetresonanzto-
mographie (MRT). Somit können die Läsionen in der Prostata genauer 
lokalisiert werden. Diese Variante erlaubt auch eine fokale Ablation 
der Prostata. 
Anhand der beiden Varianten der Ablation wurde im vorliegenden Bericht 
zwischen einer kompletten und einer teilweisen (fokal) Ablation der Prostata 
differenziert. Es besteht kein Konsens, was eine fokale Therapie auszeichnet, 
daher wurden alle Ablationen, die Teile der Prostata erhalten, unter „fokal“ 
gezählt (z.B. Hemiablation). 
Die Therapie eines lokal begrenzten Prostatakarzinoms wird als primärer 
HIFU und die Therapie eines Rezidivkarzinom wird als Salvage-HIFU (d. h. 
„rettender“ HIFU) bezeichnet. 
 
Prostatakarzinom  
eine der häufigsten 
Krebsarten bei Männern 
 
Inzidenz in Europa  
35-132 pro 100.000 
Männer 
Zielpopulation: 
Patienten mit lokal 
begrenztem Karzinom 
und lokalem 
Rezidvkarzinom 
HIFU nutzt Ultraschall, 
um Gewebe zu 
zerstören 
Schallkopf in Rektum, 
Anästhesie 
zwei Kategorien 
mit Ultraschall-
Visualisierung 
mit MRT-Visualisierung 
Unterscheidung 
Ablation gesamte 
Prostata oder Teile 
primärer HIFU und 
Salvage-HIFU 
Zusammenfassung 
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Die CE-Zertifizierung von HIFU wurde für die Behandlung von Patienten 
mit primärem, lokal begrenztem oder rezidivierendem Prostatakrebs nach 
bereits erfolgter Therapie, erteilt. 
Der Vorteil von HIFU soll in der signifikant geringeren Anzahl von Kom-
plikationen liegen, aber auch in der Reduktion von Toxizitäten im Vergleich 
zu anderen Ablationstechniken und geringerer Blutverlust, besonders im Ver-
gleich zu chirurgischen Verfahren. 
Die Vergleichsinterventionen 
Aktive Überwachung und wachsames Abwarten sind Behandlungsoptionen 
für Männer mit lokal begrenztem Prostatakarzinom, die nicht für einen Ein-
griff geeignet sind. Diese beiden Optionen sollen vor allem eine Überbehand-
lung reduzieren. 
Radikale Prostatektomie ist eine Behandlungsmethode, bei der die Prostat-
adrüse, inklusive der Samenstränge und umliegendem Gewebe, entfernt wird. 
Bei der Behandlung soll möglichst die Kontinenz und Potenz erhalten blei-
ben. 
Die Strahlentherapie ist eine weitere Behandlungsstrategie, bei der das Tu-
morgewebe bestrahlt wird (entweder perkutan, mittels Brachytherapie oder 
einer Kombination aus beidem).  
 
Methoden 
Der vorliegende Bericht ist ein Update eines Berichts des LBI-HTA aus dem 
Jahr 2010. Daher wurde die Literatursuche –in vier Datenbanken (Cochrane 
Library, Centre for Research and Dissemination, Embase, Medline) – auf 
Publikationen begrenzt, die nach Jänner 2010 publiziert wurden. Die Suche 
wurde zudem durch eine Handsuche in den Referenzlisten der eingeschlos-
senen Studien ergänzt. Laufende Studien wurden durch Suchen in Studien-
Registern identifiziert. 
Das Bias-Risiko der Studien wurde mittels der IHE-20-Checkliste für Fall-
serien und mittels ROBINS-I für nicht randomisierte kontrollierte Studien 
bewertet. Die Qualität bzw. die Stärke der Evidenz wurde mittels GRADE 
(Grading of Recommendations, Assessment, Development and Evaluation) 
vorgenommen. 
Zur Bewertung der klinischen Wirksamkeit von HIFU wurden ausschließlich 
Studien mit einer Kontrollgruppe eingeschlossen (entweder randomisierte 
oder nicht randomisierte kontrollierte Studien). Zur Bewertung der Sicher-
heit wurden zusätzlich auch prospektive Studien ohne Kontrollgruppe, aber 
mit mindestens 50 Patienten, eingeschlossen (Fallserien, Registerstudien, 
etc.).  
 
Ergebnisse 
Verfügbare Evidenz 
Wirksamkeit 
Die systematische Literatursuche identifizierte eine nicht randomisierte kon-
trollierte Studie (eine Matched-Pair-Analyse), die den Einschlusskriterien 
entsprach. In dieser Studie wurde der HIFU (Ablation der gesamten Prosta-
ta) mit der Brachytherapie zur Behandlung von lokal begrenztem Prostata-
krebs verglichen. In den Studiengruppen waren jeweils 70 Patienten. 
CE-Zertifizierung 
propagierter Vorteil: 
weniger Komplikationen 
aktive Überwachung 
und wachsames 
Abwarten 
radikale Prostatektomie 
Strahlentherapie 
Update eines 
existierenden Berichts 
aus 2010 
 
Suche in Datenbanken, 
ergänzt durch 
Handsuche 
Bias-Risiko und  
Qualität der Evidenz  
mit verschiedenen Tools 
Vergleichsstudien für 
Wirksamkeit, zusätzlich 
Fallserien für Sicherheit 
Wirksamkeit:  
eine nicht randomisierte 
kontrollierte Studie 
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Es konnten keine weiteren kontrollierten Studien identifiziert werden, die 
primären oder Salvage-HIFU mit anderen Behandlungsmodalitäten (siehe 
oben) verglichen 
Sicherheit 
Die Literatursuche konnte, zusätzlich zu o. g. kontrollierter Studie, fünf wei-
tere prospektive Fallserien zur Bewertung der Sicherheit generieren. In vier 
dieser Fallserien wurde primärer HIFU mittels Hemiablation und in einer 
Studie wurde eine Salvage-HIFU mittels Ablation der gesamten Drüse ange-
wendet.  
Klinische Wirksamkeit 
Primärer HIFU 
Um den Effekt von HIFU auf die Mortalität zu untersuchen, wurden zwei 
Endpunkte herangezogen: Gesamtüberleben und krebsspezifisches Überleben. 
Beide Raten waren mit HIFU etwas geringer als mit Brachytherapie, die Un-
terschiede waren aber nicht statistisch signifikant (88 vs. 97.5 %, Hazard Ra-
tio 0,24, Konfidenzintervall 0,01-1,34 und 89 % vs. 92 %, Hazard Ratio 0,67, 
Konfidenzintervall 0,32-1,29). 
Um den Effekt von HIFU auf die Progression (oder die Rezidivbildung) bei 
lokal begrenztem Prostatakrebs zu beschreiben, wurde der Endpunkt „bio-
chemisches Rezidiv-freies Überleben“ herangezogen (ein Surrogat-Parameter 
und nicht zu verwechseln mit „lokale Rezidive“). Das biochemische Rezidiv-
freie Überleben war bei HIFU-Patienten signifikant geringer, als bei Patien-
ten, die mit Brachytherapie behandelt wurden (53,1 vs. 68,5 %, Hazard Ra-
tio 0,41, Konfidenzintervall 0,19-0,81 nach Phoenix, 51,3 vs. 60,9 %, Hazard 
Ratio 0,39, Konfidenzintervall 0,19-0,74 nach Stuttgart, p<0,05 für beide)2. 
Zusätzliche Endpunkte, wie insbesondere der kritische Endpunkt „lokale Re-
zidive“ wurden nicht berichtet. 
Salvage-HIFU 
Es konnte keine Evidenz identifiziert werden, die die Wirksamkeit von Sal-
vage-HIFU mit anderen Interventionen verglich.  
Sicherheit 
Primärer HIFU 
Zur Bewertung der Sicherheit wurden die Interventions-bedingte Mortalität, 
Funktionsstörungen (Blase betreffend und sexuell) und unerwünschte Ereig-
nisse als Endpunkte herangezogen. 
In keiner der identifizierten Studien starben Patienten aufgrund von HIFU. 
Blasenfunktionsstörungen wurden in allen Studien erhoben. In der kontrol-
lierten Studie waren nach HIFU 7,2 % und nach Brachytherapie 3,8 % der 
Patienten inkontinent (p=0,44). Die Messung der Inkontinenz anhand des 
IPSS (International Prostate Symptom Score) wurde in drei Fallserien vor-
genommen, wobei in zwei Studien keine signifikanten Änderungen festge-
stellt wurden und in einer Fallserie eine signifikante Verbesserung berichtet 
wurde. 
                                                             
2 Phoenix: tiefster PSA-Wert +2ng/ml; Stuttgart: tiefster PSA-Wert +1.2 ng/ml).  
keine weiteren Studien 
Sicherheit:  
eine nicht randomisierte 
kontrollierte Studie und 
fünf Fallserien 
primärer HIFU:  
keine signifikanten 
Unterschiede bezüglich 
Mortalität zwischen 
HIFU und 
Brachytherapie 
biochemisches  
Rezidiv-freies Überleben 
mit HIFU signifikant 
niedriger 
Salvage-HIFU:  
keine Evidenz 
Sicherheits-Endpunkte 
kein Todesfall mit HIFU 
in kontrollierter Studie 
keine signifikanten 
Unterschiede bei 
Inkontinenz; 
in zwei Fallserien bei 
IPSS keine signifikanten 
Verbesserungen  
Zusammenfassung 
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Erektionsstörungen wurden entweder anhand des IIEF (International Index 
of Erectile Function) oder anhand der Anzahl der impotenten Männer ange-
geben. In der kontrollierten Studie wurden nach HIFU insgesamt fünf Män-
ner impotent (11,6 %, ein Vergleich war nicht gegeben, da Erektionsstörun-
gen nur bei HIFU-Patienten erhoben wurden). Zwei der Fallserien gaben an, 
dass 20-22 % der Männer nach HIFU impotent waren. In einer Fallserie war 
diese Rate 48 % hoch. Zwei Fallserien berichteten über eine signifikante Ver-
schlechterung der Erektion nach HIFU mit dem IIEF-Score (p<0,001). 
Die häufigsten unterwünschten Ereignisse in den Studien waren Grad 1 und 2 
(Infektionen, unerwünschter Harnabgang, etc.). Aus der kontrollierten Stu-
die ging hervor, dass Komplikationen mit Grad 3 bei HIFU häufiger waren, 
als bei Brachytherapie (35 % vs. 13 %). In den Fallserien, wo eine Hemiabla-
tion der Prostata angewendet wurde, war die Komplikationsrate etwas nied-
riger, als in der kontrollierten Studie, wo die gesamte Prostata einer Ablation 
unterzogen wurde. Rektale Fisteln traten ausschließlich in der kontrollierten 
Studie auf. Grad 4 Komplikationen traten in keiner der Studien auf. 
Salvage-HIFU 
Die Fallserie zu Salvage-HIFU konnte keine signifikanten Effekte bezüglich 
Inkontinenz feststellen (gemessen mit IPSS; sechs Monate nach HIFU, p= 
0,06). Jedoch lag auch in dieser Studie ein negativer Effekt von HIFU auf die 
Potenz vor (gemessen mit IIEF-5 Score sechs Monate nach HIFU, p<0,001). 
Grad 3 Komplikationen traten zu 62 % auf und es gab drei Grad 4 Kompli-
kationen. 
Laufende Studien 
Die Suche nach laufenden Studien ergab, dass von zwei randomisierten kon-
trollierten Studien eine in der Planungsphase ist und eine einen unbekann-
tem Status hat (die Publikation sollte 2014 erfolgen, es wurde jedoch keine 
gefunden). Weiters waren drei nicht randomisierte kontrollierte Studien re-
gistriert, von der eine im November 2019 beendet werden soll. Von den bei-
den anderen Studien wurde eine abgebrochen und die andere sollte 2008 pu-
bliziert werden, aber eine Publikation konnten nicht gefunden werden. 
 
Diskussion 
Die Qualität der Evidenz von HIFU als primäre Behandlung von lokal be-
grenztem Prostatakrebs mit geringem und mittlerem Risiko sowie als Salva-
ge-Therapie von rezidivierendem Prostatakrebs ist sehr gering. Es fehlen vor 
allem Studien mit einer entsprechend großen Fallzahl, mit einer Vergleichs-
gruppe und genügend langen Nachbeobachtungszeiträumen. Somit lassen 
sich die Studienergebnisse kaum generalisieren. Alle Aussagen bezüglich der 
Wirksamkeit beruhen auf lediglich einer kontrollierten Studie, die jedoch ei-
ne sogenannte Matched-Pair-Analyse war. Die Bewertung der Sicherheit be-
ruht, zusätzlich zu o. g. kontrollierter Studie, auf fünf Fallserien. Somit gibt 
es keine direkten Vergleiche von HIFU zu anderen Interventionen, wie aktive 
Überwachung oder auch radikale Prostatektomie. Eine weitere Limitation ist, 
dass in der Matched-Pair-Analyse die gesamte Prostata mittels HIFU zer-
stört wurde, in den Fallserien wurde jedoch die Hemiablation angewendet, 
die mit einer geringeren Komplikationsrate assoziiert ist. 
insgesamt  
negativer Effekt von 
HIFU auf Potenz 
Komplikationen 
vorwiegend Grad 1 und 2 
 
HIFU im Vergleich zu 
Brachytherapie: etwas 
mehr schwerwiegendere 
unerwünschte 
Ereignisse mit HIFU 
Salvage-HIFU:  
keine signifikanten 
Veränderungen bei 
Inkontinenz, aber bei 
Potenz, 62 % Grad 3 
Komplikationen 
ein RCT in Planung,  
ein non-RCT Ende 2019 
sehr geringe Qualität 
der Evidenz 
 
Mangel an 
Vergleichsstudien, 
geringe Fallzahlen, 
kurze 
Nachbeobachtungszeit 
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Die Limitationen des vorliegenden Berichts liegen insbesondere in der feh-
lenden Stratifizierung nach den zwei Kategorien der Visualisierung (MRT 
oder Ultraschall) und nach begleitenden Interventionen. Jedoch waren diese 
Informationen in den Studien zum Teil nicht gegeben. Weiters wurde die 
kontrollierte Studie eingeschlossen, obwohl in dieser ein Teil der Patienten 
mit einem veralteten HIFU-Gerät behandelt wurde, welches nicht mehr er-
worben werden kann. Es kann aber davon ausgegangen werden, dass gerade 
die Art der Visualisierung, begleitende Interventionen und auch das HIFU-
Gerät einen entscheidenden Einfluss auf Studienergebnisse haben. Eine wei-
tere Limitation ist der Verzicht auf indirekte Vergleiche, da dies im Rahmen 
der relativ kurzen Projektdauer nicht möglich gewesen wäre.  
Evidenzlücken  
Aktuell fehlen randomisierte kontrollierte Studien, die HIFU (sowohl zur Ab-
lation der gesamten als auch Teile der Prostata) mit anderen Therapieoptio-
nen vergleichen. Außerdem ist HIFU unter MRT-Visualisierung noch so neu, 
dass hier Studien erst kürzlich beendet wurden. 
 
Empfehlung  
Die derzeitige Evidenz ist nicht ausreichend, um die Effektivität und Sicher-
heit des primären HIFU als auch des Salvage-HIFU im Vergleich zu aktiver 
Überwachung, wachsamen Abwarten, radikaler Prostatektomie oder Radio-
therapie zu demonstrieren. Daher wird eine Aufnahme in den Leistungska-
talog nicht empfohlen. 
Es besteht der Bedarf an randomisierten kontrollierten Studien mit einer 
ausreichend großen Patientenzahl und genügend langen Nachbeobachtungs-
zeiträumen. 
 
 
 
Limitationen 
vorliegender Bericht: 
fehlende Stratifizierung, 
Studie mit veraltetem 
Gerät eingeschlossen, 
keine indirekten 
Vergleiche 
keine randomisierten 
kontrollierten Studien 
keine ausreichend 
robuste Evidenz,  
Aufnahme derzeit  
nicht empfohlen 
randomisierte 
kontrollierte Studien 
von Nöten 
 LBI-HTA | 2018 17 
Summary of the assessment 2010  
Commissioned by the Austrian Ministry of Health, the HTA-report “High-
intensity focused ultrasound (HIFU) for the treatment of prostate cancer” was 
prepared by the Ludwig Boltzmann Institute of Health Technology Assess-
ments (LBI-HTA) in March 2010 [15]. This report provides the basis for the 
current update. The following paragraphs summarize the scope, the results 
and the recommendation of the 2010 report. 
 
 
Scope 2010 
1. Is HIFU for primary treatment of men with clinically localised or locally 
advanced prostate cancer an effective and safe alternative to conventional 
surgical and non-surgical treatment methods, such as radical prostatec-
tomy, radiotherapy (with/without hormone therapy for locally advanced 
tumour) or active surveillance? 
2. Is HIFU for treating men with locally recurrent prostate cancer after failed 
radical prostatectomy or external beam radiotherapy an effective and safe 
alternative to radical prostatectomy or radiotherapy (with or without hor-
mone therapy)? 
Inclusion criteria for relevant studies are summarised in Table 1.  
Table 1: Inclusion criteria 
Population  Men with localised (T1-T2, N0-Nx, M0) primary prostate cancer 
 Men with locally advanced (T3-T4, N0-Nx, M0) primary prostate cancer 
 Men with locally recurrent prostate cancer after failed radical prostatectomy  
or external beam radiotherapy  
Intervention High-intensity focused ultrasound (HIFU): 
 Ablatherm® (Prototypen, Maxis, Integrated Imaging) by EDAP TMS, France 
 Sonablate® (200, 500) by Focus Surgery, Inc., USA  
Control 
intervention 
 Radical prostatectomy with or without pelvic lymph node dissection 
 External radiation therapy (with or without hormone therapy) or interstitial brachytherapy 
 Active surveillance  
Outcomes  Effectiveness: 
 Clinical (surrogate) endpoints: PSA-kinetics, histology 
 Patient-relevant: 5 year survival, disease-free survival, overall survival, quality of life 
Safety:  
 Morbidity: acute/chronic urinary tract disorder, urinary incontinence, urinary tract infection, 
stricture/stenosis (bladder neck/urethra), erectile dysfunction, urethrorectal fistula, chronic pain 
 Mortality 
Study design  for Effectiveness: prospective studies with >50 patients 
 for Safety: prospective studies with > 50 patients 
 
  
Update von  
HTA- Bericht 2010 
PIKO -Frage 
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The following outcomes were defined as crucial to derive a recommendation 
in the report 2010. 
Clinical effectiveness: 
 Biochemical disease-free survival 
 Overall survival 
 Negative biopsy rate 
 Prostate cancer specific survival 
Safety: 
 Adverse events urinary tract 
 Adverse events potency 
 Adverse events rectum 
 Pain 
 IPSS score 
 IPSS-Quality of life 
 
 
Results 
No comparative studies to assess the effectiveness and safety of HIFU could 
be identified. In total 21 studies were included, all of which were case series.  
For assessing HIFU as primary therapy 18 studies were included of which 
eleven investigated the Ablatherm® and seven investigated the Sonablate® de-
vices. As described in the report, many of the studies reported on the same 
patient population. For the assessment of salvage HIFU the included three 
studies investigated the Ablatherm® device.  
The biochemical disease-free survival rate in clinically localised PCa ranged 
between 66 and 77% after five years and 69% after seven years in the Ab-
latherm® studies, whereas it was 78% after five years in the Sonablate® stud-
ies. A direct comparison of disease-free survival was not possible on the basis 
of the available data; an indirect comparison showed that the biochemical dis-
ease-free survival of both Ablatherm® and Sonablate® corresponded that of 
radical prostatectomy, which ranged between 69 and 84% after five years and 
between 52 and 75% after ten years in clinically localised prostate cancer.  
Overall survival or disease-specific survival was reported in only one study. 
Other patient-relevant outcomes such as quality of life were measured with 
questionnaires in a total of 14 studies, however, only a few studies presented 
evaluable data. Adverse events of HIFU therapy mainly affected the urinary 
tract, the rectum, and the erectile function.  
The report highlighted important limitations of the available evidence, name-
ly that most of the case series involved patients with localised prostate can-
cer with favorable prognostic factors, usually younger than 70 years. Further-
more, the report also pointed out that in addition to radical prostatectomy 
and radiation therapy, active surveillance would be also an option in this pa-
tient population, although would require short-term control (digital rectal ex-
amination, PSA measurement, biopsy), but with fewer side effects, and would 
impair patient quality of life less than HIFU treatment. 
The quality of evidence was rated “very low” due to the uncontrolled study 
design and that publication bias was suspected in 16 case series. 
entscheidende 
Endpunkte 
keine Vergleichsstudien 
vorhanden 
21 Fallserien:  
11 Ablatherm® 
7 Sonablate® 
disease-free survival 
rate: 66-77% nach 7 
Jahren mit Ablatherm®  
78% nach 5 Jahren  
mit Sonablate® 
Overall survival: nur von 
einer Studie berichtet 
QoL in 14 Studien 
berichtet 
Limitation: 
PatientInnenselektion 
Qualität der Evidenz: 
sehr niedrig 
Summary of the assessment 2010 
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Recommendation 
The available evidence included in the report 2010 was insufficient to prove, 
that HIFU is an effective and safe alternative to conventional surgical and 
non-surgical prostate cancer treatments (such as radical prostatectomy, radio-
therapy). Therefore the inclusion in the service catalog was not recommended. 
 
 
keine Empfehlung  
zur Aufnahme in 2010 
aufgrund unzureichender 
Evidenzlage 
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1 Scope (2018) 
1.1 PICO questions 
Is primary HIFU in comparison to AS, WW, RP or RT in patients with low-
risk or intermediate-risk clinically localised prostate cancer more effective (or 
at least as effective) concerning overall survival, prostate cancer specific sur-
vival, local disease recurrence, and/or safer (or at least as safe) concerning in-
tervention-specific mortality, serious adverse events and functional outcomes 
(urinary function and sexual function)? 
Is salvage HIFU in comparison to AS, WW, salvage RT, or salvage RP in pa-
tients with low-risk or intermediate-risk locally relapsed/recurrent prostate 
cancer after failed RP, RT or HIFU more effective (or at least as effective) 
concerning overall survival, prostate cancer specific survival, local disease 
recurrence, and/or safer (or at least as safe) concerning intervention-specific 
mortality, serious adverse events and functional outcomes (urinary function 
and sexual function)? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Description Project scope 
Population   Adult men with clinically localised prostate cancer (cT1a-T2, N0-Nx, M0) based on TNM staging, 
Gleason score (GS), serum PSA 
 Low-risk: clinical stage cT1a-T2a, GS≤ 6, PSA < 10 ng/mL 
 Intermediate-risk: clinical stage T2b, GS 7, PSA 10 to 20 ng/mL  
 Adult men with locally relapsed/recurrent prostate cancer after failed radical prostatectomy (RP), 
radiation therapy (RT), or high-intensity focused ultrasound (HIFU) (cT1a-T2, N0-Nx, M0) 
 MeSH: prostatic neoplasms C04.588.945.440.770, C12.294.260.750,  
C12.294.565.625, C12.758.409.750 
 ICD-10: C61 Malignant neoplasm of prostate 
 Intended use of the technology: first-line treatment or salvage therapy. 
Rationale: population was defined based on the EAU guideline [1], NICE guideline [27], S3 Leitlinie 
(German oncology guideline program) [28] and the indications of CE mark approvals. 
Intervention   Whole gland ablation or focal therapy of the prostate gland using HIFU with trans-rectal 
ultrasound imaging (TRUS) guidance or with magnetic resonance imaging (MRI) guidance 
 MeSH: E02.565.280.945.399, E04.014.380  
 Products/manufacturers: 
 Ablatherm® (company: EDAP TMS, France) 
 Ablatherm® Integrated Imaging and its predecessors (Ablatherm® Maxis and Ablatherm® 
prototype) 
 Focal One® 
 Sonablate® (company: Focus Surgery, Inc., USA) 
 Sonablate® 500 and its predecessors (Sonablate® 200, Sonablate® 450) 
 Sonasource® 
 ExAblate® system (company: Insightec, Israel): focal therapy 
 TULSA-PRO® (company: Profound Medical, Canada): focal therapy 
 
PIKO-Frage  
zu primärer HIFU 
PIKO-Frage  
zu Salvage-HIFU 
Einschlusskriterien  
für relevante Studien 
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Comparison  Deferred treatment: 
 Active surveillance/monitoring (AS) 
 Watchful waiting (WW) 
 Radical prostatectomy (RP) with or without pelvic lymphadenectomy including: 
 Laparoscopic surgery 
 Robotic surgery 
 Open surgery 
 Definitive radiotherapy (RT) including but not restricted to: 
 External-beam radiation therapy (EBRT) with or  
without short-term androgen deprivation therapy (ADT) 
 3D conformal radiotherapy 
 Intensity modulated radiotherapy (IMRT) with or without image guided radiotherapy (IGR) 
 Brachytherapy 
 Low dose rate (LDR) or  
 High dose rate (HDR)  
 Combination of EBRT and brachytherapy 
Rationale: standard interventions for the target population according to the clinical guidelines  
(S3 Leitlinie [28], NICE [27], EAU [1]). 
Outcomes Effectiveness-related: 
 Overall survival/mortality (e.g. 5 and 10 year survival) (critical) 
 Prostate cancer specific survival/mortality (critical) 
 Local disease recurrence (presence of clinically significant PCa measured by biopsy and/or 
mpMRI) (critical) 
 Distant disease recurrence/metastases (important) 
 Biochemical recurrence/failure (increasing PSA level according to ASTRO or Phoenix definition) 
(important) 
 Disease progression/pathological progression (increase in GS or tumour volume evidenced  
by a larger number of positive biopsies or larger per-core tumour involvement) (important) 
 Quality of life (QoL): generic and/or disease specific (measured by one of the following: UCLA-EPIC, 
EORTC-QLQ-30, FACIT (FACT-P and FACT-G), MAX-PC, PORPUS, EQ-5D) (important) 
 Need for salvage local therapy and need for systemic (hormonal or chemotherapeutic) therapy 
(important) 
 Ablation failure (failure of the technique to destroy the tissue in the treated zone, including 
targeting failure) (important) 
Safety-related: 
 Intervention-specific mortality (peri-operative death) (critical) 
 Functional outcomes (critical) 
 Urinary (dys)function: urinary incontinence (reported as number of patients with urinary 
leakage or number of patients with new onset of pads required) or worsening of urinary tract 
symptoms (increase in the IPSS score) 
 Sexual (dys)function: loss of erectile function (reported as number of patients with new onset 
of importance) or worsening in erectile function (decrease in the IIEF-5, IIEF-15, or BMSFI score)  
 Clavien-Dindo grade 1-2 procedural complications/adverse events (AEs), including but not 
restricted to (important) 
 Urinary tract infection 
 Storage or voiding lower urinary tract symptoms (LUTS) 
 Acute/chronic urinary retention 
 Burn, injuries, bleeding 
 Proctitis 
 Pain 
 Anaesthesia-related complications 
 Thromboembolic disease (phlebitis)  
 Clavien-Dindo grade 3-4 procedural complications/serous adverse events (SAEs),  
including but not restricted to (critical) 
 Bladder neck/urethral stricture/stenosis 
 Bladder neck obstruction  
 Rectal fistula 
Rationale: we have chosen the outcomes based on the recommended core outcome set for localised 
prostate cancer [29], Consensus paper on the standardization of definitions on focal therapy of prostate 
cancer [30], EUnetHTA guidelines on clinical endpoints and safety [31-33], EAU guideline [1]. 
Study design Effectiveness: randomized controlled trials (RCTs), prospective non-RCTs 
Safety: RCTs, prospective non-RCTs, single arm prospective cohort studies with ≥ 50 patients 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What is high intensity focused ultrasound (HIFU) ablation with trans-rectal ultrasound 
(TRUS) imaging guidance or with magnetic resonance imaging (MRI) guidance?  
What is active surveillance (AS)? What is watchful waiting (WW)? 
What is radical prostatectomy (RP)?  
What is definitive radiotherapy (RT)? 
A0020 For which indications has HIFU received marketing authorisation or CE marking? 
B0002 What is the claimed benefit of HIFU in relation to AS, WW, RP and RT? 
B0003 What is the phase of development and implementation of HIFU? 
B0004 Who administers HIFU? In what context and level of care is HIFU provided? 
B0008 What kind of special premises are needed to use HIFU? 
B0009 What supplies are needed to use HIFU? 
A0021 What is the reimbursement status of HIFU? 
 
Health problem and Current Use 
Element ID Research question 
A0002 What is clinically localised prostate cancer and locally relapsed/recurrent prostate cancer? 
A0003 What are the known risk factors for prostate cancer? 
A0004 What is the natural course of prostate cancer? 
A0005 What is the burden of disease for the prostate cancer patient? 
A0006 What are the consequences of prostate cancer for the society? 
A0024 How is prostate cancer currently diagnosed according to published guidelines and in practice? 
A0025 How is prostate cancer currently managed according to published guidelines and in practice? 
A0007 What is clinically localised prostate cancer (cT1a-T2, N0-Nx, M0) and locally 
relapsed/recurrent prostate cancer (cT1a-T2, N0-Nx, M0)? 
A0023 How many people belong to the clinically localised prostate cancer (cT1a-T2, N0-Nx, M0)  
and locally relapsed/recurrent prostate cancer (cT1a-T2, N0-Nx, M0) patients? 
A0011 How much is HIFU utilised? 
 
Clinical Effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of HIFU on mortality? 
D0005 How does HIFU affect symptoms and findings (severity, frequency) of localised  
and locally recurrent prostate cancer? 
D0006 How does HIFU affect progression (or recurrence) of localised and  
locally recurrent prostate cancer? 
D0011 What is the effect of HIFU on patients’ body functions? 
D0016 How does the use of HIFU affect activities of daily living? 
D0012 What is the effect of HIFU on generic health-related quality of life? 
D0013 What is the effect of HIFU on disease-specific quality of life? 
D0017 Were patients satisfied with the use of HIFU? 
 
High-intensity focused ultrasound for the treatment of prostate cancer 
24 LBI-HTA | 2018 
Safety 
Element ID Research question 
C0008 How safe is HIFU in comparison to AS, WW, RT, RP? 
C0002 Are the harms related to dosage or frequency of applying HIFU? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed  
through the use of HIFU? 
C0007 Is HIFU associated with user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor the use of HIFU? 
 
 
2.2 Sources 
Description of the technology 
 Handsearch in the CRD databases for Health Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Questionnaire completed by the submitting hospital  
Health problem and Current Use 
 Handsearch in the CRD databases for Health Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Questionnaire completed by the submitting hospital 
 
 
2.3 Systematic literature search 
The systematic literature search was conducted on 01.12.2017  
in the following databases:  
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
Since the present assessment is an update of the systematic review on HIFU 
from 2010 [15], the time period of the search was limited from January 2010 
to December 2017. The search strategy of the 2010 LBI-HTA report was com-
plemented with search for MRI-guided focused ultrasound as this new HIFU 
approach received CE mark in 2016. Detailed tables on search strategy are 
included in the Appendix. 
Clinical Practice Guidelines (CPGs) were searched in the UptoDate database, 
through handsearch and consultation with clinical experts comprehensive to 
the systematic search. 
 
 
Quellen zu Technologie 
Quellen zu Erkrankung 
und derzeitigem Einsatz 
systematische 
Literatursuche in  
4 Datenbanken  
Suche nach neuen 
Publikationen nach 
Jänner 2010 
Suche Leitlinien in 
“UptoDate-Datenbank” 
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Furthermore, to identify ongoing and unpublished studies, a search in three 
clinical trial registries (ClinicalTrials.gov; WHO-ICTRP; EU Clinical Tri-
als) was conducted on 29.12.2017 and on 02.01.2018 resulting in 42 potential 
relevant hits. 
Manufacturers did not submit any publications, or submission files, as well 
as a cross-reference search did not identify any additional publications. 
 
 
2.4 Flow chart of study selection 
Overall 1200 hits were identified, after deduplication 884 hits remained for 
screening. The author and co-author independently screened the titles and 
abstracts and selected studies according to the pre-defined inclusion as out-
lined in Table 1-1 for full-text examination. In case of disagreement a third 
researcher was involved to solve the differences. The selection process is dis-
played in Figure 2-1.  
 
Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
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Full-text articles  
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(n=43) 
Full-text articles excluded,  
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(n=37) 
 Other study design (n = 4) 
 ≤ 50 patients with evaluable 
data (n = 2) 
 Other population (n = 20) 
 Other intervention (n = 2) 
 Other comparator (n = 3) 
 Other outcomes (n = 5) 
 Not English/German (n =1) 
Studies included in qualitative synthesis 
(n=6) 
Primary therapy: 
 Non-RCTs (n = 1) 
 Single arm prospective studies (n = 4) 
Salvage therapy: 
 Single arm prospective studies (n = 1) 
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43 full-text publications were assessed for eligibility by the author and the 
co-author independently. 37 publications were excluded according to the pre-
defined exclusion criteria: retrospective study design (other study design), less 
than 50 patients (low-and intermediate-risk) with evaluable data, studies with 
patients from all risk groups where the number of low-and intermediate risk 
patients cannot be distinguished (other population), studies in which HIFU 
is administered as combination therapy (other intervention), comparison of 
two HIFU modalities (other comparator), none of the study outcomes includ-
ed in the present assessment (other outcomes), and language other than Eng-
lish or German. Disagreements were resolved by consensus. In the end, a total 
of six studies were included for data synthesis, of which one was a controlled 
trial (matched-pair analysis) and five were single arm studies. 
 
 
2.5 Analysis 
Data was extracted by the author and checked by the co-author. Evidence 
tables were created based on the pre-defined outcomes set and information 
about the study. 
As raw data could not be retrieved, the definition for clinical significance was 
accepted as used by the single studies. Nevertheless, clinically significant dis-
ease has no universally accepted definition. The most frequently used defini-
tions are summarized in the Appendix. 
Continuous variables were given using median, interquartile range (IQR), or 
overall range according to availability. The mean with standard deviation was 
used when the former was not available. Categorical variables were given us-
ing frequencies and percentages. In determining the rate of positive biopsy 
results only patients who underwent biopsy were part of the denominator. 
Functional outcomes were determined in relative rates and as continuous 
values depending on the available outcome measures. To determine inconti-
nence rate in case of physician reported events, only the number of patients 
for whom this was reported were part of the denominator. In determining the 
rate of potency in case of physician reported events, only men who were pre-
HIFU potent were part of the denominator. When functional outcomes were 
reported as continuous values, the pre- and post-intervention data were ex-
tracted where available, otherwise mean difference and statistical significance 
was extracted. To calculate the frequency of adverse events, men lost to-follow 
up with this outcome were excluded from the denominator.  
We could not pool data and perform a meta-analysis on specific outcomes 
because the available evidence comes exclusively from observational studies 
with heterogeneous outcome measures.  
For Description and Technical Characteristics of Technology (TEC) and 
Health Problem and Current Use of the Technology (CUR) domains, no qual-
ity assessment tool was used, but multiple sources were used in order to val-
idate individual, possibly biased, sources. Descriptive analysis of different in-
formation sources was performed. 
43 Studien auf  
Volltext-Basis, davon  
37 ausgeschlossen, 
letztlich 6 Studien  
für Datensynthese 
Datenextraktion  
und Kontrolle 
Definition klinischer 
Signifikanz aus Studien 
übernommen 
Angabe von Variablen, 
je nach Verfügbarkeit 
und Art der Variable 
Meta-Analyse und 
zusammenfügen der 
Daten nicht möglich 
Beschreibung 
Technologie und 
Erkrankung ohne 
Qualitätsbewertung 
Methods 
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For the Effectiveness (EFF) and the Safety (SAF) domains we applied EU-
netHTA guidelines in the selection of quality rating tools. Risk of bias on 
study level was assessed using the IHE-20-checklist [16] for the single arm 
studies (case series) and ROBINS-I [17] for the non-RCT. The author and co-
authors performed the risk of bias assessment independently. Disagreements 
were resolved by consensus. 
 
 
2.6 Synthesis 
Based on the data extraction tables (see Appendix Table A-1, Table A-2, Ta-
ble A-3), data on each selected outcome were synthesized. The quality of the 
body of evidence was assessed using GRADE (Grading of Recommendations, 
Assessment, Development and Evaluation) [18]. The author performed the 
GRADE assessment and the co-author checked it. Disagreements were re-
solved by consensus. The research questions were answered in plain text for-
mat. Please note that some research questions were answered together, i.e. 
these questions are listed below each other and the answer is provided sub-
sequently. 
 
 
Bewertung 
Studienqualität  
und Bias-Risiko zu 
Wirksamkeit und 
Sicherheit durch  
2 Wissenschaftler, 
mittels IHE- Checkliste 
nach Datenextraktion  
in Tabellen, Bewertung 
der Evidenzsynthese 
anhand von GRADE 
durch zwei AutorInnen 
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3 Description and technical 
characteristics of technolgy 
Features of the technology and comparators 
B0001 –What is HIFU ablation with trans-rectal ultrasound (TRUS) 
imaging guidance or with magnetic resonance imaging (MRI) guidance?  
HIFU is characterised by the use of ultrasound (US) waves, emitted from a 
transducer, to cause tissue damage by mechanical and thermal effects, as well 
as by cavitation. It is called high-intensity referring to the power density of 
the US waves that exceeds 5 W per cm2. In the clinical setting HIFU uses 
frequencies within the range of 0.8-3.5 mHz. Cell death occurs through two 
physiological mechanisms. Firstly, the energy of the US waves are absorbed 
by the target tissue and converted to heat (exceeding 60 °C), causing coagu-
lative necrosis. Secondly, inertial cavitation is caused by alternating cycles of 
compression and rarefaction [1, 5].  
To administer HIFU, a probe is inserted into the rectum (or urethra) while the 
patient is anaesthetised. This probe or the MRI in the MRI-guided approach 
enables real-time visualisation of prostatic tissue and also delivers HIFU en-
ergy to destroy the desired target parenchyma [5]. A catheter (suprapubic or 
urethral) is inserted at the end of the treatment to help the bladder to empty 
comfortably during recovery. It is removed as soon as possible (one to three 
weeks). The length of the procedure depends on the size of the prostate gland. 
Larger glands will take longer to treat completely. A way to estimate time is 
one hour for every 10 grams of tissue to be treated. Most procedures take 1.5 
to 4 hours. Depending on equipment and treatment scheme, e.g. half-gland 
or focal therapy, treatment time can be shorter. Men may return to office-
based work the following day. More intense physical activity can be resumed 
within 3 to 5 days, though no activity should be started that dislodges the 
catheter or stirs up bleeding from the catheter insertion site [34].  
Two major systems of HIFU exist based on the type of imaging guidance 
during the treatment.  
1. HIFU with TRUS imaging guidance is the traditional approach and has 
been in use in Europe for many years. Its major limitation is that visual-
ising the focus of the prostate cancer using current ultrasound systems is 
not possible. Therefore the treatment strategy with TRUS-guided HIFU 
is to ablate the whole prostate gland or a relatively large region (hemi or 
partial ablation) where the site of cancer was found using a mapping biop-
sy and/or mpMRI. There are three commercially available HIFU systems 
with TRUS imaging guidance: Ablatherm®, Sonablate 500®, and Focal-
One®. The baseline technology of the systems is the same, however, there 
are some technical differences between the devices: the imaging and ther-
apeutic transducers, the position of the patient, the type of software appli-
cation for treatment planning and safety monitoring [6-9]. 
 Ablatherm® integrates both the imaging transducer and the therapeu-
tic transducer in a single endorectal probe focused at 40 mm. The 
probe is covered by a latex condom filled with liquid to thermally pro-
tect the rectal wall. The probe is mounted on a holder that allows 
movements in three spatial directions. The patient lies in a lateral sit-
ting position during the treatment. There are four treatment protocols: 
primary care, retreatment, radiation failure and post-brachytherapy. 
HIFU nutzt gebündelte 
Ultraschallwellen, um 
Gewebe zu zerstören 
unter Narkose 
Einführung Schallkopf 
durch Rektum, Katheter 
für Blasenentleerung, 
Dauer 1,5-4 Stunden 
HIFU in zwei Systeme 
unterteilbar: 
HIFU mit transrektalem 
Ultraschall 
 
dazu zählen: 
 
Ablatherm®,  
Sonablate 500®,  
FocalOne®. 
Ablatherm®  
integriert Schallgeber 
für Visualisierung und 
Ablation in einer Sonde 
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Before the treatment the probes are set up to target the thermal lesion 
within the prostate, and the operator defines the boundaries of the tar-
get area. The device has a real-time ultrasound monitoring [7].  
 Sonablate 500® and its predecessors have a console (portable system 
with display monitor, motor with three axis, probe holding arm), a ful-
ly integrated probe and a module for degassing and circulating chilled 
water. The probe uses double-sided and dual-mode transducers for im-
aging and treatment. The transducer has two focal lengths (30-40 mm). 
The user can switch between these lengths to treat the ventral and the 
dorsal part of the prostate consecutively. The patient lies in a supine 
position during the treatment. The treatment is carried out in two or 
three consecutive layers, depending on the anterior-posterior dimen-
sions of the prostate, starting with the anterior portion and moving to 
the posterior part by changing the focal length during the procedure. 
The maximum distance from the transducer that can be treated is 40 
mm. The device has a real-time ultrasound monitoring [7].  
 FocalOne® device has integrated software for the image fusion of re-
al-time transrectal ultrasound and pretreatment MRI images. This al-
lows the image-guided HIFU treatment of a defined zone and sparing 
the rest of the prostate tissue. The transducer’s focal length is maxi-
mum 60 mm and can be modified during treatment. This dynamic fo-
cusing makes it possible to better match the treated area to the mor-
phology of the prostate, keeping the focal point always inside the pros-
tate. This allows the treatment of various sized prostates with various 
anterior-posterior distances and shortens the duration of treatment [7].  
2. The novel approach is the HIFU system with MRI guidance. MR imaging 
provides high resolution imaging for patient-specific treatment planning 
and real-time thermometry for temperature monitoring throughout the 
treatment. MRI makes the localisation of lesions within the prostate pos-
sible allowing the optimisation of ablation treatment zone; hence the fo-
cal treatment (FT) of the prostate is also possible. There are currently two 
MRI-integrated systems using transrectal or transurethral transmission 
routes for treatment of the prostate lesions. These systems are fully inte-
grated with the MRI console with temperature feedback control to adjust 
power, frequency, and rotation rate [6].  
 ExAblate®: a movable endorectal focused ultrasound transducer gen-
erates an adjustable focus that can ablate cancerous tissue. The sharp 
margin of the ultrasound beam allows targeting of tumours within less 
than 1 mm of the sphincters and neurovascular bundles, with no heat 
applied to these structures. The active rectal cooling system further 
safeguards the rectal wall. Final assessment with contrast MRI pro-
vides immediate verification of complete ablation [35]. 
 TULSA-PRO®: the technology is designed for the destruction of the 
whole prostate gland in a single procedure that lasts about an hour, but 
can also be used for any targeted or focal ablation of cancerous tissue. 
After the ultrasound probe is placed in the prostatic urethra near the 
target, the treatment is performed with MRI real-time planning and 
guidance. The ten ultrasound transducers along the probe are selec-
tively activated to deliver energy to the whole gland or the targeted part 
of the prostate only, heating it and in the process killing its tissue. 
The probe slowly rotates in order to deliver the ablative energy across 
the entire prostate or at the planned target. During treatment, real-
time MRI is used to verify that the planned heating pattern is accu-
Sonablate 500® nutzt 
doppelseitige Sonde 
FocalOne®.nutzt  
MRT zur präoperativen 
Visualisierung 
neuerer Ansatz:  
HIFU unter MRT 
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rately delivered. Although no energy is delivered transrectally, an en-
dorectal cooling device is used to prevent any unwanted destruction 
of nearby tissues. Final assessment with contrast MRI provides im-
mediate verification of complete ablation [36]. 
The characteristics of HIFU systems and the available devices are outlined 
in Table 3-1. 
Table 3-1: Features of HIFU systems 
 TRUS-guided 
HIFU 
TRUS-guided 
HIFU with MRI-
image-fusion 
TRUS-guided 
HIFU 
MRI-guided HIFU MRI-guided HIFU 
Name Ablatherm® FocalOne® Sonablate®500 ExAblate® system TULSA-PRO® 
Manufacturer EDAP TMS, 
France 
EDAP TMS, 
France 
SonaCare Medical, 
LLC, USA 
InSightec Ltd., 
Israel 
Profound Medical 
Inc, Canada 
Classification3 IIb IIb IIb IIb IIb 
Frequency 
used (MHz) 
7.5 for imaging 
and 3 for 
treatment 
NA 6.3 for imaging 
and 4 for 
treatment 
2.34 Low frequency:  
4 to 4.8 
High frequency: 
13.4 to 14.45 
Imaging 
guidance 
Real time with 
ultrasound 
Pre-treatment 
MRI import and 
fusion with real-
time ultrasound 
Real time with 
ultrasound 
3 D visualisation 
Real time with 
MRI6 (1.5 T and 3 T) 
Real-time7 with 
MRI 
Mode of 
administration 
Transrectal Transrectal8 Transrectal Transrectal Transurethral 
Patient 
positioning 
Right lateral 
decubitus9 
Lateral8 Supine or 
lithotomy10 
Supine in a knee-
bent position11, 12 
or lithotomy13 
Supine14 or 
lithotomy 
Therapeutic 
transducer  
2 transducers:  
1 for imaging,  
1 for treatment 
Multielement 
transducer15 with  
1 treatment and  
1 ultrasound 
imaging probe16 
4 (2 for imaging,  
2 for treatment)17 
Moveable 
endorectal probe 
and focused 
ultrasound 
transducer18 
Array with 10 
transducers 
Abbreviations: MHz = megahertz, MRI = magnetic resonance imaging 
Sources: FDA, Profound Medical, FUS Foundation, USCF, HIFU-planet, European Urology, Radiology Key, Lindner [37], 
Yuh [26], HIFUprostateservices, Minogue Med, Gelet [38] 
                                                             
  3 According to MEDDEV 2. 4/1 Rev. 9 of the European Commission  
  4 https://radiology.ucsf.edu/mr-guided-focused-ultrasound-mrgfus-research-china-basin  
  5 http://www.profoundmedical.com/wp-content/uploads/2015/05/BrochureEmailable_PDF.pdf  
  6 https://dev.fusfoundation.org/news/1853-insightec-earns-ce-mark-for-prostate-cancer  
  7 https://dev.fusfoundation.org/news/1740-profound-earns-european-approval-for-prostate-device  
  8 http://www.specialiste-en-urologie.fr/wp-content/uploads/2015/04/Focal-One_Livret-Patient-148x210-V-FR_20140206.pdf  
  9 https://www.accessdata.fda.gov/cdrh_docs/pdf15/k153023.pdf  
10 https://radiologykey.com/high-intensity-focused-ultrasound-for-prostate-cancer/  
11 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788859/  
12 http://www.europeanurology.com/article/S0302-2838(12)01333-4/fulltext  
13 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529739/  
14 http://www.profoundmedical.com/new-tulsa/  
15 https://books.google.lt/books...  
16 http://www.minogue-med.com/focalone.html  
17 https://www.hifuprostateservices.com/sonablate-vs-ablatherm/ 
18 http://www.europeanurology.com/article/S0302-2838(12)01333-4/fulltext  
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Based on the ablation strategy approach we differentiate whole gland ablation 
and focal therapy.  
 Because of the often multi focal and multi clonal nature of PCa, whole 
gland treatment or ablation was considered standard.  
 Focal therapy is a tissue-preserving strategy to reduce treatment-relat-
ed toxicity by minimising the damage caused to the prostate and ad-
jacent tissues. Focal or targeted treatment is delivered only to the tar-
get, not the whole gland. This can be all tissue identified as cancerous, 
or that half of the gland, in which the biopsies were positive. Howev-
er, in cases with multifocal tumours, it is also possible to treat the only 
the index lesion (the largest lesion with the highest grade), or all le-
sions with intermediate or high risk cancer and leave low risk cancer 
lesions untreated [10].  
What is active surveillance (AS)? What is watchful waiting (WW)? 
Many men with localised PCa will not benefit from definitive treatment and 
are candidates for deferred treatment. AS and WW are the two strategies for 
conservative management that aim to reduce over-treatment. AS applies to pa-
tients with a life expectancy over ten years, and low-risk of developing PCa, 
whereas WW applies to patients with all stages, and a life expectancy of less 
than ten years [1].  
In AS the patients remain under close surveillance and treatment is started 
if they reach predefined thresholds that indicate relevant progression or po-
tential for a life threatening disease. Hence the correct timing for a curative 
treatment is aimed to be achieved [1].  
In WW the patients receive the palliative treatment when the disease-related 
complaints are developed, according to their symptoms, in order to maintain 
QoL [1].  
What is radical prostatectomy (RP)?  
RP means the removal of the prostate gland between the urethra and bladder, 
and resection of both seminal vesicles, along with sufficient surrounding tis-
sue to obtain negative margins. Often this procedure is accompanied by bi-
lateral pelvis node dissection, or so-called extended lymph node dissection. 
The goal of the procedure is to eradicate the disease, while preserving conti-
nence and if possible, potency. Patients should have at least ten years life ex-
pectancy to be offered this treatment [1]. Moreover, RP can be done laparo-
scopically, in open surgery or laparoscopically under the assistance of a sur-
gical robot. 
What is definitive radiotherapy (RT)?  
The goal of RT – either external beam RT (EBRT), brachytherapy or a com-
bination of both – in localised prostate cancer is to deliver a therapeutic dose 
of radiation to the tumour while minimizing the radiation to normal tissue. 
EBRT utilizes an external source of radiation to treat the prostate gland and 
a margin of adjacent normal tissue. Brachytherapy directly implants radio-
active source within the prostate, thus providing the highest dose of radiation. 
It is supposed to maximize irradiation of the tumour while minimizing radi-
ation to normal tissue [14]. In low-dose rate brachytherapy radioactive seeds 
are permanently implanted. It is widely used in combination with EBRT. 
High-dose rate brachytherapy means the temporary insertion of radioactive 
sources. It is used mainly in high-risk PCa [8]. 
Unterscheidung Ablation 
gesamte Prostata oder 
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wachsames Abwarten 
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Prostataentfernung 
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A0020 – For which indications has HIFU 
received marketing authorisation or CE marking? 
The CE mark has been awarded for the treatment of patients with primary 
localised PCa or locally recurrent PCa following prior therapy for the HIFU 
technology. The various HIFU systems and their regulatory status with the 
verbatim wording of the indications are presented in Table A-12 in the Ap-
pendix. Contraindications are also presented in Table A-12, described only 
for one device, Sonablate® 500. However, they are generalizable to all trans-
rectal HIFU devices.  
HIFU also received CE mark for various other indications including the treat-
ment of hypertension, thyroid nodules, soft tissue benign tumours, osteoid os-
teoma, facetogenic back pain, essential tremor, neuropathic pain, parkinsoni-
an tremor, glaucoma, breast fibroadenoma, uterine fibroids, uterine adenomy-
osis, bone metastasis and various cancer types (soft tissue, breast, pancreas, 
liver, kidney and soft tissue) [11].  
B0002 – What is the claimed benefit  
of HIFU in relation to AS, WW, RT, or RP? 
A major claimed benefit of HIFU is the lack of induction of apoptosis avoid-
ing late complications of treatment, a lack of cumulative effect with the pos-
sibility of repeating treatment [7]. It is claimed that HIFU treatment has sig-
nificantly lower side-effect profile (sexual and urinary dysfunction) [12], and 
reduces toxicity (due to less damage to the adjacent or intervening tissues) 
compared to other ablation techniques [10, 13].  
HIFU has the potential to ablate internal tumour tissue with great precision, 
and during treatment the tumour can be visualized [7]. HIFU is also able to 
treat only a small focus, hence the ablation of the entire gland can be spared 
and it is possible to ablate the targeted tissue or the index lesion only. Focal 
therapy enables the neurovascular bundle to be spared thereby reducing the 
risk of sexual dysfunction [5].  
Although AS and WW are options to avoid overtreatment and hence treatment-
related side effects, they may also carry an increased risk of psychological dis-
tress (anxiety, depression), which might considerably affect quality of life. 
Apart from psychological distress, untreated patients may have a higher level 
of obstructive urinary symptoms compared to patients treated with definitive 
therapies. Consequently, appropriate patient selection is a crucial issue [1, 5].  
B0003 – What is the phase of development and implementation of HIFU? 
The first description of HIFU about its ability to destroy tissue was made in 
1944, but the technology has been approved only recently for clinical indica-
tions. The first experiments on the prostate were made in the early 1990s. The 
first treatments in men were performed in 1992. The results of a pilot study 
on PCa treatment were first published in 1996. HIFU devices are available 
commercially since the early 2000s. The first two commercially available HIFU 
devices (Ablatherm® and Sonablate®) used ultrasound imaging guidance. Fo-
calOne® was the first device to implement MRI/TRUS image fusion to guide 
transrectal treatment. HIFU performed with real-time magnetic resonance 
tomography is the newest and most precise imaging to localise and ablate 
prostate cancer. In addition, this allows real-time temperature monitoring 
and visualization of treatment effects [7]. To date, there are two MRI-
guided HIFU systems which have CE mark, TULSA PRO® and ExAblate®.  
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Administration, Investments, personnel and tools  
required to use the technology and the comparator(s) 
B0004 – Who administers HIFU? In what context and level  
of care is HIFU provided? 
While a multi-specialist team is required to deliver the whole procedure, the 
urological surgeon performs the HIFU treatment itself. For image fusion, the 
radiologist is involved to perform pre-treatment MRI and provide image da-
ta required by the software of the HIFU system. If HIFU is performed under 
MRI guidance, the urological surgeon and the radiologist and their teams are 
working hand in hand. Internal technical support is needed to set up, tear-
down, and disinfect the system after the procedure. The manufacturers re-
quire that as part of the training of the surgeons a certain number of proce-
dures need to be done with the assistance of a supervisor/specialist. After-
wards the surgeon gets certified HIFU user and is able to use the device with-
out the assistance of the supervisor [39-41].  
Although HIFU can be delivered in a day-surgery setting, patients usually 
spend two to four days in the hospital due to local reimbursement practice and 
preoperative evaluation – as reported in one of the included studies conduct-
ed in Belgium [42], as well as in the topic submission to the Austrian Minis-
try of Health.  
B0008 – What kind of special premises are needed to use HIFU? and 
B0009 – What supplies are needed to use HIFU? 
HIFU treatment can be performed wherever the required resources (anaes-
thesia, power, internet, nursing, recovery room, etc.) are available [43]. It is 
usually done in a urological day-case suite with cystoscopy facilities, degassed 
water (<3 ppm oxygen) and nonsterile sheaths [8]. The required equipment 
depends on the type of device. The treatment table with the attached probe 
is part of the Ablatherm® device. The Sonablate® device has a probe holder 
which can be attached to any operating table; therefore the treatment can be 
done in any setting where an operating table is available. MRI-guided HIFU 
devices require MRI [7]. Most devices require few disposables, usually tub-
ing and covers, gels and fluids. 
 
Regulatory & reimbursement status  
A0021 – What is the reimbursement status of HIFU? 
Detailed information on the reimbursement status and recommendations are 
included in Table A-12 and Table A-13 in the Appendix.  
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4 Health Problem and Current Use 
Overview of the disease or health condition 
A0002 – What is clinically localised prostate cancer and locally 
relapsed/recurrent prostate cancer? 
Prostate cancer (PCa) is the most common non-skin cancer in men in Europe 
[1]. The malignancy usually originates from glandular epithelial cells, often 
multi focal and multi clonal. Depending on parameters such as tumour grade, 
tumour volume and PSA concentration at time of diagnosis, risk stratification 
is possible. Small low grade cancer is a frequent finding, and usually charac-
terized by slow local growth and the lack of metastasis. This type of tumour 
is named latent or clinically insignificant, because there is a low risk of pro-
gression. With increasing tumour grade, in particular, there is an increasing 
risk of progression. High-risk prostate cancer shows rapid local growth and a 
high likelihood of metastasis [2, 3, 44].  
In early stage, prostate cancer is localised and organ-confined [2]. Depend-
ing on the risk of progression, the cancerous lesion increases in volume and 
produces more PSA over time. PCa is called locally advanced when the can-
cer infiltrates the central or transitional zone of the prostate and adjacent tis-
sues and organs, depending on localisation of the initial lesion in the prostate. 
Depending on the risk of progression, the cancer can metastasize early or late, 
into regional or distant lymph nodes. Metastatic prostate cancer is also very 
likely to produce bone metastases with high variation in size and numbers, 
in any location [1, 45, 46]. 
High-risk PCa carries a high likelihood of early locally advanced stage and 
early metastasis. Therefore it is, in general, life-threatening and has a high 
rate of cancer-specific morbidity, in particular if diagnosed in younger men 
[47]. In contrast low risk prostate cancer, in particular in elderly men, most 
often can be left untreated. It might never cause  any problems or affect over-
all survival [27, 44]. Because risk stratification is based on biopsy findings, 
however, there is a risk of under or overestimation because of sampling error. 
During follow-up, a shift of grading can also occur [1, 48]. 
Recurrence of PCA can be local or due to metastasis. Locally relapsed/recur-
rent PCa occurs when the cancer is still present or comes back after failed 
primary therapy. After RP, if it was curative, there is no PSA. After RT, or 
any other procedure which leaves healthy or noncancerous prostatic tissue 
behind, PSA is still detectable, the lowest value during follow-up being named 
the nadir. After RT, any PSA above zero is a proof of recurrence or remaining 
prostate tissue, either locally or metastatic. In most cases, this is a sign the in-
itial tumour was understaged. After RT, the definition of recurrence is more 
difficult, and is based on increasing PSA in consecutive measures (Phoenix 
definition). Biochemical recurrence is a term at first used for patients after 
RP who had a nadir of zero, showed some PSA increase to a low value which 
stays on a low level during further follow-up, with no detectable lesion. The 
term biochemical recurrence is also used for recurrence after other therapies, 
usually with low tumour burden [49-53]. 
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A0003 – What are the known risk factors for prostate cancer? 
PCa can be divided into three groups: hereditary, familial, and sporadic. Pos-
itive family history is a strong epidemiological risk factor for prostate can-
cer. Gene-environment interactions also play a crucial role in cancer develop-
ment. Hereditary PCa is demonstrated only in 5% of cases with family histo-
ry, whereas familial prostate cancer accounts for about 13–25% of cases. He-
reditary PCa patients have three or more affected relatives or at least two re-
latives who have developed early-onset disease, i.e. before the age of 55, and 
have onset usually six to seven years earlier than spontaneous cases. Epide-
miologic studies have shown strong evidence for a genetic predisposition to 
PCa based on ethnic background too [1, 54].  
Exogenous factors may also affect the risk of progression from latent PCa to 
clinical PCa. These factors such as life-style (diet, sexual behaviour, alcohol 
consumption), exposure to ultraviolet radiation, chronic inflammation, and 
occupational exposure are all being considered aetiologically important [1]. 
A0004 – What is the natural course of prostate cancer? 
The natural history of PCa is not totally clarified yet. It might arise from 
damaged prostate epithelium and progressively develop over many decades, 
but its heterogeneity and multifocal nature makes it difficult to fully under-
stand its progression. About one-third of men over the age of 50 display his-
tological evidence of PCa. However, the majority of these cases remain clini-
cally insignificant. The likelihood of disease progression is difficult to predict. 
The progression of the disease is usually slow, nevertheless certain high-grade 
tumours proceed on a more aggressive course than low-grade, well-differen-
tiated tumours [44]. Nevertheless, PCa can lead to metastases and to death.  
 
Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of disease for the prostate cancer patient? 
The signs and symptoms of PCa are unspecific. In the age group affected by 
PCa, benign prostatic hyperplasia (BPH) and chronic prostatitis are com-
mon pre-existing comorbidities causing LUTS. Patients with the primary 
diagnosis of locally advanced or metastatic disease might suffer from symp-
toms of these conditions, such as haematuria, incontinence, urinary reten-
tion, uni- or bilateral hydronephrosis, urinary tract infection, skeletal pain 
at various locations. PCa (especially localised disease) is mostly diagnosed as 
a result of PSA screening, not based on the perceived symptoms. The symp-
toms of problems in the prostate may be like symptoms of PCA [55].  
Prostate cancer diagnosis and treatment could have a significant impact on a 
man’s life and cause physical problems such as sexual dysfunction and uri-
nary incontinence, fatigue, pain, hot flashes, body image changes, distant 
metastasis, lower back pain, weight loss, haematuria, anaemia, inability to 
walk and force lifestyle changes [56]. Failures to address physical and psy-
chosocial problems can result in suffering for both the patient and their fam-
ily, and potentially affect the course of the disease [57]. 
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A0006 – What are the consequences of prostate cancer for the society? 
PCa is the most common cancer in men in Europe and as life-expectancy in-
creases a subsequent rise in the incidence of PCa is expected along with an 
increase of the disease’s economic burden. There will also be an increased 
need for resources such as treatment facilities and trained specialists [27].  
The mean direct costs per patient for initial treatment for PCa were estimat-
ed at around EUR 2,800 in the UK, EUR 2,900 in Spain, EUR 3,600 in Ger-
many, EUR 4,650 in Italy, and EUR 5,200 in France. The total estimated costs 
for all patients in the first year from diagnosis, when the highest proportion 
of the costs occur, were estimated to be EUR 106 million in the UK, EUR 
223 million in Germany, and EUR 352 million in France. This does not in-
clude indirect costs, such as time and productivity loss (due to cancer-related 
illnesses, the impact of the physical and mental suffering of both patients and 
relatives during diagnosis and follow-up), or end-of-life costs [27]. It is esti-
mated that the total economic costs of PCa in Europe exceeded EUR 8.43 bil-
lion in 2009 [1]. 
 
Current clinical management of the disease or health condition 
A0024 – How is prostate cancer currently diagnosed according  
to published guidelines and in practice? 
PCa is suspected on the basis of digital rectal examination (DRE) and/or PSA 
levels; however definitive diagnosis is based on histopathological verification 
in prostate biopsy cores or specimen from transurethral resection of the pros-
tate (TURP) or prostatectomy for benign prostatic enlargement (BPE). The 
need for prostate biopsy depends on PSA level and/or suspicious DRE. Alt-
hough there is no general agreement on the benefit of PSA screening, and no 
general agreement on the cut-off value to perform a biopsy, it is obvious that 
higher PSA concentrations indicate a greater likelihood of a positive result, 
but not definitive sign for PCa [1].  
Clinical staging is used to stage PCa. It describes the extent of the primary 
tumour (T stage), the absence or presence of spread to nearby lymph nodes 
(N stage) and the absence or presence of distant spread, or metastasis (M 
stage) [1]: 
 T-staging: the first level of assessment is local tumour stage because the 
distinction between organ-confined T1/T2 and extraprostatic T3/T4 dis-
ease affects treatment decisions. DRE, imaging (transrectal ultrasound 
(TRUS), multiparametric magnetic resonance imaging (mpMRI)), PSA 
level and biopsy are tools to predict the final pathological stage of PCa. 
 N-staging: it should be performed only when it might directly influ-
ence treatment decisions. High PSA values, T2b-T3 stage, poor tumour 
differentiation and perineural invasion are associated with high risk 
of nodal metastasis. CT-scan or MRI is used to predict N-stage. 
 M-staging: evaluation of bone metastases of PCa using bone scan, PET/ 
CT or MRI.  
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Figure 4-1: TNM classification of prostate cancer 
Source: EAU-ESTRO-SIG Guidelines on Prostate cancer, 2016 [1] 
Diagnosis of disease recurrence 
Biochemical recurrence after curative primary treatment can be a sign of re-
lapse as it universally precedes progression. PSA, although often used as a 
tumour marker for metastatic disease or subsequent disease progression, is 
an imprecise marker of risk and PSA rise is not a surrogate for survival end-
points. Treatment failure defined by the PSA level differs between the prima-
ry treatment modality the patient received. Following primary RP, there is 
international consensus that recurrent cancer may be defined by two consecu-
tive PSA values of >0.2 ng/mL and rising. After primary RT, the Phoenix def-
inition of PSA failure is used which defines BCR as any PSA increase >2 ng/ 
mL higher than the PSA nadir value, regardless of the serum concentration 
of the nadir. To define BCR after primary HIFU the Stuttgart criteria (> PSA 
nadir + 1.2 ng/mL) was proposed by consensus groups [1].  
Once a PSA relapse is diagnosed, it is important to determine whether the 
recurrence developed at local or distant sites [1]. In the diagnosis of this mpMRI 
is the first step in current clinical practice and it should precede TRUS-guided 
biopsy, which should follow mpMRI for confirmation. Biopsies should be 
performed first only at least 24 months after primary therapy. Before con-
sidering any local salvage therapy, residual tumour must be demonstrated 
on histopathology. Once local recurrence is proven, further efforts are need-
ed to rule out metastasis [58].  
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Biochemical failure was defined according to the Stuttgart definition (a rise 
of 1.2 ng/ml or more above the nadir PSA) and the Phoenix definition (a rise 
of 2 ng/ml or more above the nadir PSA). 
A0025 – How is prostate cancer currently managed according to 
published guidelines and in practice? 
The factors which are considered in the selection of the initial treatment for 
newly diagnosed localised PCa patients are: 
 Anatomic extent of the disease (TNM stage), 
 Histologic grade (Gleason score) of the tumour, 
 Serum PSA level,  
 Estimated outcome with different treatment options, 
 Potential complications with each treatment approach, 
 The patient’s general medical condition, comorbidities, 
 The patient’s age and life expectancy, as well as  
 The individual patient preferences. 
Standard options for patients with clinically localised low-risk PCa: 
 Active surveillance (AS) 
 Radiation therapy (RT) 
 External beam (EBRT) or  
 Low-dose rate brachytherapy (LDRB) 
 Radical prostatectomy (RP) with optional lymph node dissection 
 (Other ablative techniques like cryotherapy and HIFU  
are not standard)  
Standard options for patients with clinically localised intermediate-risk PCa:  
 RT with optional androgen deprivation therapy (ADT) 
 EBRT or  
 High-dose rate brachytherapy (HDRB) or 
 Combination of EBRT and brachytherapy  
 RP with pelvic lymph node dissection  
 (Other ablative techniques like cryotherapy and HIFU  
are not standard)  
 Watchful waiting (WW) if the life expectancy is limited based  
upon age and comorbidities [14]. 
There are no standards for patient selection for salvage treatments; however 
most investigations include patients with biochemical recurrence, local dis-
ease and no metastasis and there are some further considerations which help 
in the treatment decision [49].  
 After failed RT: patients cannot be treated with additional radiation 
due to radiation toxicity. They either choose to undergo salvage RP or 
salvage HIFU. However, these patients often have contraindications 
for RP (that is the reason they opted for RT), meaning that salvage 
HIFU remains an option for them.  
 After failed RP: patients often cannot be treated with salvage RP due 
to technical constraints (for example in patients with positive mar-
gins), as well as imaging limitations which may not be able to identify 
residual sites of disease. For these reasons salvage RT and salvage 
HIFU remain options for them.  
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Treatment options for locally recurrent prostate cancer are: 
 Local salvage therapy:  
 RP 
 RT 
 (Other ablative techniques like cryotherapy and HIFU  
are not standard).  
 Systemic therapy: hormonal therapy (ADT) is only recommended to 
patients who have metastasis, PSA doubling time of <3 months, or 
have a symptomatic local disease progression [27]. Systemic therapy 
offer no prospect of cure, patients should fully explore curative salvage 
options before initiating systemic therapies [49].  
Considering only HIFU in the guidelines, the EAU guideline [1], along with 
the unique guidelines from selected European countries (Germany [28], Unit-
ed Kingdom [27]), as well as the American Urologists guideline [59] all rec-
ommend the use of HIFU only in the course of clinical trials as it is an ex-
perimental treatment (and the same applies for cryotherapy). Available guide-
lines on HIFU are provided in Table A-11 in the Appendix.  
 
Target population 
A0007 – What is clinically localised prostate cancer (cT1a-T2, N0-Nx, M0) 
and locally relapsed/recurrent prostate cancer (cT1a-T2, N0-Nx, M0)? 
The target population in this assessment is low-risk and intermediate-risk lo-
calised and locally recurrent/relapsed prostate cancer patients without any 
regional lymph nodes (NX-N0) and without any distant metastasis (MX-M0).  
 Low-risk is defined as PSA<10 ng/mL, Gleason Score (GS) <7 and 
cT1a-T2a.  
 Intermediate risk is defined as PSA 10-20 ng/mL, or GS 7, or cT2b [1].  
The reason for the choice of the target population is outlined in the Scope.  
A0023 – How many people belong to the low-intermediate-risk  
localised and locally relapsed/recurrent prostate cancer patients  
(cT1a-T2, N0-Nx, M0)? 
The incidence of PCa is higher in Northern and Western Europe (>200 per 
100,000 men), while rates in Eastern and Southern Europe have shown con-
tinues increase [60]. Incidence rates per country reported by the Internation-
al Agency for Research on Cancer (IARC) in 2014 were as high as 132 per 
100,000 men in France, around 100 per 100,000 in Belgium, Finland, Sweden, 
Switzerland and Lithuania, around 70 per 100,000 in Denmark, the Nether-
lands, Estonia, Italy, Spain and Portugal, and in Poland and Slovakia around 
35 per 100,000 men [4].  
A recent study [60] described a rapid increase in the incidence and a pro-
nounced peak in Austria in the last three decades. The annual average local-
ised PCa incidence in Austria is approx. 2,600 cases which is 58% of all PCa 
cases [61]. During the most recent decade, incidence rates increased the most 
in Lithuania with an average annual percent change of 19.3% and with the 
most rapid increase for ages <65 years [60].  
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Incidence rates of recurrent prostate cancer were not found. However, the 
proportion of patients who experience recurrence after primary RP and RT 
has been reported: 20–40% of patients after RP and 30–50% of patients un-
dergoing RT perceive biochemical recurrence within 10 years [3].  
A0011 – How much is HIFU utilised? 
Data is available for the two biggest manufacturers on approximate number 
of treated patients. Sonacare Medical’s Sonablate® is claimed to be used by 
over 300 physicians worldwide and over 15,000 procedures had been complet-
ed as of 2015 [34]. 
EDAP TMS’s three generations of commercial devices – Ablatherm® Maxis 
(from 1993 to 2005), Ablatherm® Integrated Imaging (since 2005) and Focal 
One® (since 2013) – are claimed to be routinely used for more than 20 years 
throughout the world with more than 40,000 treatments performed [62]. 
According to the information of the submitting hospital, total utilisation rate 
in Austria is unclear. In the submitting hospital (1,200 beds; 88,000 inpatients 
per annum), though, around 30 procedures are delivered annually. 
 
 
keine Daten zu Inzidenz 
Rezidivkarzinom 
15.000 Eingriffe  
mit Sonablate® 
40.000 Eingriffe  
mit Ablatherm® 
einreichendes 
Krankenhaus:  
30 Eingriffe pro Jahr 

 LBI-HTA | 2018 43 
5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Overall survival 
 Prostate cancer specific survival 
 Local disease recurrence 
The clinical outcomes chosen as critical to derive a recommendation are aim-
ing at the avoidance of the natural course of prostate cancer (see A0004). 
Overall survival is an outcome to measure how many of the treated patients 
survived. Ideally, this outcome should be collected after a longer period of 
time (e.g. after 5 or 10 years after the initial treatment). 
Prostate cancer specific survival is measuring how many patients survive and 
are not dying due to the prostate cancer (but maybe due to other causes, like 
age). Again, this outcome should also be collected after a longer period of 
time (e.g. after 5 or 10 years after the initial treatment). 
Local disease recurrence, though, is a measure of the return of the cancer. It 
can be measured, for example, by biopsy and/or multiparametric MRI.  
 
 
5.2 Included studies 
The inclusion criteria for assessing the clinical effectiveness of HIFU, was 
exclusively restricted to studies with a comparison group, including RCTs 
and non-RCTs. The systematic literature search identified one non-RCT 
(matched-pair analysis) that met our inclusion criteria. This study compared 
whole gland HIFU with brachytherapy, a type of radiotherapy for the treat-
ment of localised prostate cancer, including 70 patients in each treatment 
arm [19]. Study characteristics and results of included studies are displayed 
in Table A-1 and in the evidence profile in Table A-6. 
We could not identify any controlled trials comparing HIFU with other 
treatments, like deferred treatment (AS, WW) or RP (laparoscopic, open or 
robotic surgery) (see also Scope).  
Patient characteristics 
The median age of patients was 74 years in the HIFU-group and 69 years in 
the brachytherapy-group. Thus, patients in the intervention group were sta-
tistically significantly older than patients in the control group (p<0.01). 
Tumour stage was between T1a and T2b for all patients, whereas only 12 vs. 
9 patients had an intermediate-risk with stage T2b. The Gleason score was 6 
or below 6 in 72.9%, and it was 7 in 27.1% of the included patients in each 
arm. According to D’Amico, the study included only low and intermediate-
risk patients. A total of 19 patients in the HIFU-group and 14 patients in the 
brachytherapy-group received ADT therapy prior the actual treatment. The  
 
entscheidende 
Endpunkte für 
Wirksamkeit 
Auswahl basierend auf 
Abwendung Verlauf 
Erkrankung 
 
Gesamtüberleben, 
möglichst langfristig 
erheben 
 
Prostatakrebs-
spezifisches Überleben 
auch langfristig erheben 
 
lokale Rezidive,  
z. B. mittels Biopsie 
für Bewertung 
Wirksamkeit eine  
nicht-randomisierte 
kontrollierte Studie 
(matched-pair) zu HIFU 
vs. Brachytherapie 
keine Studien  
mit anderen  
Vergleichsinterventionen 
Durchschnittsalter  
74 vs. 69 Jahre 
 
Tumorstadium zwischen 
T1a und T2b 
 
Nachbeobachtung im 
Mittel 83 vs. 44 Monate 
High-intensity focused ultrasound for the treatment of prostate cancer 
44 LBI-HTA | 2018 
pre-HIFU prostate volume and PSA level were not stated. The median fol-
low-up was 83 months for the HIFU-group and 44 months for the brachy-
therapy-group (difference was statistically significant, p<0.01).  
HIFU procedure and follow-up  
HIFU treatment was performed by the use of the Ablatherm® device. How-
ever, the first series of patients was treated with Ablatherm® Maxis, which is 
not commercially available anymore [62]. The second series was treated with 
Ablatherm® Integrated Imaging. The control group was treated by a perma-
nent transperineal interstitial preloaded-free needles implantation of Iode125 
using a real-time biplanar ultrasound-guided system [19]. 
 
 
5.3 Results 
D0001 – What is the expected beneficial effect of HIFU on mortality? 
Two outcomes were considered relevant to assess the expected beneficial ef-
fect of HIFU on mortality: overall survival and prostate cancer specific sur-
vival. After five years, overall survival in the brachytherapy-group compared 
to HIFU was not significantly different (88 vs. 97.5%, HR 0.24, CI 0.01-1.34) 
[19]. 
Regarding prostate cancer specific survival, after five years, the rate was 89% 
for patients in the HIFU-group and 92% for patients in the brachytherapy-
group. Even though the rate was higher for patients treated with brachythera-
py, the difference between the study groups was not significant (HR 0.67, 
CI 0.32-1.29) [19].  
 
Morbidity 
D0005 – How does HIFU affect symptoms and findings (severity, 
frequency) of clinically localised and locally recurrent prostate cancer? 
and 
D0006 – How does HIFU affect progression (or recurrence)  
of clinically localised prostate cancer? 
Biochemical recurrence-free survival was considered eligible to answer this 
research question. This outcome (a surrogate and not to be mistaken for “lo-
cal disease recurrence”) was significantly lower for patients in the HIFU-
group than for patients in the control group: 53.1 vs. 68.5 % according to the 
Phoenix and 51.3 vs. 60.9 % according to the Stuttgart definitions (HR 0.41, 
CI 0.19-0.81 for Phoenix, HR 0.39, CI 0.19-0.74 for Stuttgart, p<0.05 for both) 
[19]19.  
However, the study did not report on additional outcomes that are suitable 
to answer this research question: need for salvage/systemic therapy, ablation 
failure, distant disease recurrence/metastases or disease progression/patho-
logical progression or the critical outcome “local disease recurrence”. 
 
                                                             
19 Phoenix criteria: PSA nadir +2ng/mL; Stuttgart criteria: PSA nadir +1.2 ng/mL). 
See also chapter 4, question A0024 
HIFU mittels 
Ablatherm® 
Gesamtüberleben 88 vs. 
97,5 %, Unterschied 
nicht signifikant 
krebsspezifisches 
Überleben: 89 vs. 92 %, 
Unterschied nicht 
signifikant 
biochemisches rezidiv-
freies Überleben:  
mittels HIFU  
signifikant niedriger 
keine Evidenz zu 
anderen Endpunkten 
(z. B. zu Bildung von 
Rezidiven oder 
Metastasen) 
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Function 
D0011 – What is the effect of HIFU on patients’ body functions? and 
D0016 – How does the use of HIFU affect activities of daily living? 
These two research question will be answered in the next chapter, by present-
ing the functional outcomes on urinary and sexual (dys)functions (see research 
question C0008). 
 
Health-related quality of life 
D0012 – What is the effect of HIFU on  
generic health-related quality of life? and 
D0013 – What is the effect of HIFU on disease-specific quality of life? 
No evidence was identified to answer this research question.  
 
Patient satisfaction 
D0017 – Were patients satisfied with the use of HIFU ? 
No evidence was identified to answer this research question.  
 
 
Beantwortung im 
nächsten Kapitel 
keine Evidenz 
keine Evidenz 
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Urinary (dys)function which was defined as the loss of continence 
(measured with the number of patients with new onset leakage or who 
started to use pads, or physician reported events), or as worsening of 
urinary symptoms (measured with the International Prostate Symp-
tom Score (IPSS), which is based on the answers to seven questions 
concerning urinary symptoms (frequency, emptying, intermittency, ur-
gency, weak stream, straining, nocturnia) and one question concern-
ing quality of life. Each question concerning urinary symptoms allows 
the patient to choose one out of six answers indicating increasing se-
verity of the particular symptom. The answers are assigned points from 
0 to 5. The total score can therefore range from 0 to 35 (asymptomatic 
to very symptomatic)) [63]. 
 Sexual (dys)function which was defined as the loss of erectile function 
(reported as number of patients with new onset of impotence) or wors-
ening of erectile function (decrease in the IIEF-5, IIEF-15, or BMSFI 
score. IIEF-5 is used to diagnose the presence and severity of erectile 
dysfunction (ED). The questions are focused on erectile function and 
intercourse satisfaction. The possible scores for the IIEF-5 range from 
5 to 25, and ED was classified into five categories based on the scores: 
severe (5-7), moderate (8-11), mild to moderate (12-16), mild (17-21), 
and no ED (22-25)) [64]. 
 Serious adverse events/procedural complications: grade 3-4 adverse 
events according to Clavien-Dindo classification. In Clavien-Dindo risk 
classification there are four risk categories (Grade 1, 2, 3, 4) where 1 
represents any deviation from the normal intraoperative or postoper-
ative course, including need for pharmacologic treatment other than 
antiemetics, antipyretics, analgesics, diuretics, electrolytes, or physio-
therapy; grade 2 represents complications needing only the use of in-
travenous medications, total intravenous nutrition, or blood transfu-
sion; grade 3 complications are those where surgical, endoscopic or 
radiologic intervention under local or general anaesthesia is needed; 
whereas grade 4 complications are life-threatening and require inten-
sive care unit management [24]. 
 
  
entscheidende 
Endpunkte für 
Sicherheit: 
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6.2 Included Studies 
Primary HIFU 
Study characteristics 
The single-arm primary HIFU studies [20-23] reported on a total of 279 pa-
tients treated with Ablatherm®, originating from France, Germany and Bel-
gium. The matched-pair analysis [19] study reported on 70 patients treated 
with the Ablatherm® HIFU device and 70 patients treated with brachythera-
py in Belgium.  
Patient characteristics 
Mean patient ages ranged between 63.4 and 73 years in the single arm stud-
ies [20-23]. The median patient ages were 74 years in the HIFU group and 69 
years in the brachytherapy group in the matched-pair analysis [19]. Tumour 
stage T1-T2 was reported in two single-arm studies (in one study 16 patients 
had T1 and 34 T2, in the other study 77 had T1 and 33 had T2) [22, 23] and 
in the matched-pair analysis [19], two studies did not report the tumour stage 
[20, 21]. The Gleason score for HIFU-patients was 6 or below 6 in 221 (60%) 
of the included patients, 7 in 85 patients (23%) and unknown for the rest of 
the patients (one study [21] stated only the number of patients with Gleason 
Score 7 and that the median was 6). All four single-arm studies and the 
matched-pair analysis included only low-and intermediate-risk patients. The 
single-arm studies did not report on the percentage of patients who received 
ADT therapy before HIFU, however, one study [21] excluded patients with 
previous ADT according to the study’s exclusion criteria. The matched-pair 
analysis [19] reported that 27% of HIFU patients received ADT before treat-
ment, whereas 20% of brachytherapy patients received ADT. Mean pre-HIFU 
PSA level ranged between 6.2 and 6.6 ng/mL (one study [20] reported the me-
dian which was 6.1 ng/mL) in the single-arm studies and it was not reported 
in the matched-pair analysis (only the number of patients below 10 and be-
tween 10 and 20 ng/mL). The mean pre-HIFU prostate volume ranged be-
tween 31 and 39.3 mL in the single-arm studies and it was not reported in 
the matched-pair analysis.  
HIFU procedure and follow-up 
All studies used the Ablatherm® device in the procedure, except for one [21], 
which used both Ablatherm® and the newer device from the same manufac-
turer, FocalOne®. Hemiablation was applied in the single-arm studies [20-
23], whereas the matched-pair analysis [19] applied whole gland ablation of 
the prostate. Only one study [22] reported on TURP performed prior to or in 
combination with HIFU. This study reported that 60% of patients had TURP 
prior or in combination with HIFU treatment due to large prostate volume. 
The duration of the treatment was reported in two studies [20, 21] mean treat-
ment time was 62.2 minutes in one study [21] and an average of 120 minutes 
in the other study [20]. Catheterisation time was also reported in two studies 
[21, 23] and ranged between 2.8 and 2.9 days. The mean follow-up ranged be-
tween 17.41 and 39 months (one study [20] did not report mean follow-up time, 
but median which was 12 months) in the single-arm studies. The median fol-
low-up was 83 months in the HIFU group and 44 months in the brachythera-
py group in the matched-pair analysis. The number of treatment per patient 
was reported in two studies [21, 22] and was comparable within the studies, 
90% had only one intervention and around 10% had two HIFU treatments. 
vier unkontrollierte 
Studien mit  
279 Patienten,  
1 kontrollierte Studie 
mit je 70 Patienten 
in Fallserien: 
Durchschnittsalter  
63-73 Jahre, 
Tumorstadium T1-T2, 
Prostatavolumen  
31-39 ml 
 
in kontrollierter Studie:  
Durchschnittsalter  
74 vs. 69 Jahre, 
Tumorstadium zwischen 
T1a und T2b 
HIFU mittels 
Ablatherm®, in einer 
Studie auch FocalOne® 
 
Nachbeobachtung in 
Fallserien im Mittel  
17-39 Monate, in 
kontrollierter Studie  
83 vs. 44 Monate 
Safety 
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Study characteristics and results of included studies are displayed in Table 
A-2 and in the evidence profile in Table 7-1.  
Salvage HIFU 
Study characteristics 
The study on salvage HIFU [24] reported on 84 patients treated with the Son-
ablate® device in the United Kingdom and Canada. Whole-gland ablation was 
applied.  
Patient characteristics 
The mean age of patients was 68.3 years, the tumour stage and risk catego-
ries were not reported, but according to the inclusion criteria it was lower 
than T3a. A total of 30 patients (36%) received neoadjuvant ADT before the 
salvage treatment with HIFU. The median Gleason Score was 7, ranging be-
tween 6 and 7. All patients failed after EBRT, according to the inclusion cri-
teria. The mean pre-HIFU PSA level was 5.7 ng/mL. Mean pre-HIFU prostate 
volume was 25.1 mL [24].  
HIFU procedure and follow-up 
The Sonablate® 500 device was used to deliver the treatment. The mean fol-
low-up was 19.8 months. The treatment duration time was available for 40 pa-
tients and it was 158 minutes with a mean of 1.4 days of hospital stay. Over 
90% of the patients (78) were treated with one salvage HIFU intervention 
and 7% (6 patients) had two salvage HIFU treatments [24].  
Study characteristics and results of included studies are displayed in Table 
A-3 and in the evidence profile in Table 7-2.  
 
 
6.3 Results 
Patient safety 
C0008 – How safe is HIFU in comparison to AS, WW, RT, RP? 
Comparative study 
The only available evidence which compared HIFU with any of the compar-
ators was the matched-pair analysis that compared whole-gland HIFU to 
brachytherapy, as described above [19].  
Intervention-related death 
No intervention-related deaths occurred in any of the groups. 
Urinary (dys)function 
Urinary dysfunction showed no significant difference in HIFU-patients com-
pared to patients who received brachytherapy (occurred in 7.2% of patients 
in the HIFU group and 3.8% in the brachytherapy group, p=0.44). 
Sexual (dys)function 
Erectile dysfunction was reported only for the HIFU-group (and for patients 
who were preoperatively potent) and occurred in 5 patients (11.6%). 
Studiencharakteristika 
und Ergebnisse in 
Tabellen 
eine Studie mit  
83 Pateinten 
Durchschnittsalter  
68 Jahre, 
Prostatavolumen 25 ml 
Sonablate® 
Nachbeobachtung im 
Mittel 20 Monate 
Studiencharakteristika 
und Ergebnisse in 
Tabellen 
HIFU im Vergleich zu 
Brachytherapie: 
keine Interventions-
bedingte Mortalität 
keine signifikanten 
Unterschiede bei 
Blasenfunktions-
störungen 
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Adverse events 
The most frequent adverse events reported were urinary retention, urinary 
tract infection, urethral stricture, and storage and voiding LUTS. Urinary re-
tention and urethral stricture (particularly in patients treated with the first 
generation device) were significantly higher in the HIFU cohort compared 
to the brachytherapy cohort (p=0.02 resp. p ≤ 0.01). Urinary tract infection 
and storage and voiding LUTS were the most frequent early and late post-
operative complications with no statistically significant difference across the 
two cohorts (p=0.07 resp. p=1). Serious adverse events that required surgi-
cal or endoscopic treatment occurred in the form of fistulas and haemorrhagic 
cystitis: one patient per each cohort developed rectourethral fistula, which was 
managed surgically. One patient in the brachytherapy cohort had haemor-
rhagic cystitis managed by endoscopic fulguration.  
When comparing the severity of adverse events, the rate of grade 3 adverse 
events was higher for HIFU patients than for patients treated by brachy-
therapy (35% vs. 13%, see also Table 6-1). Especially acute urinary retention 
and stricture occurred more often in the HIFU-group than in the brachyther-
apy-group (more than 20% vs. less than 6% each). However, information on 
statistical significance was not provided [19]. 
We found no comparative evidence on HIFU in relation to other treatment 
options, such as RP, AS, and WW.  
Single-arm observational studies 
All four single-arm studies on primary HIFU applied hemiablation [20-23]. 
The study on salvage HIFU [24] applied whole-gland ablation.  
Intervention-related mortality 
No intervention-related deaths occurred in any of the studies. 
Urinary (dysfunction) 
Urinary symptoms with the IPSS score were reported in three studies of which 
two studies [20, 21] concluded that there was no significant change in urinary 
function (even without TURP) as there was no change in mean IPSS score 
from baseline post-HIFU to 3-12 months follow-up visit, and one study [22] 
concluded that there was a significant improvement in the IPSS score from 
baseline to 12 months post-intervention (95% CI: 1.6; 4.4). The study on sal-
vage HIFU [24] did not show any significant effect on the IPSS score 6 months 
post-interventional (p=0.06). Urinary incontinence was reported using phy-
sician reported events and number of patients who started using pads. One 
study [23] reported that all patients were continent pre-HIFU and three pa-
tients (6%) were incontinent at 12 months follow-up. Three studies measured 
incontinence with usage of pads [20-22] of which two studies [21, 22] had a 
follow-up of 12 months and both reported that one patient was incontinent 
pre-HIFU and three (3% resp. 5.9%) patients had persistent incontinence at 
12 month follow-up. One study [20] reported that none of the patients had in-
continence at follow-up, but the month of the follow-up was not reported).  
Harnretention und 
Harnröhrenstriktur 
signifikant häufiger  
bei HIFU 
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Sexual (dys)function 
All four single-arm primary HIFU studies reported on erectile dysfunction 
using the IIEF-5 scale, physician reported rates or both. Three studies [20-
22] used the IIEF-5 scale of which two [20, 21] showed a significant negative 
impact on erectile function 3-12 months after HIFU (p<0.001). Two studies 
using physician reported rates identified 20-22% de novo erectile dysfunction 
in pre-intervention potent patients, whereas one study [20] reported that 
nearly 48% of previously potent patients became impotent post-intervention 
(none of the studies reported the time point when this was measured). The 
study on salvage HIFU [24] also reported a significant negative effect on the 
sexual function based on the IIEF-5 scores 6 months after the intervention 
(p<0.001).  
Adverse events 
The most frequent adverse events reported in the single-arm studies [20-23] 
were: urinary tract infection, dysuria, anejaculation, pain and urinary reten-
tion. Additionally, in the study on salvage HIFU [24] bladder outlet obstruc-
tion and rectal fistula were common adverse events. Compared to the matched-
pair analysis [19], the rate of storage or voiding LUTS [22, 23] (grade 1 com-
plication), acute urinary retention [20, 22, 23] and stricture [21-23] (grade 3 
complications) was considerably lower in the single-arm studies. Rectal fis-
tula (grade 3 complication) occurred only in the matched-pair analysis [19] 
and in the study on salvage HIFU [24], which both applied whole-gland ab-
lation. Bladder outlet obstruction, another grade 3 complication, was observed 
only in the study on salvage HIFU [24] with a rate of 20%. Grade 4 compli-
cations did not occur in any of the primary HIFU studies, but three such 
complications were observed in the study on salvage HIFU [24]. The adverse 
events are presented in Table 6-1 categorized per study and severity. 
C0002 – Are the harms related to dosage or frequency of applying HIFU? 
No evidence was found on the relation of the dosage or frequency to the harms 
associated with both primary and salvage HIFU. 
C0004 – How does the frequency or severity  
of harms change over time or in different settings? 
One single arm study [20] reported that all complications were encountered 
within the first postoperative month. Another single-arm study [23] and the 
matched-pair analysis [19] did not report when the complications occurred 
first, but reported that seven, respectively one patient after HIFU had tran-
sient incontinence during follow-up. This transient incontinence was self-re-
solving in three of the seven patients in the single-arm study and for the one 
patient in the matched-pair analysis at 12 months postoperatively. These com-
plications were likely to occur shortly after treatment and were only tempo-
rary in most of the patients. The matched-pair analysis [19] reported that stor-
age and voiding LUTS developed immediately after the intervention and that 
these symptoms were generally mild and self-resolving after several months. 
Three months postoperatively HIFU was more associated with voiding LUTS 
whereas brachytherapy was more associated with storage LUTS.  
 
alle Fallserien zeigten 
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C0005 – What are the susceptible patient groups  
that are more likely to be harmed through the use of HIFU? 
No evidence was found on the patient groups that are more likely to be harmed 
through the use of HIFU.  
C0007 – Is HIFU associated with user-dependent harms? 
The included studies did not report explicitly on user-dependent harms. One 
study [19] stated that the technical improvements with the introduction of 
the new Ablatherm® device and the changes in surgical protocol have lowered 
the high rate of urinary tract infection and bladder outlet obstruction encoun-
tered at earlier HIFU interventions. The incidence of rectal fistula has low-
ered in the last decade which is mainly due to the fact that rectal bleeding 
has been managed better [19]. This is also underlined by the study on sal-
vage HIFU [24] which reported rectourethral fistula occurred early in the 
learning curve in the first 20 cases.  
 
Investments and tools required 
B0010 – What kind of data/records and/or registry  
is needed to monitor the use of HIFU? 
No evidence was found to answer this research question. 
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Table 6-1: Frequency and severity of adverse events 
Clavien-Dindo grade class/ 
adverse events 
Adverse event  
with HIFU n (%) 
Primary HIFU study  
with control group 
Primary HIFU studies  
without control group 
Salvage HIFU study 
without control group 
Aoun, 2015 [19] Van Velthoven, 
2016 [23] 
Rischmann,  
2017 [22] 
Ganzer,  
2017 [21] 
Feijoo,  
2015 [20] 
Uddin Ahmed,  
2012 [24] HIFU brachytherapy 
Number of patients with available data on adverse events 70 70 50 105 21 67 84 
Grade 1  Primary HIFU: 108/313 (34.5) 
s-HIFU: 27/84 (32.1) 
29 (41.4) 20 (28.6) 79 (32.5) 27 (32.1) 
Urge incontinence 4/105 (3.8) - - - 4 (3.8) - - - 
Dysuria 18/126 (14.3) - - - 17 (16.2) 1 (4.7) - - 
Storage or voiding LUTS 42/225 (18.7) 26 (37.120) 20 (28.6)20 9 (18) 7 (6.7) - - - 
Hematospermia 2/105 (1.9) - - - 2 (1.9) - - - 
Aspermia 1/21 (4.7) - - - - 1 (4.7) - - 
Anejaculation 17/126 (13.6) - - - 16 (15.2) 1 (4.7) - - 
Anal and perineal pain 15/196 (7.6) 3 (4.3) 0 - 10 (9.5) 2 (9.5) - - 
Hematuria 4/21 (19) - - - - 4 (19) - - 
Urine retention 5/21 (23.8) - - - - 5 (23.8) - - 
Grade 2 Primary HIFU: 106/313 (33.7) 
s-HIFU: 10/84 (11.9) 
36 (51.4) 24 (34.2) 70 (28.8) 10 (11.9) 
Thromboembolic disease 
(phlebitis) 
2/105 (1.9) - - - 2 (1.9) - - - 
Urge incontinence 2/21 (9.5) - - - - 2 (9.5) - - 
Storage or voiding LUTS 21/70 (30) 21 (30)20 18 (25.7)20 - - - - - 
Urinary tract infection  49/313 (15.6) 15 (21.4) 5 (7.1) 3 (6) 18 (17.1) 9 (42.9) 4 (6) - 
Orchitis 8/105 (7.6) - - - 8 (7.6) - - - 
Prostatitis 8/105 (7.6) - - - 8 (7.6) - - - 
Hematuria  5/105 (4.7) - - - 5 (4.7) - - - 
Chronic urine retention  11/222 (4.9) - - 4 (8) 3 (2.8) - 4 (6) - 
Gastrointestinal toxicities 0/70 (0) 0 (0) 1 (1.4) - - - - - 
                                                             
20 LUTS includes also hematuria. 
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Clavien-Dindo grade class/ 
adverse events 
Adverse event  
with HIFU n (%) 
Primary HIFU study  
with control group 
Primary HIFU studies  
without control group 
Salvage HIFU study 
without control group 
Aoun, 2015 [19] Van Velthoven, 
2016 [23] 
Rischmann,  
2017 [22] 
Ganzer,  
2017 [21] 
Feijoo,  
2015 [20] 
Uddin Ahmed,  
2012 [24] HIFU brachytherapy 
Grade 3 Primary HIFU: 50/313 (16) 
s-HIFU: 52/84 (61.9) 
35 (50) 9 (12.9) 15 (6.2) 52 (61.9) 
Storage or voiding LUTS 0/70 (0) 0 (0) 1 (1.4)20 - - - - - 
Acute urinary retention 27/292 (9.2) 16 (22.8) 4 (5.7) 4 (8) 5 (4.7) - 2 (3) - 
Stricture 21/246 (8.5) 17 (24.3) 2 (2.8) 2 (4) 1 (1) 1 (4.7) - - 
Rectal fistula 5/154 (3.2) 1 (1.4) 1 (1.4) - - - - 4 (4.8) 
Gastrointestinal toxicities 1/70 (1.4) 1 (1.4) 1 (1.4) - - - - - 
Bladder outlet obstruction 17/84 (20.2) - - - - - - 17 (20.2) 
Grade 4 Primary HIFU: 0 
s-HIFU: 3/84 (3.5) 
- - 0 0 0 0 3 (3.5) 
Total adverse events n (%) Primary HIFU: 254/313 (81.1) 
s-HIFU: 92/84 (109) 
9021 (128) 5921 (84.3) 22 (44) 10621 (109) 2621 (123) 10 (15) 92 (109) 
Total deaths n (%) 0 0 0 0 0 0 0 0 
Abbreviations: LUTS = lower urinary tract symptoms, s-HIFU = salvage high-intensity focused ultrasound 
Sources: [19-24] 
Clavien-Dindo risk classification  
Grade 1: any deviation from the normal intraoperative or postoperative course, including need for pharmacologic treatment other than antiemetics,  
antipyretics, analgesics, diuretics, electrolytes, or physiotherapy; 
Grade 2: complications needing only the use of intravenous medications, total intravenous nutrition, or blood transfusion; 
Grade 3: complications where surgical, endoscopic or radiologic intervention under local or general anaesthesia is needed; 
Grade 4: complications that are life-threatening and require intensive care unit management [24] 
 
 
                                                             
21 The study reported a higher number of total adverse events than the total number of patients. 
 LBI-HTA | 2018 55 
7 Quality of evidence 
RoB for individual studies was assessed with the IHE-20 checklist and ROB-
INS-I and is presented in Table A-5, respectively Table A-4 in the Appendix. 
The overall quality of the studies was very low.  
The strength of evidence was rated according to GRADE (Grading of Rec-
ommendations Assessment, Development and Evaluation) Schema [18] for 
each endpoint individually. Each study was rated by two independent re-
searchers. In case of disagreement a third researcher was involved to solve the 
difference. A more detailed list of criteria applied can be found in the recom-
mendations of the GRADE Working Group [18].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that  
of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in the summary of findings table below and in the evidence profile 
in Appendix Table A-6. 
Overall the strength of evidence for the effectiveness and safety of primary 
HIFU in comparison to brachytherapy is very low. The strength of evidence 
for the safety of primary HIFU, as well as for salvage HIFU is very low.  
No evidence was available for the comparison of primary HIFU and AS, 
WW or RP, as well as for the comparison of salvage HIFU and AS, WW, sal-
vage RP or salvage RT.  
 
 
Bias-Risiko mittels 
Checklisten 
Qualität der Evidenz 
nach GRADE 
Evidenzstärke  
sehr gering 
keine Evidenz zu 
anderen Vergleichen 
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Table 7-1: Summary of findings table of primary HIFU 
 
Outcome 
Anticipated absolute effects  
Relative effect 
(95% CI) 
Number of 
participants  
(studies) 
Quality Comments 
Risk with HIFU 
Risk with 
Radiotherapy Difference 
EFFICACY 
Overall survival rate 
Follow up: 5 years  
574 per 1,000 971 per 1,000 397 fewer per 1,000 
(20 more to  
936 fewer) 
HR 0.24  
(0.01 to 1.34) 
140 
(1 CT) 
⨁⨀⨀⨀ 
VERY 
LOW22,,23 
Overall survival was 
lower (but not 
significantly) for HIFU. 
Prostate cancer specific survival rate  
Follow up: 5 years 
807 per 1,000 914 per 1,000 397 fewer per 1,000 
(20 more to  
936 fewer)) 
HR 0.67  
(0.32 to 1.29) 
140 
(1 CT) 
⨁⨀⨀⨀ 
VERY  
LOW22, 23 
Prostate cancer specific 
survival rate was lower 
(but not significantly) 
for HIFU. 
Local disease recurrence - - - - - - Outcome not reported. 
SAFETY 
Intervention specific mortality 
(comparative) 
Follow up: median 83 vs. 44 months 
0 per 1,000 0 per 1,000 0% fewer/more Not estimable 140 
(1 CT) 
⨁⨀⨀⨀ 
VERY  
LOW22, 23, 24 
There was no 
intervention specific 
mortality. 
Intervention specific mortality 
(single-arm) 
Follow up: mean 16.3 vs. 44.5 months 
See comment. Not estimable 279 
(4 observational 
studies) 
⨁⨀⨀⨀ 
VERY  
LOW25, 26, 27 
There was no 
intervention specific 
mortality. 
Functional outcomes: urinary 
(dys)function (comparative) 
Assessed with: physician reported rate 
Follow up: median 83 vs. 44 months 
72 per 1,000 38 per 1,00028 34 more per 1,000 
(14 fewer to 359 more)  
RR 1.92 (0.39 
to 9.51)28 
122 
(1 CT) 
⨁⨀⨀⨀ 
VERY  
LOW23, 29 
Urinary dysfunction 
was higher (but not 
significantly) for HIFU. 
                                                             
22 Risk of bias for this endpoint was considered high due to the difference in age between study groups (see also risk of bias assessment of study). 
23 Indirectness was set “serious” for this endpoint, since this study was claimed to be the first to compare patients treated by HIFU and brachytherapy.  
Furthermore, in this study two generations of Ablatherm devices were used, whereas Ablatherm Maxis is not commercially available anymore.  
Moreover, there was no information provided on additional treatments and pre-treatment prostate volume. 
24 Imprecision was set “serious” for this particular endpoint, since the probability of intervention-specific mortality is estimated to be low and  
patient number must be higher to detect differences. 
25 Risk of bias for this particular outcome was set high due to study design (no control group).  
26 Indirectness for this particular outcome was set serious because the studies can only yield indirect evidence regarding the safety of HIFU compared  
to standard therapies as there was no control arm (safety outcomes could only be compared to historical controls). 
27 Imprecision for this particular outcome was set serious due to the low sample size.  
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Outcome 
Anticipated absolute effects  
Relative effect 
(95% CI) 
Number of 
participants  
(studies) 
Quality Comments 
Risk with HIFU 
Risk with 
Radiotherapy Difference 
Functional outcomes: urinary 
(dys)function (single-arm)  
Assessed with: IPSS score, usage of pads 
Follow up: 3-12 months  
Mean difference in the IPSS score in 1 study was 3 (95% CI 1.6; 
4.4), 2 studies showed no significant difference. 
0.7% (0 to 2%) of patients pre-HIFU were incontinent 
(used pads) and 3.3% (0 to 6%) of patients were 
incontinent post-HIFU (2.6% (0 to 6%) more  
patients were incontinent)  
- IPSS: 198  
(3 observational 
studies) 
Usage of pads: 270  
(4 observational 
studies) 
⨁⨀⨀⨀ 
VERY  
LOW25, 26, 27, 30 
There may be little or 
no difference in the 
urinary function 
characterized by the 
usage of pads or by  
the IPSS score.  
Functional outcomes: sexual 
(dys)function (comparative) 
Assessed with: physician reported rate 
Follow up: median 83 vs. 44 months 
116 per 1,000 
(11.6%) 
NA - Not  
estimable 
43 
(1 CT) 
⨁⨀⨀⨀ 
VERY LOW31, 32 
Sexual dysfunction was 
only reported for 
HIFU-patients. 
Functional outcomes: sexual 
(dys)function (single-arm) 
Assessed with: IIEF-5 score, de novo 
erectile dysfunction  
Follow up: 3-12 months 
Mean difference in the IIEF-5 score in 1 study was 1.2  
(95% CI -0.4; 2.7), 2 studies showed significant difference 
(pre-HIFU score of 17.6 to 17.97 and post-HIFU score of 
13.6 to NA, p<0.001) 
De novo erectile dysfunction ranged from 20% to 47.6% 
of pre-HIFU potent patients. 
- De novo erectile 
dysfunction: 122  
(3 observational 
studies) 
IIEF-5: NA (3 
observational studies) 
⨁⨀⨀⨀ 
VERY  
LOW25, 26, 27, 33 
HIFU may increase the 
rate of de novo erectile 
dysfunction.  
HIFU may worsen 
sexual function.  
Serious adverse events (SAEs) 
(comparative) 
Assessed with : number of events 
Follow up: mean 12 months 
Overall SAEs: 17 vs. 5 (in 70 patients each) Not  
estimable 
140 
(1 CT) 
⨁⨀⨀⨀ 
VERY  
LOW23, 34, 35 
In the HIFU group  
17 SAEs occurred in  
70 patients and in the 
radiotherapy group  
5 SAEs occurred in  
70 patients. 
                                                                                                                                                                                                                                                                                   
28 Caclulated with MedCalc© (http://www.medcalc.org/calc/relative_risk.php). 
29 Risk of bias for this particular endpoint was set "serious", due to the difference between study groups in age and length of follow-up (see also risk of bias assessment of study). 
Furthermore, it was not stated how many patients suffered from incontinence before the interventions. 
30 There is inconsistency in the results of IPSS cores as two studies reported no significant change in the score, while one study reported a significant mean decrease (meaning 
improvement) in the score. 
31 Risk of bias for this particular endpoint was set high, due to the difference between study groups in age and length of follow-up (see also risk of bias assessment of study). 
Furthermore, maesurement of sexual (dys) function was exclusively done for HIFU-patients. 
32 Indirectness cannot be assessed, because study exclusively reported sexual (dys)function for HIFU-patients.  
33 Inconsistency was set serious as two studies reported around 20% of pre-HIFU potent patients being post-HIFU impotent, while one study reported over 47% of pre-HIFU potent 
patients being post-HIFU impotent. 
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Outcome 
Anticipated absolute effects  
Relative effect 
(95% CI) 
Number of 
participants  
(studies) 
Quality Comments 
Risk with HIFU 
Risk with 
Radiotherapy Difference 
Serious adverse events (SAEs) 
(comparative) 
Assessed with : number of events 
Follow up: median 83 vs. 44 months 
Overall SAEs: 18 vs. 4 (in 70 patients each) Not  
estimable 
140 
(1 CT) 
⨁⨀⨀⨀ 
VERY  
LOW23, 34, 35 
In the HIFU group  
18 SAEs occurred in  
70 patients and in the 
radiotherapy group  
4 SAEs occurred in  
70 patients. 
Serious adverse events (SAEs)  
(single arm) 
Assessed with: number of events 
Follow up: 1-12 months 
Overall SAEs: 15 in 273 patients - 273  
(4 observational 
studies) 
⨁⨀⨀⨀ 
VERY  
LOW25, 26, 27, 36 
Overall 15 SEAs 
occurred in the studies. 
Abbreviations: CI confidence interval, HIFU high-intensity focused ultrasound, HR hazard ratio, IIEF international index of erectile function,  
IPSS international prostate symptom score, NA not available 
  
                                                                                                                                                                                                                                                                                   
34 Risk of bias for this particular endpoint was set "serious", due to the difference between study groups in age (see also risk of bias assessment of study).  
Furthermore, the study exclusively reported the number of complications and not the number of patients with complications. 
35 Imprecision was set "serious" for this particular endpoint, because the patient number was too low to detect rare adverse events.  
36 There is inconsistency in the percentage of patients presented with an adverse event per study as one study reported in 41% of patients occurred adverse event,  
another study reported 15%, two studies did not report the percentage of patients in whom adverse event occurred, but the total number of adverse events  
and these studies did not specify how many patients experienced the adverse event. 
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Table 7-2: Summary of findings table of salvage HIFU 
Outcome 
Anticipated absolute effects 
Relative effect 
(95% CI) 
Number of 
participants  
(studies) 
Quality Comments Risk with  
s-HIFU 
Risk without  
s-HIFU Difference 
SAFETY 
Intervention-specific mortality  
(peri-operative death) 
Assessed with: number of events 
Follow up: mean 19.8 months 
See comment. Not  
estimable 
84  
(1 observational 
study) 
⨁⨀⨀⨀ 
VERY  
LOW25, 27, 37 
There was no 
intervention specific 
mortality. 
Functional outcomes: urinary 
(dys)function 
Assessed with: IPSS score 
Follow up: 6 months 
No significant difference in IPSS scores  
(8.3 pre salvage-HIFU and 11.6 post salvage-HIFU). 
- 39  
(1 observational 
study) 
⨁⨀⨀⨀ 
VERY  
LOW25, 27, 37 
There may be no 
difference in urinary 
function characterized 
by the IPSS score. 
Functional outcomes: sexual 
(dys)function 
Assessed with: IIEF-5 score 
Follow up: 6 months 
Significant decrease in the IIEF-5 score  
(8.6 pre salvage-HIFU and 6.2 post salvage-HIFU). 
- 43  
(1 observational 
study) 
⨁⨀⨀⨀ 
VERY  
LOW25, 27, 37 
Salvage HIFU may 
increase the risk of 
sexual dysfunction. 
Serious adverse events (SAEs) 
Assessed with: number of events 
Follow up: mean 19.8 months 
Overall SAEs: 3 in 84 patients Not  
estimable 
84  
(1 observational 
study) 
⨁⨀⨀⨀ 
VERY  
LOW25, 27, 37 
Overall 3 SAEs 
occurred. 
Abbreviations: CI = confidence interval, IIEF = international index of erectile function, IPSS = international prostate symptom score, s-HIFU = salvage high-intensity focused ultrasound 
 
                                                             
37 Indirectness was set serious because only failed EBRT patients were included (we do not have information on patients failed after other treatment modalities  
like prostatectomy or HIFU). The studies can only yield indirect evidence on HIFU compared to standard therapies as there was no control group. 
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8 Discussion 
High-intensity focused ultrasound (HIFU) is a technology that uses ultra-
sound waves to destroy tissue, cancer tissue in particular. The present report 
focused on the treatment of prostate cancer with HIFU. The ultrasound can 
be applied for the ablation of the whole gland or in parts, called hemiablation, 
or focal therapy. Treatment planning can be done under the assistance of ul-
trasound or MRI, whereas the letter is more appropriate for a focal treatment. 
In 2010, the LBI-HTA published a report on HIFU for prostate cancer [15] 
which concluded that the available evidence was not sufficient to determine 
any benefit of the intervention. All studies in the previous report were single-
arm studies with an overall very low strength of evidence. A re-evaluation was 
suggested not earlier than two years based on the estimated completion date 
of the identified ongoing studies. The aim of the present assessment is to up-
date the LBI-HTA report from 2010 to examine the latest, since 2010 pub-
lished evidence. Nevertheless, the scope of the present assessment has notably 
changed in two aspects: the population has been limited to low and interme-
diate risk patients according to the latest guidelines and more patient relevant 
outcomes formed the basis of the conclusions.  
Interpretation of findings 
The present assessment does not alter the general conclusions of the 2010 LBI-
HTA report. Overall, we could identify five single-arm studies and one com-
parative study (a matched-pair analysis) comparing HIFU with brachythera-
py (a type of radiotherapy), that met our inclusion criteria. The single-arm 
studies included 50 to 111 patients and had a mean or median follow-up of 12 
to 39 months. The matched-pair analysis included 70 patients in each study 
arm and had a median follow-up of 83 months in the HIFU and 44 months 
in the brachytherapy-arm. Therefore, there is still a lack of comparative stud-
ies for the most common comparators. 
The single available comparative study [19] has shown slightly lower prostate 
cancer specific survival rates after five years, as well as overall survival rates 
in HIFU-patients, compared to brachytherapy-patients. Even though the dif-
ferences were not significant, the given confidence intervals, however, indi-
cated considerable harm due to HIFU. However, patients in the HIFU-group 
were significantly older than patients treated with brachytherapy. This could 
have had a confounding effect on the survival rates. Local disease recurrence, 
a critical effectiveness-related outcome, was not reported in the study. 
Although quality of life was not measured in the comparative study included 
in the present assessment, three single-arm studies (two primary HIFU [21, 
22] and one study on salvage HIFU [24]) reported on this outcome. All three 
studies used various outcome measures. One primary study reported a signif-
icant improvement in the quality of life scores 12 months post-treatment [22], 
the other primary HIFU study and the study on salvage HIFU could not show 
any significant change in the depression and anxiety scores, as well as in the 
global quality of life scores at 12 months post-HIFU.  
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Regarding safety-related functional outcomes, the matched-pair analysis has 
not shown a significant difference in urinary incontinence between HIFU and 
brachytherapy. In the absence of data on sexual (dys)function for the brachy-
therapy cohort, no comparative conclusions can be drawn. However, the sin-
gle-arm primary studies [20-23], as well as the study on salvage HIFU [24] 
have shown a significant negative impact on sexual function. Concerning 
complications, in the matched-pair analysis [19] considerably more adverse 
events have been observed in HIFU-patients than in brachytherapy-patients, 
especially complications of higher severity occurred more often.  
Comparing the matched-pair analysis [19] with the single-arm studies [20-23], 
storage and voiding LUTS, acute urinary retention and stricture was consid-
erably more frequent in the matched-pair analysis. More severe, grade 3 and 
4 complications, like rectal fistula and bladder outlet obstruction did not oc-
cur in the primary single-arm studies at all. The applied ablation type might 
have influence on the severity of adverse events as the matched-pair analysis 
[13] and the study on salvage HIFU [18] both applied whole-gland ablation, 
whereas the primary single-arm studies [20-23] applied hemiablation.  
Study quality, validity and level of evidence 
The overall quality of evidence on high-intensity focused ultrasound (HIFU) 
as primary treatment for clinically localised low-risk and intermediate-risk 
prostate cancer as well as on HIFU as salvage treatment for locally recurrent 
prostate cancer is very low. Studies are lacking sufficiently high patient num-
bers, comparators and sufficiently long periods of follow-up. The small num-
bers considerably limit the generalizability of the findings and only two stud-
ies reported on outcomes with a follow-up of five years, therefore no signifi-
cant conclusion can be made on disease control. All outcomes estimates on 
the efficacy of primary HIFU compared to brachytherapy, a type of radiation 
therapy, are based on only one comparative study. This comparative study, 
however, consisted of two matched single-arm studies, which cannot accom-
plish a high evidence level. Moreover, the safety outcome estimates of prima-
ry HIFU are based on single-arm studies in addition to the comparative study. 
Regarding salvage HIFU all outcomes estimates are based on one single-arm 
study. Direct prospective comparison between deferred treatment modalities 
(active surveillance, watchful waiting) and radical prostatectomy or radiation 
for salvage treatment are completely lacking. 
There was also a considerable heterogeneity in the HIFU studies due to the 
large variation in follow-up protocols and definitions of outcome measures. 
Although we considered only the matched-pair analysis in the effectiveness 
assessment, we noticed that studies had different effectiveness end points 
(biochemical, variable definitions of PSA end points, and/or biopsy data, and 
various survival end points: overall, actuarial recurrence-free, biochemical re-
currence-free, prostate cancer specific, metastases-free, progression-free, rad-
ical treatment-free). Definition of treatment failure was not universal among 
the studies: some studies defined it as positive biopsy control (indicating lo-
cal relapse [9]), while others used the need for salvage treatment, initiation 
of definitive treatment, presence of clinically significant cancer. Biochemical 
recurrence rates were defined according to Phoenix or Stuttgart criteria, but 
there is currently no consensus regarding the drop in PSA level which may 
indicate a treatment success. In addition, Phoenix criteria are not validated 
for other than radiotherapy, and it tends to generate lower rates of recur-
rence. It may also be less sensitive in focal ablation because the nadir may 
have less relevance with the preservation of a large proportion of the pros-
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tate tissue [12]. The Stuttgart criteria (> PSA nadir + 1.2 ng/mL) have been 
proposed to define BCR after HIFU treatment, though is not yet validated. 
Similarly for the safety end points, there is no standard measurement tool and 
the studies showed heterogeneity in the outcome measures used for sexual 
and urinary function and when the outcome was measured. Sexual function 
was measured with the IIEF-5 score and/or physician reported rates of de 
novo erectile dysfunction of previously potent patients at 3 months, or at 12 
months. Urinary function was measured with the usage of pads and/or with 
IPSS at 3 months, or at 12 months. A common problem with such measure-
ment tools is that physician reported rates often do not correlate with patient 
self-assessment questionnaires. In some of the primary HIFU studies there 
was a lack of data on the IPSS or IIEF-5 score: for instance in one study [22] 
only the mean difference before and 12 months after treatment was stated or 
in another study the values after treatment were missing [20].  
Additional limitations that hinder the generalizability of the findings include 
that the matched-pair analysis applied whole-gland ablation, whereas the sin-
gle-arm studies applied hemiablation of the prostate. Whole-gland ablation is 
associated with a worse side-effect profile (more frequent toxicities, inconti-
nence and erectile problems) compared to hemiablation [25, 26] (see also ap-
plicability table Table A-9).  
Overall, the lack of comparative studies, the lack of standardization, the heter-
ogeneity in the type of ablation and the type of HIFU device used (and device 
generations), the poor reporting of additional interventions (TURP, ADT), the 
heterogeneity in follow-up schedule and outcome measures do not allow per-
forming a meta-analysis of the available evidence, nor a stratification to dif-
ferent generations of HIFU (and magnetic resonance imaging guidance), and 
additional interventions.  
Limitations of the present report 
Limitations of the present assessment are the lack of stratification to differ-
ent generations of HIFU (and magnetic resonance imaging guidance), and 
additional interventions (TURP, ADT) as these information was often lack-
ing. The MRI guidance, for instance, is a relatively new approach and studies 
evaluation its effectiveness and safety are still ongoing. Moreover, we includ-
ed the comparative study [19], in which in the first period patients were treat-
ed with an older version of device that is not commercially available anymore. 
However, it can be expected that the used device, the type of guidance and 
any concomitant treatments will have a considerable effect on the effective-
ness and safety of HIFU.  
Another limitation is the abstinence of indirect comparisons (for instance 
matching and comparing single-arm trials on laparoscopic prostatectomy and 
HIFU) which was not feasible within the timeframe of the rapid assessment. 
Regarding the literature search, despite meticulous hand searching, we did 
not identify any evidence additional to the systematic search. However, it is 
possible that we did not identify any relevant evidence.  
Due to some changes in the project protocol, the present report slightly dif-
fers from the original one, especially with regard to patient population and 
endpoints. Therefore, we also surrendered to merge the findings of the exist-
ing report with those of the present one. Nevertheless, it can be concluded 
that the strength of evidence has not changed, still being on a very low level. 
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Evidence gaps and ongoing studies 
To date there are no published RCTs comparing oncological and safety out-
comes of HIFU (either as whole gland or hemiablation) and any radical treat-
ment modalities or any deferred treatment modalities or even radiation. MRI 
guided HIFU ablation is such a new approach that the first pivotal studies 
have been completed lately and their effectiveness and safety is currently be-
ing investigated.  
A search for ongoing studies identified two RCTs and three non-randomised 
controlled trials (non-RCTs) of which one non-RCT was terminated due to 
lack of inclusions, two had unknown status, however according to the regis-
try data completion was planned for 2008 for one non-RCT and 2014 for an 
RCT (but no publication was found on the study results). One RCT is current-
ly in the planning phase of recruitment, and one non-RCT is expected to be 
completed in November 2019 (for further information see Table A-10). It is 
often claimed that ethical considerations hinder the implementation of ran-
domised controlled trials. To overcome this problem there are some alterna-
tive approaches to be considered: cohort embedded multiple RCTs or pref-
erence-based randomizations. A pragmatic approach would be to implement 
other trial designs, such as patient preference trials and parallel prospective 
cohort studies [12].  
 
 
derzeit (noch)  
keine randomisierten 
kontrollierten Studien 
derzeit eine 
randomisierte 
kontrollierte Studie  
in Planungsphase 
 LBI-HTA | 2018 65 
9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is not sufficient to prove that primary HIFU, as well as 
salvage HIFU is more effective and safe or as effective but safer than the 
comparators AS, WW, RP or RT.  
On the basis of the limited evidence demonstrating a benefit of HIFU relative 
to the comparators, the inclusion in the hospital benefit catalogue is currently 
not recommended. 
The re-evaluation is recommended not earlier than 2020. 
 
 
Empfehlungsschema 
keine ausreichend 
robuste Evidenz 
Aufnahme derzeit  
nicht empfohlen 
Reevaluierung nicht  
vor 2020 
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Appendix 
Evidence tables of individual studies included 
for clinical effectiveness and safety 
Table A-1: Primary HIFU versus brachytherapy: Results from non-randomised controlled trials 
Author, year, reference number Aoun, 2015 [19] 
Country BE 
Funding NA 
HIFU device Ablatherm® (Maxis (2001-2006) and Integrated Imaging (2006-2012)) 
Type of ablation Whole gland ablation 
Comparator Brachytherapy (permanent implantation of Iode125) 
Study design Prospective matched-pair analysis38 
Study timeframe 2001-2012 
Number of patients 70 vs. 70 
Inclusion/exclusion criteria Inclusion: whole gland primary therapy with curative intent for an organ 
confined prostate cancer, PSA < 20 ng/mL, Gleason score ≤ 7 (3 + 4), 
T1N0M0-T2N0M0, FU > 12 months 
Exclusion: patients with incomplete oncologic data or limited FU<12 m 
Patient characteristics 
Age of patients 
Mean (median) [IQR] 
NA (74 ± 4.47 vs. 69 ± 6.5) [62-86] vs. [54-79], (p<0.01) 
Tumour stage n (% of pts) T1a : 2 vs. 1 (2.9 vs. 1.4) 
T1b : 6 vs. 2 (8.6 vs. 2.9) 
T1c : 31 vs. 38 (44.3 vs. 54.3) 
T2a :19 vs. 20 (27.1 vs. 28.6) 
T2b : 12 vs. 9 (17.1 vs. 12.9) 
Gleason score n (% of pts) ≤6: 51 vs. 51 (72.9 vs. 72.9) 
7: 19 vs. 19 (27.1 vs. 27.1) 
Pre-HIFU PSA level (ng/mL) 
Mean (median) (range) 
NA39 
 
Risk categories n (% of pts)  
according to  
D’Amico: 
Low: 31 vs. 33 (44.3 vs. 47.1) 
Intermediate: 39 vs. 37 (55.7 vs. 52.9) 
Pre-HIFU prostate volume (mL) 
Mean (median) (IQR) 
NA40 
Neoadjuvant ADT n (%) 19 vs. 14 (27.1 vs. 20) 
HIFU procedure and follow-up 
TURP prior to/combined with HIFU  
n (% of pts) 
NA 
Anaesthesia NA 
Number of treatments/patient  
n (% 0f pts) 
NA 
Duration of treatment (min) NA 
                                                             
38 Study consisted of two matched single-arm studies. In one study 110 patients received HIFU and in the other 
study 106 patients received brachytherapy. Of each study, 70 patients were selected for matching. Matching 
criteria were: Gleason score, PSA, clinical tumour stage, D’Amico risk, and age.  
39 PSA ≤10: 50 vs. 57 patients, PSA>10 ≤20: 20 vs. 13 patients. 
40 Pre-HIFU prostate volume was only given for the 110 patients of the initial HIFU study. 
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Author, year, reference number Aoun, 2015 [19] 
Hospital stay (d) NA 
Catheterisation time (d) NA 
Follow-up (m) Mean (range) Median 83 vs. 44 (IQR: 29-98 vs. 21-70) (p<0.01) 
Loss to follow-up n (%) NA 
Effectiveness-related outcomes 
Overall survival % at X years After 5 years: 
62 vs. 6841 (88 vs. 97.5%), HR 0.24, CI 0.01-1.34, p=N.S. 
Prostate cancer specific survival n (%)  
at X years 
After 5 years: 
62 vs. 6441 (89 vs. 92%), HR 0.67, CI 0.32-1.29, p=N.S. 
Local disease recurrence n NA 
Distant disease recurrence/metastases n NA 
Biochemical recurrence/failure n (%)  
at X years according to 
After 5 years42: 
Phoenix: 37 vs. 48 (53.1 vs. 68.5%), HR 0.41, CI 0.19-0.81, p<0.05  
[low risk: 48 vs. 5441 (68% vs. 77.5%), HR 0.31, CI 0.09-0.94, p=0.05, 
intermediate risk: 31 vs. 4141 (44.9 vs. 58.8%), HR 0.47, CI 0.17-1.13, p=0.12] 
Stuttgart: 36 vs. 4341 (51.3 vs. 60.9%), HR 0.39, CI 0.19-0.74, p<0.05  
[low risk: 39 vs. 5441 (56.3 vs. 77.5%), HR 0.31, CI 0.10-0.84, p=0.03, 
intermediate risk: 29 vs. 4141 (42 vs. 58.8%), HR 0.41, CI 0.15-0.97, p=0.05] 
Disease progression/pathological 
progression 
NA 
QoL measured by (tool) NA 
Need for salvage/systemic therapy (%) NA 
Ablation failure n (%) NA 
Safety-related outcomes 
Intervention-specific mortality 0 vs. 0 
Functional outcomes:  
urinary (dys)function n (%) according to 
Physician reported events: 
Urinary incontinence: 5 vs. 2 (7.2 vs. 3.8%), p=0.44 
Functional outcomes:  
sexual (dys)function n (%) according to 
Events43: 
Erectile dysfunction: 544 vs. NA (11.6 vs. NA), p=NA 
Complications/adverse events (AEs) 
(grade 1-2) n at x months 
Urinary tract infection  
Storing or voiding lower urinary tract 
symptoms (LUTS) 
Acute/chronic urinary retention 
Burn, injuries, bleeding 
Proctitis 
Pain 
Anaesthesia-related complications 
Thromboembolic disease (phlebitis) 
Other AEs 
43 vs. 3145, p=NA within 1 year post-intervention; 22 vs. 13, p=NA after 
more than 1 year post-intervention 
Urinary tract infection: 15 vs. 5 (21.4 vs. 8.5%), p=0.07 within 1 year post-
intervention 
LUTS: 28 vs. 25 (40 vs. 42.4%), p=0.93 within 1 year post-intervention;  
19 vs. 13 (27.5 vs. 24.5%), p=NA46 after 1 year post-intervention 
Burn, injuries, bleeding: NA 
Proctitis: NA 
Pain47: 3 vs. 0 (4.3 vs. 0), p=0.34 after 1 year post-intervention 
Anesthesia-related complications: NA 
Thromboembolic disease (phlebitis): NA 
Gastrointestinal toxicity48: 0 vs. 1 (0 vs.1.7%) within 1 year post-intervention 
                                                             
41 Own calculations. 
42 Study reported biochemical recurrence-free survival. 
43 Method to document erectile dysfunction was not stated. 
44 Measured in 43 patients 
45 These numbers were reported for early and long-term postoperative complications (events that occurred within 
one year after intervention or more than one year after the intervention). Furthermore, these are the numbers of 
complications and not the number of patients with complications. 
46 Study did not report p values separately for grade 1-2 and grade 3-4 events after 1 year post-intervention. 
47 Study reported chronic pelvic pain 
48 Study reported gastrointestinal toxicity. The p value (p=0.59) was reported for all events (grade 1-3).  
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Author, year, reference number Aoun, 2015 [19] 
Serious adverse events (SAEs)  
(grade 3-4) n at x months 
Bladder neck/urethral stricture/stenosis 
Bladder neck obstruction 
Rectal fistula 
Other SAEs 
17 vs. 5, p=NA within 1 year post-intervention; 18 vs. 4,  
p=NA after 1 year post-intervention 
Stricture: 17 vs. 2 (24.6 vs. 3.8%), p<0.0149 after 1 year post-intervention 
Bladder neck obstruction: NA 
Rectal fistula: 1 vs. 1 (1.4 vs. 1.9%), p=150 after 1 year post-intervention 
Acute urinary retention: 16 vs. 4 (22.9 vs. 6.8%),  
p=0.02 within 1 year post-intervention 
LUTS/hematuria: 0 vs. 1 (1.9%), p=NA after 1 year post-intervention 
Gastrointestinal toxicity: 1 vs. 1 (1.4 vs. 1.7%),  
p=NA within 1 year post-intervention 
Abbreviations: ADT = androgen deprivation therapy. AE = adverse event, BE = Belgium, d = day, FU = follow-up, 
HIFU = high-intensity focused ultrasound, IQR = interquartile range, LUTS = lower urinary tract symptoms, n number, 
min = minute, NA = not available, pts patients, PSA = prostate-specific antigen, QoL = quality of life,  
TURP = transurethral resection of the prostate 
 
 
 
 
                                                             
49 Study reported urethral stricture. 
50 Study reported rectourethral fistula. 
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Table A-2: Primary HIFU: Results from single-arm observational studies 
Author, year, reference number Van Velthoven, 2016 [23] Rischmann, 2017 [22] Ganzer, 2017 [21] Feijoo, 2015 [20] 
Country BE FR D FR 
Funding NA None  NA None 
HIFU device Ablatherm® Ablatherm® Ablatherm®, FocalOne® Ablatherm® 
Type of ablation Hemiablation Hemiablation Hemiablation Hemiablation 
Study design Prospective single-centre single-arm 
phase 2a study 
Prospective multicentre single-arm 
phase 2b study 
Prospective multicentre single-arm 
phase 2 study 
Prospective single-centre single-
arm study 
Study timeframe 2007 2009-2014 2013-2016 2009-2013 
Number of patients 50 111 51 67 
Inclusion/exclusion criteria Inclusion: ≤T2, PSA<15 ng/ml,  
≥5 y life expectancy,  
prostate volume <40 cm3. 
Exclusion: extraprostatic extension 
disease on mpMRI, suspected 
regional lymph nodes, or distant 
metastases, previous HIFU or RT. 
Inclusion: treatment naïve, T1/T2, 
unilateral cancer, Gleason score ≤7. 
Exclusion: biopsy confirmed 
mpMRI lesion located <6 mm from 
the apex or <5 mm from the 
sagittal midline.  
Inclusion: age≥18, T1c-T2a, Gleason 
score ≤7, max cancer core length  
5 mm, PSA≤10 ng/ml, height of the 
peripheral zone ≤30 and ≤ 40 mm 
on TRUS. 
Exclusion: significant cancer on  
the contralateral side on mpMRI 
(PI-RADS v.1 or 2 ≥4), in case of 
previous prostatic/urethral surgery 
and/or intake of 5-ARIs ≤6 m 
and/or previous ADT. 
Inclusion: unilateral cancer, T1c-T2a, 
max positive biopsies <33%, 
Gleason score≤7, PSA<15 ng/ml, 
>10 y life expectancy. 
Exclusion: previous PCa related 
treatment, extraprostatic 
extension disease on mpMRI. 
Patient characteristics 
Age of patients 
Mean ± SD (median) [IQR] 
73 (74) [70-77]  64.8 ± 6.2 (64.9) [61-69] 63.4 ± 8.3 70.2 ± 6.8 
Tumour stage n (% of pts) T1c : 16 (32) 
T2 : 34 (68) 
T1 : 77 (69) 
T2 : 33 (30) 
Unknown : 1 (1) 
NA NA 
Gleason score n (% of pts) 3+3: 30 (60) 
3+4: 14 (28) 
4+3: 6 (12) 
≤6: 82 (74) 
=7: 29 (26) 
3+4: 8 (15.7) 
Median 6 
3+3: 58 (86.6) 
3+4: 9 (13.4) 
Pre-HIFU PSA level (ng/mL) 
Mean ± SD (median) [range] 
6.6 (6.3) [3.9-8.3]  6.2 ± 2.5 (5.6) [4.7-7.6] 6.2 ± 2.1 (6.1) [IQR: 1.6-15.5] 
Risk categories n (% of pts) 
according to  
D’Amico: 
low 24 (48) 
intermediate 26 (52) 
NA: 
low 75 (68) 
intermediate 36 (32) 
NA: 
low NA 
intermediate NA 
NA: 
low: 67 (100) 
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Author, year, reference number Van Velthoven, 2016 [23] Rischmann, 2017 [22] Ganzer, 2017 [21] Feijoo, 2015 [20] 
Pre-HIFU prostate volume (mL) 
Mean ± SD (median) [IQR] 
31 (27) [20-38] 31.6 ±12.3 (28.3) [23-39] 34.1 ± 15.0 39.3 ± 13.7 
Neoadjuvant ADT n (%)  NA NA NA NA 
HIFU procedure and follow-up 
TURP prior to/combined with 
HIFU n (% of pts) 
NA 67 (60) NA NA 
Anaesthesia Spinal, general51 Spinal, general General  NA 
Number of treatments/patient  
n (% of pts) 
NA NA NA NA 
Duration of treatment (min) ± SD NA NA 62.2 ± 20.3 ∅ 120 
Hospital stay (d) 452 NA NA NA 
Catheterisation time (d) 2.853 NA 2.9 ± 4.3 NA 
Follow-up (m) Mean ± SD 
(median) [range] 
39 (34) [IQR: 13-58]54 30.4 ±14.1 17.41 ± 4.5 [12-24] (12) [IQR: 6-50] 
Loss to follow-up n (%) 39 (78) over 5 y 10 (10)55 
32 (29) over 2 y 
0 15 (22.4) over 16 m 
Effectiveness-related outcomes 
Overall survival n (%) at X years 4656 (87)/5 y 109 (98.2)57/1 y 51 (100)/1 y NA 
Prostate cancer specific survival 
% at X years 
100/5 y NA 100/1 y NA 
                                                             
51 Procedure described in Van Velthoven, 2014 
52 Procedure described in Van Velthoven, 2014 
53 Procedure described in Van Velthoven, 2014 
54 The data is presented in a table and described in the text, however they slightly differ. We applied data from the table. In the results section 40 (35),  
in the summary section (39.5) is stated. 
55 In study it is stated that no patient was lost but control biopsy was performed in 101 patients, 10 patients refused or had contraindication, or died from other cause. 
56 Three patients with severe comorbidities died from unrelated confirmed cause, and one patient died from a heart attack.  
Study authors reported 87% overall survival rate which is lower than the rate if we calculate with the 4 deaths.  
57 Two patients died from other causes: pancreatic and ethmoidal bone cancers. 
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Author, year, reference number Van Velthoven, 2016 [23] Rischmann, 2017 [22] Ganzer, 2017 [21] Feijoo, 2015 [20] 
Local disease recurrence n  Positive biopsy: 6/8/NA of which  
3 (50%) were significant on the 
contralateral side 
Positive biopsy: 8/12/NA of which  
5 (63%) were significant 
Positive biopsy: 13/49/1 y in the 
treated lobe of which 4 (8.2%) 
were significant; 17/49/1 y on the 
contralateral side of which 1 (2%) 
was significant  
Positive biopsy: 17/67/NA of which 
11 (64.7%) were significant 
Distant disease 
recurrence/metastasis n 
NA NA NA NA 
Biochemical recurrence/failure n 
(%) at X years according to 
Phoenix: 14 (28)/NA 
Stuttgart: 18 (36)/NA 
NA NA Phoenix: 6 (9.7)/NA 
Disease/pathological progression  NA NA NA NA 
QoL measured by (tool) NA EORTC QLQ-C28 at 0 m/12 m FU 
(n=76): 
mean increase 0.4  
(95% CI: –1.0; 1.7) 
Global health status/quality of life 
score (± SD) at 0 m/12 m FU: 
74.6±17.8/73.9±22.0, p=0.39 
HADS-D depression score (± SD)  
at 0 m/12 m FU: 
8.8±4.7/10.1±3.2, p=0.276 
HADS-D anxiety score (± SD) at  
0 m/12 m FU: 
6.5±3.8/6.8±2.6, p=0.804 
NA 
Need for salvage therapy n (%) s-HIFU:3 (6) 
s-RT: 3 (6) 
AS: 2 (4) 
AS: 16 (15.8) 
s-RP: 6 (5.9) 
s-EBRT: 3 (3.0) 
s-HIFU: 9 (8.9) 
4 pts needed 3rd line therapy 
s-RT: 4 (7.8) 
s-HIFU: 5 (9.8) 
s-RP: 1 (1.9) 
= 10 (19.6)  
AS: 8 (15.7) 
NA 
Ablation failure n (%) NA NA NA NA 
Safety-related outcomes 
Intervention-specific mortality 0 0 0 0 
Functional outcomes: urinary 
(dys)function according to 
Physician reported rate: 
incontinent pre-HIFU/12 m  
post-HIFU, n (%) (n=50): 
0 (0)/3 (6) 
(transient incontinence before  
12 m post-HIFU: 7 (14)) 
Usage of pads pre-HIFU/12 m  
post-HIFU, n (%) (n=102): 
1 (1)/3 (3) 
IPSS pre-HIFU/12 m post-HIFU 
(n=80):  
improvement with a mean 
decrease of 3 (95% CI: 1.6; 4.4) 
Usage of pads pre-HIFU/12 m  
post-HIFU, n (%) (n=51):  
1 (2)/3 (5.9) 
IPSS pre-HIFU/12 m post-HIFU: 
No significant change 
Usage of pads pre-HIFU/x m  
post-HIFU, n (%) (n=67): 
0 (0)/0 (0)  
IPSS (range) pre-HIFU/3 m post-
HIFU: 6.24 (0-26)/NA, p=0.217  
ICS (range) pre-HIFU/3 m post-HIFU: 
0.42 (0-8)/NA, p=0.840  
  
A
p
p
en
d
ix 
LB
I-H
T
A
| 20
18
 
77 
Author, year, reference number Van Velthoven, 2016 [23] Rischmann, 2017 [22] Ganzer, 2017 [21] Feijoo, 2015 [20] 
Functional outcomes: sexual 
(dys)function according to 
Physician reported rate pre-HIFU 
potent/NA m post-HIFU potent 
(n=50): 30/24  
De novo erectile dysfunction n (% 
of previously potent): 6 (20) 
IIEF-5 pre-HIFU/12 m post-HIFU: 
mean difference 1.2 (95% CI: –0.4; 2.7) 
Physician reported rate pre-HIFU 
potent/NA m post-HIFU potent 
(n=51): 51/40  
De novo erectile dysfunction n (% 
of previously potent): 11 (21.6) 
IIEF-5 score (± SD) pre-HIFU/12 m 
post-HIFU: 
17.6±6.1/13.6±8.6, p<0.001 
ICS-male score at 0 m/12 m FU: 
0.9±2.3/1.4±3.0, p=0.131 
IIEF-5 score (range) pre-HIFU/3 m 
post-HIFU: 
17.97 (0-25)/NA, p<0.001 
Physician reported rate pre-HIFU 
potent/NA m post-HIFU potent 
(n=21): 21/11  
De novo impotence n (% of 
previously potent): 10 (47.6) 
Complications/adverse events 
(AEs) (grade 1-2) n at x months  
Urinary tract infection  
Storage or voiding lower urinary 
tract symptoms (LUTS) 
Acute/chronic urinary retention 
Burn, injuries, bleeding 
Proctitis 
Pain 
Anesthesia-related complications 
Thromboembolic disease 
(phlebitis) 
Other AEs 
 
16/NA m (n=50) 
Urinary tract infection: 3  
LUTS: 9  
Chronic urinary retention: 4 
 
100/12 m (n=105)  
Urinary tract infection: 18  
LUTS: 7 
Urge incontinence: 4 
Gross hematuria: 5  
Transient dysuria: 17  
Chronic urinary retention: 3  
Hematospermia: 2 
Anejaculation: 16  
Orchitis: 8  
Proctitis: 8  
Transient anal and perineal pain: 10  
Deep phlebitis: 1  
Superficial phlebitis: 1  
 
25/NA m (n=21) 
Urinary tract infection: 9  
Transient hematuria: 4  
Urge incontinence: 2 
Dysuria: 1  
Chronic urinary retention: 5 
Anejaculation: 1  
Pelvic pain: 2  
Aspermia: 1  
 
8 within 1 m (n=67) 
Urinary tract infection: 4  
Urinary retention: 4 
Serious adverse events (SAEs) 
(grade 3-4) n at x months (n pts) 
Bladder neck/urethral 
stricture/stenosis 
Bladder neck obstruction 
Rectal fistula 
Other SAEs 
 
6/NA m (n=50) 
Stricture: 2  
 
Bladder neck obstruction: NA 
Rectal fistula: NA 
Acute urinary retention: 4 
 
6/12 m (n=105) 
Stricture: 1  
 
Bladder neck obstruction: NA 
Rectal fistula: NA 
Acute urinary retention: 5 
 
1/NA m (n=21) 
Stenosis: 1  
 
Bladder neck obstruction: NA 
Rectal fistula: NA 
 
2 within 1 m (n=67) 
Urinary retention: 2 
Abbreviations: ADT = androgen deprivation therapy, AE = adverse event, ARI = Alpha reductase inhibitor, AS = active surveillance, BE = Belgium, d = day,  
EBRT=  external beam radiation therapy, EORTC-QLQ = European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire, D = Germany, FR = France,  
FU = follow-up, HADS = hospital anxiety and depression scale, HIFU = high-intensity focused ultrasound, ICS = International Continence Society score, IIEF = international index of erectile 
function, IPSS = international prostate symptom score, IQR = interquartile range, LUTS = lower urinary tract symptoms, n = number, min = minute, mpMRI = multiparametric magnetic 
resonance imaging, NA = not available, pts = patients, PCa = prostate cancer, PI-RADS = prostate imaging reporting and data system, PSA = prostate-specific antigen, QoL = quality of life, 
RP = radical prostatectomy, RT = radiation therapy, SD = standard deviation, TURP = transurethral resection of the prostate 
High-intensity focused ultrasound for the treatment of prostate cancer 
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Table A-3: Salvage HIFU: Results from single-arm observational studies 
Author, year, reference number Uddin Ahmed, 2012 [24] 
Country UK, CAN 
Funding Med. Research Council, Pelican Cancer Foundation, Prostate Action,  
St Peters Trust, Prostate Cancer Research Centre 
HIFU device Sonablate® 500 
Type of ablation Salvage-whole gland ablation 
Study design Prospective registry after a multicentre single-arm phase 2 feasibility study 
Study timeframe 2004-2009 
Number of patients 84 
Inclusion/exclusion criteria Inclusion: biochemical failure after EBRT, localised PCa < T3aNoMo 
Patient characteristics 
Age of patients 
Mean (median) [IQR] 
68.3 [65-72] 
Tumour stage n (% of pts) NA 
Gleason score n (% of pts) Median 7 (range 6-7) 
Pre-HIFU PSA level (ng/mL) 
Mean (median) [range] 
5.7 (3.8) [1.5-7.7] 
Risk categories n (% of pts) according to  NA 
Pre-HIFU prostate volume (mL) 
Mean (median) [IQR] 
25.1 (24) [19-30] 
Neoadjuvant ADT n (%) 30 (36) 
HIFU procedure and follow-up 
TURP prior to/combined with HIFU  
n (% of pts) 
NA 
Anaesthesia NA 
Number of treatments/patient  
n (% 0f pts) 
1: 78 (92.9) 
2: 6 (7.1) 
Duration of treatment (min) 15858  
Hospital stay (d) Mean 1.4 
Catheterisation time (d) NA 
Follow-up (m) Mean (median) [range] 19.8 [3.0-35.1] 
Loss to follow-up n (%) 0 
Effectiveness-related outcomes 
Overall survival % at X years NA 
Prostate cancer specific survival % at  
X years 
NA 
Local disease recurrence n Positive biopsy: 21/49/NA of which NA were significant  
Distant disease recurrence/metastasis n NA 
Biochemical recurrence/failure n (%)  
at X years according to 
NA 
Disease/pathological progression  NA 
QoL measured by (tool) RAND-SF36 at 0m/6 m (n=39): 
102.7 (103)/100.4 (100), p=0.03 
Need for salvage therapy n (%) WW or ADT: 21 (25) 
Ablation failure n (%) 6 patients needed redo-s-HIFU 
                                                             
58 Data available only on 40 patients 
Appendix 
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Author, year, reference number Uddin Ahmed, 2012 [24] 
Safety-related outcomes 
Intervention-specific mortality 0 
Functional outcomes:  
urinary (dys)function according to 
IPSS pre-salvage-HIFU/6 m post-salvage-HIFU (n=39): 
8.3 (7)/11.6 (9.5), p=0.06 
Functional outcomes:  
sexual (dys)function according to 
IIEF-5 pre-salvage-HIFU/6 m post-salvage-HIFU (n=43): 
8.6 (6)/6.2 (3), p<0.001 
Complications/adverse events (AEs) 
(grade 1-2) n at x months (n pts) 
Urinary tract infection  
Lower urinary tract symptoms (LUTS) 
Acute/chronic urinary retention 
Burn, injuries, bleeding 
Proctitis 
Pain 
Anesthesia-related complications 
Thromboembolic disease (phlebitis) 
Other AEs 
 
37/NA m (n=84) 
Grade 1: 27 
Grade 2: 10 
Serious adverse events (SAEs)  
(grade 3-4) n at x months (n pts) 
Bladder neck/urethral stricture/stenosis 
Bladder neck obstruction 
Rectal fistula 
Other SAEs 
 
55/NA m (n=84) 
Grade 3: 52 
Grade 4: 3 
(Bladder outlet obstruction: 17  
Rectal fistula: 4 (2 after 1 treatment, 2 after redo-s-HIFU)) 
Abbreviations: ADT = androgen deprivation therapy. AE = adverse event, d = day, CAN = Canada,  
EBRT = external beam radiation therapy, FU = follow-up, HIFU = high-intensity focused ultrasound,  
IIEF = international index of erectile function, IPSS = international prostate symptom score, IQR = interquartile range, 
LUTS = lower urinary tract symptoms, n = number, min = minute, NA = not available, pts = patients, PCa = prostate cancer, 
PSA = prostate-specific antigen, QoL = quality of life, RAND-SF = Research ANd = Development Short Form,  
SD = standard deviation, TURP = transurethral resection of the prostate, UK = United Kingdom, WW = watchful waiting 
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Risk of bias tables and GRADE evidence profile 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement a third researcher was involved to solve the differences. 
A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the LBI-HTA 
[2] and in the Guidelines of EUnetHTA [3].  
Table A-4: Outcome – specific risk of bias of non – randomised studies comparing primary HIFU versus brachytherapy [19] 
Responses underlined in green are potential markers for low risk of bias, and responses in red are potential markers for a risk of bias.  
Where questions relate only to sign posts to other questions, no formatting is used. 
Risk of bias assessment applies for all critical outcomes together (prostate cancer specific survival, local disease recurrence, functional outcomes and complication),  
since judgement is similar for all outcomes (any additional considerations were added in the GRADE assessment). 
 Signalling questions Description Response options 
Bias due to confounding  
 1.1 Is there potential for confounding of the effect of intervention  
in this study? 
Based on the information given, confounding cannot be excluded. Main potential 
confounders are the difference in age (age was a matching criteria) and difference 
in follow-up time between study groups (see also 1.4). Both might have an influence 
on treatment effects. Another important confounder is the fact that HIFU was 
performed by one surgeon and brachytherapy by two different surgeons. 
Y 
 If Y/PY to 1.1: determine whether there is a need to assess time-varying 
confounding: 
  
 1.2. Was the analysis based on splitting participants’ follow up time 
according to intervention received? 
If N/PN, answer questions relating to baseline confounding (1.4 to 1.6)  
If Y/PY, go to question 1.3. 
It is not clear how it was decided that patients receive HIFU or brachytherapy. 
Thus, it is not clear if patients could switch between study groups. 
PY 
 1.3. Were intervention discontinuations or switches likely to be related 
to factors that are prognostic for the outcome? 
If N/PN, answer questions relating to baseline confounding (1.4 to 1.6) 
If Y/PY, answer questions relating to both baseline and time-varying 
confounding (1.7 and 1.8)  
 N 
 Questions relating to baseline confounding only  
 1.4. Did the authors use an appropriate analysis method that controlled 
for all the important confounding domains? 
Wilcoxon’s rank-sum or 𝜒² tests were used to asses absence of clinical and 
pathological differences. However, no sufficient infor-mation was provided if 
other confounders were controlled for (e.g., age). 
PN 
 1.5. If Y/PY to 1.4: Were confounding domains that were controlled for 
measured validly and reliably by the variables available in this study? 
- - 
 1.6. Did the authors control for any post-intervention variables that 
could have been affected by the intervention? 
No sufficient information given in study. NI 
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 Signalling questions Description Response options 
 Questions relating to baseline and time-varying confounding  
 1.7. Did the authors use an appropriate analysis method that controlled 
for all the important confounding domains and for time-varying 
confounding? 
- - 
 1.8. If Y/PY to 1.7: Were confounding domains that were controlled for 
measured validly and reliably by the variables available in this study? 
- - 
 Risk of bias judgement Due to the lack of information and the potential risk of confounding, risk of bias 
was considered as “serious”. 
Serious 
 Optional: What is the predicted direction of bias due to confounding? In HIFU-group patients were older and the follow-up period was longer, which 
lead in a potential favouritism of brachytherapy (even though there are no other 
studies for confirmation). 
Favours 
comparator 
(brachytherapy) 
Bias in selection of participants into the study   
 2.1. Was selection of participants into the study (or into the analysis) based 
on participant characteristics observed after the start of intervention? 
If N/PN to 2.1: go to 2.4 
Study is a matched-pair analysis of two single-arm studies. Thus, selection of the 
participants for matched-pair analysis was done after the start of both interventions 
(matching was based on Gleason score, PSA, clinical tumour stage, D’Amico risk, 
and age). Furthermore, the study says: “Patients […] were matched 1:1 […]. The 
matching procedure was blinded to the outcome […].” The blinding process, though, 
was not properly described. Thus, study personnel could have been aware of 
characteristics and outcomes. Plus, patients in the interventions group were  
older than in control group (p<0.01). 
PY 
 2.2. If Y/PY to 2.1: Were the post-intervention variables that influenced 
selection likely to be associated with intervention? 
2.3 If Y/PY to 2.2: Were the post-intervention variables that influenced 
selection likely to be influenced by the outcome or a cause of the outcome? 
 
 
- 
N 
 
- 
 2.4. Do start of follow-up and start of intervention coincide for most 
participants? 
- - 
 2.5. If Y/PY to 2.2 and 2.3, or N/PN to 2.4: Were adjustment techniques 
used that are likely to correct for the presence of selection biases? 
- - 
 Risk of bias judgement  Moderate 
 Optional: What is the predicted direction of bias due to selection of 
participants into the study? 
 Unpredictable 
Bias in classification of interventions    
 3.1 Were intervention groups clearly defined?  Interventions were not very well defined. Not clear how many patients had 
earlier HIFU version applied, and how many the new one. Criteria for considering 
individuals to have received each intervention was not mentioned (e.g. type, 
setting, dose, intensity, and timing of intervention). 
PN 
 3.2 Was the information used to define intervention groups recorded  
at the start of the intervention? 
Explicit information about interventions received was not given. It is not clear 
how many patients received ADT, how many patients had earlier HIFU version 
applied. Patients of intervention group were collected from a bigger intervention 
group after initial intervention. 
N 
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 Signalling questions Description Response options 
 3.3 Could classification of intervention status have been affected  
by knowledge of the outcome or risk of the outcome? 
Study says: “The matching procedure was blinded to the outcomes in order to 
avoid selection bias.” But blinding procedure was not described in detail. 
PY 
 Risk of bias judgement  Serious 
 Optional: What is the predicted direction of bias due to classification of 
interventions? 
 Unpredictable 
Bias due to deviations from intended interventions   
 If your aim for this study is to assess the effect of assignment to intervention, answer questions 4.1 and 4.2  
 4.1. Were there deviations from the intended intervention beyond what 
would be expected in usual practice? 
It seems that there were no deviations. N 
 4.2. If Y/PY to 4.1: Were these deviations from intended intervention 
unbalanced between groups and likely to have affected the outcome? 
- - 
 If your aim for this study is to assess the effect of starting and adhering to 
intervention, answer questions 4.3 to 4.6 
  
 4.3. Were important co-interventions balanced across intervention groups? Study says: “Patients with prostates exceeding this threshold are offered 
neoadjuvant cytoreductive androgen deprivation therapy (ADT). Hormonal 
treatment is always discontinued at the time of surgery.“ Thus, it is not clear  
how many patients received ADT (see also 3.2). 
N 
 4.4. Was the intervention implemented successfully for most participants?  Y 
 4.5. Did study participants adhere to the assigned intervention regimen?  Y 
 4.6. If N/PN to 4.3, 4.4 or 4.5: Was an appropriate analysis used to 
estimate the effect of starting and adhering to the intervention? 
 - 
 Risk of bias judgement  Serious 
 Optional: What is the predicted direction of bias due to deviations from 
the intended interventions? 
 Unpredictable 
Bias due to missing data   
 5.1 Were outcome data available for all, or nearly all, participants?  Y 
 5.2 Were participants excluded due to missing data on intervention status? Patients were a-priori excluded when outcome data of 12 months or more was not 
available. However, patients were not excluded from study, when matched-pair 
analysis was done. 
N 
 5.3 Were participants excluded due to missing data on other variables 
needed for the analysis? 
Patients with missing oncological data were excluded. PY 
 5.4 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Are the proportion of participants 
and reasons for missing data similar across interventions? 
It is not clear how many patients, who received control intervention, were 
excluded for final analysis. 
NI 
 5.5 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Is there evidence that results were 
robust to the presence of missing data? 
 NI 
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 Signalling questions Description Response options 
 Risk of bias judgement  Serious  
 Optional: What is the predicted direction of bias due to missing data?  Unpredictable 
Bias in measurement of outcomes    
 6.1 Could the outcome measure have been influenced by knowledge  
of the intervention received? 
Study mainly measured “soft” outcomes. Y 
 6.2 Were outcome assessors aware of the intervention received by  
study participants? 
Study is a matched-pair analysis of two single-arm studies. Therefore, it was 
assumed that assessors were aware of intervention.  
Y 
 6.3 Were the methods of outcome assessment comparable across 
intervention groups? 
The same outcome detection methods and thresholds, same definition, and same 
measurements were used. However, it is not clear, if outcome assessment was 
done at same time point for all patients. 
PY 
 6.4 Were any systematic errors in measurement of the outcome related 
to intervention received? 
Same classification systems were used. N 
 Risk of bias judgement  Serious 
 Optional: What is the predicted direction of bias due to measurement  
of outcomes? 
 Unpredictable 
Bias in selection of the reported result   
 Is the reported effect estimate likely to be selected, on the basis of  
the results, from ... 
  
 7.1. ... multiple outcome measurements within the outcome domain?   N 
 7.2 ... multiple analyses of the intervention-outcome relationship?  N 
 7.3 ... different subgroups?  N 
 Risk of bias judgement  Low 
 Optional: What is the predicted direction of bias due to selection of the 
reported result? 
 Towards null 
Overall bias   
 Risk of bias judgement  Serious 
 Optional: What is the overall predicted direction of bias for this outcome?  Unpredictable 
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Table A-5: Risk of bias – study level (case series), (IHE-20-Criteria checklist)  
Y/N/Partial/Unclear 
Van Velthoven, 
2016 [23] 
Ganzer,  
2017[21] 
Rischmann,  
2017 [22] 
Feijoo,  
2015 [20] 
Ahmed,  
2012 [24] 
Study objective 
1 Was the hypothesis/aim/objective of the study clearly stated? Yes Partial Yes Yes Partial 
Study design 
2 Was the study conducted prospectively? Yes Yes Yes Yes Unclear 
3 Were the cases collected in more than one centre? No Yes No Yes Yes 
4 Were patients recruited consecutively? Unclear Yes Unclear Unclear Yes 
Study population 
5 Were the characteristics of the patients included in the study described? Yes Yes Yes Yes Yes 
6 Were the eligibility criteria (i.e. inclusion and exclusion criteria) for entry into the study clearly stated? Yes Yes Yes Yes Partial 
7 Did patients enter the study at a similar point in the disease? Yes Yes Yes Yes Yes 
Intervention and co-intervention 
8 Was the intervention of interest clearly described? Yes Yes Yes Yes Partial 
9 Were additional interventions (co-interventions) clearly described? Yes Partial Yes Yes Partial 
Outcome measure 
10 Were relevant outcome measures established a priori? Yes Yes Yes Yes Yes 
11 Were outcome assessors blinded to the intervention that patients received? No No No No No 
12 Were the relevant outcomes measured using appropriate objective/subjective methods? Yes Yes Yes Yes Yes 
13 Were the relevant outcome measures made before and after the intervention? Partial Yes Yes Yes Yes 
Statistical analysis 
14 Were the statistical tests used to assess the relevant outcomes appropriate? No Yes Yes Yes Yes 
Results and conclusions 
15 Was follow-up long enough for important events and outcomes to occur?  Partial Partial Partial Partial Partial 
16 Were losses to follow-up reported? Yes Yes Yes Yes Yes 
17 Did the study provided estimates of random variability in the data analysis of relevant outcomes? No Yes Yes Yes Yes 
18 Were the adverse events reported? Yes Yes Yes Yes Yes 
19 Were the conclusions of the study supported by results? Unclear Yes Yes Yes Yes 
Competing interests and sources of support 
20 Were both competing interests and sources of support for the study reported? Partial No Yes Yes Yes 
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Table A-6: Evidence profile: efficacy and safety of primary HIFU versus brachytherapy  
Quality assessment 
Summary of findings 
Importance 
Number of patients Effect  
Quality Number  
of studies  
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other  
considerations HIFU brachytherapy 
Relative 
(95% CI) 
Absolute  
(95% CI) 
Overall survival rate (follow up: 5 years)  
1 Observational 
study 
(matched-pair 
analysis) 
Serious61 NA  
(only 1 trial) 
Serious61 Serious59 Plausible 
confounding 
(would suggest 
spurious effect) 
62/70 
(89%) 
68/70  
(97%) 
HR 0.24 
(0.01 to 
1.34) 
397 fewer  
per 1,000 
(from 20 more 
to 936 fewer) 
Very 
low 
Critical  
Prostate cancer specific survival rate (follow up: 5 years)  
1 Observational 
study 
(matched-pair 
analysis) 
Serious60 NA  
(only 1 trial) 
Serious61 Serious62 Plausible 
confounding 
(would suggest 
spurious effect) 
62/70 
(89%) 
64/70  
(92%) 
HR 0.67 
(0.32 to 
1.29) 
107 fewer  
per 1,000 
(from 44 more 
to 370 fewer) 
Very 
low 
Critical  
Local diseases recurrence (follow up: 5 years): NA  
Intervention-specific mortality (follow up: median 83 vs. 44 months)  
1 Observational 
study 
(matched-pair 
analysis) 
Serious60 NA  
(only 1 trial) 
Serious61 Serious63 None 0/70  
(0%) 
0/70  
(0%) 
Not 
estimable 
NA Very 
low 
Critical 
Functional outcomes: urinary (dys)function (physician reported events) (follow up: median 83 vs. 44 months)  
1 Observational 
study 
(matched-pair 
analysis) 
Serious64 NA  
(only 1 trial) 
Serious61 Serious65 All plausible re-
sidual confounding 
would reduce the 
demonstrated 
effect 
5/69 
(7.2%) 
2/53  
(3.8%) 
RR 1.92 
(0.39 to 
9.51)66 
34 more  
per 1,000  
(14 fewer to 
359 more) 
Very 
low 
Critical 
                                                             
59 Imprecision was set “serious” for this particular endpoint, since the confidence interval (0.01 to 1.34) indicates considerable harm due to HIFU. 
60 Risk of bias for this particular endpoint was set “serious” due to risk of bias assessment of study and particularly due to difference between study groups in age. 
61 Indirectness was set “serious” for this particular endpoint, since this study was claimed to be the first to compare patients treated by HIFU and brachytherapy.  
Furthermore, in this study two generations of Ablatherm® devices were used, whereas Ablatherm® Maxis is not commercially available anymore. Moreover,  
there was no information provided on additional treatments and pre-treatment prostate volume.  
62 Imprecision was set “serious” for this particular endpoint, since the confidence interval (0.32 to 1.29/0.39 to ) indicates considerable harm due to HIFU. 
63 Imprecision was set “serious” for this particular endpoint, since the probability of intervention-specific mortality is estimated to be low and patient number  
must be higher to detect differences. 
64 Risk of bias for this particular endpoint was set “serious”, due to risk of bias assessment of study particularly the difference between study groups in age and length of follow up. 
Furthermore, it was not stated how many patients suffered from incontinence before the interventions. 
65 Imprecision was set “serious” for this particular endpoint, since the confidence interval (0.39 to 9.51) indicates considerable harm due to HIFU. 
66 Caclulated with MedCalc© (http://www.medcalc.org/calc/relative_risk.php). 
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Quality assessment 
Summary of findings 
Importance 
Number of patients Effect  
Quality Number  
of studies  
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other  
considerations HIFU brachytherapy 
Relative 
(95% CI) 
Absolute  
(95% CI) 
Functional outcomes: sexual (dys)function (events) (follow up: median 83 vs. 44 months)  
1 Observational 
study 
(matched-pair 
analysis) 
Serious67 NA  
(only 1 trial) 
Not 
serious68 
Serious62 None 5/43 
(11.6%) 
NA Not 
estimable 
NA Very 
low 
Critical 
Serious adverse events (follow up: mean 12 months)  
1 Observational 
study 
(matched-pair 
analysis) 
Serious69 NA  
(only 1 trial) 
Serious61 Serious70 All plausible re-
sidual confounding 
would reduce the 
demonstrated 
effect 
17/70 
(24.3%) 
5/70  
(7.1%) 
Not 
estimable 
NA Very 
low 
Critical 
Serious adverse events (follow up: median 83 vs. 44 months)  
1 Observational 
study 
(matched-pair 
analysis) 
Serious69 NA  
(only 1 trial) 
Serious61 Serious70 All plausible re-
sidual confounding 
would reduce the 
demonstrated 
effect 
18/70 
(25.7%) 
4/70  
(5.7%) 
Not 
estimable 
NA Very 
low 
Critical 
Abbreviations: CI = confidence interval, HIFU = high-intensity focused ultrasound, IPSS = international prostate symptom score,  
IIEF-5 = international index of erectile function, NA = not applicable  
Sources: [19] 
  
                                                             
67 Risk of bias for this particular endpoint was set “serious”, due to risk of bias assessment of study, particularly the difference between study groups in age and length of follow-up. 
Furthermore, measurement of sexual (dys)function was exclusively done for HIFU-patients. 
68 Indirectness cannot be assessed, because study exclusively reported sexual (dys)function for HIFU-patients. 
69 Risk of bias for this particular endpoint was set “serious”, due to the difference between study groups in age (see also risk of bias assessment of study). Furthermore,  
the study exclusively reported the number of complications and not the number of patients with complications. 
70 Imprecision was set “serious” for this particular endpoint, because the patient number was too low to detect rare adverse events. 
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Table A-7: Evidence profile: safety of primary HIFU (single-arm studies) 
Quality assessment 
Summary of findings 
Importance 
Number of patients Effect 
Quality Number  
of studies  
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other 
considerations Pre-HIFU Post-HIFU 
Relative 
(95% CI) 
Absolute  
(95% CI) 
Intervention-specific mortality (follow up: range mean 16.3 months to mean 44.5 months; assessed with number of events) 
4  Observational 
study 
Serious71 Not serious Serious72 Serious73 None 0/279 
(0.0%) 
0/279  
(0.0%) 
Not 
estimable 
NA Very 
low 
Critical 
Functional outcomes: urinary (dys)function (follow up: 12 months; assessed with usage of pads) 
4 Observational 
study 
Serious71 Not serious Serious72 Serious73 None 2/270 
(0.7%) 
9/270  
(3.3%) 
Not 
estimable 
NA Very 
low 
Critical 
Functional outcomes: urinary (dys)function (follow up: range 3 months to 12; assessed with IPSS, Scale from 0 to 26 worse) 
3 Observational 
study 
Serious71 Serious74 Serious72 serious73 None 19875 198 Not pooled NA Very 
low 
Critical 
Functional outcome: sexual (dys)function (follow up: range 3 months to 12; assessed with IIEF-5, Scale from: 0 to 25 worse) 
3  Observational 
study 
Serious71 Not serious Serious72 Serious73 None NA76 NA Not 
pooled77 
NA Very 
low 
Critical 
Functional outcomes: sexual (dys)function (follow up: 3 months; assessed with physician reported rates of de novo erectile dysfunction) 
3  Observational 
study 
Serious71 Serious78 Serious72 Serious73 None 0/122 
(0.0%) 
27/122 
(22.1%) 
Not 
estimable 
NA Very 
low 
Critical 
Serious adverse events (follow up: range 1 to 12 months; assessed with number of events) 
4 Observational 
study 
Serious71 Serious79 Serious72 Serious73  None 0/273 
(0.0%) 
15/27380 
(5.5%) 
Not 
estimable 
NA Very 
low 
Critical 
                                                             
71 No control group.  
72 The studies can only yield indirect evidence regarding the safety of HIFU compared to standard therapies  
as there was no control arm (safety outcomes could only be compared to historical controls). 
73 Low sample size. 
74 There is inconsistency in the results as two studies reported no significant change in the score,  
while one study reported a significant mean decrease (meaning improvement) in the score. 
75 The number of patients answering the questionnaire pre- and post-treatment. 
76 The number of patients answering the questionnaire was not available.  
77 The range of effect: 1.2 to 4 
78 There is inconsistency as two studies reported around 20% of pre-HIFU potent patients being post-HIFU impotent,  
while one study reported over 47% of pre-HIFU potent patients being post-HIFU impotent. 
79 There is inconsistency in the percentage of patients presented with an adverse event per study as one study reported in 41% of patients occurred adverse event,  
another study reported 15%, two studies did not report the percentage of patients in whom adverse event occurred, but the total number of adverse events and  
these studies did not specify how many patients experienced the adverse event. 
80 Number of events in the total number of patients. 
Abbreviations: CI = confidence interval, HIFU = high-intensity focused ultrasound,  
IPSS = international prostate symptom score,  
IIEF-5 = international index of erectile function,  
NA = not applicable 
Sources: [20-23] 
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Table A-8: Evidence profile: safety of salvage HIFU 
Quality assessment Number of patients Effect 
Quality  Importance Number 
of studies 
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
Pre-salvage-
HIFU 
Post-salvage-
HIFU 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Intervention-specific mortality (follow up: mean 19.8 months) 
1  Observational 
study 
Serious81 NA  
(only 1 study) 
Serious83 Very 
serious84 
None  0/84 (0.0%)  0/84 (0.0%)  not 
estimable  
NA Very 
low 
Critical 
Functional outcomes: urinary (dys)function (follow up: 6 months; assessed with IPSS ) 
1  Observational 
study 
Serious82  NA  
(only 1 study) 
Serious83  Very 
serious84  
None  3985  39  NA NA Very 
low 
Critical 
Functional outcomes: sexual (dys)function (follow up: 6 months; assessed with IIEF-5 ) 
1  Observational 
study 
Serious86  NA  
(only 1 study) 
Serious83  Very 
serious84  
None  4385  43  NA NA Very 
low 
Critical 
Complications/adverse events (follow up: mean 19.8 months; assessed with number of events) 
1  Observational 
study 
Serious81  NA  
(only 1 study) 
Serious83  Very 
serious84  
None  0/84 (0.0%)  55/8480 
(65.5%)  
Not 
estimable  
NA Very 
low 
Critical 
Abbreviations: CI = confidence interval, HIFU = high-intensity focused ultrasound, IPSS = international prostate symptom score,  
IIEF-5 = international index of erectile function, NA = not applicable 
Sources: [24] 
 
                                                             
81 No control group. 
82 No control group, follow-up data available only for 39 patients (46%).  
83 Only failed EBRT patients were included (we do not have information on patients failed after other treatment modalities like prostatectomy or HIFU).  
The studies can only yield indirect evidence on HIFU compared to standard therapies as there was no control group. 
84 Very low sample size. 
85 Number of patients answering the questionnaire pre-and post-treatment.  
86 No control group, follow-up data available only for 43 patients (51%). 
Appendix 
LBI-HTA | 2018 89 
Applicability table 
Table A-9: Summary table characterizing the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The enrolled populations in the studies do not differ substantially from the target population; 
therefore the findings are generalizable to the target population.  
Intervention Only the Ablatherm® device was used in all of the primary HIFU studies and only the Sonablate® 
device in the study on salvage HIFU. This does not reflect clinical practice, as both devices can be 
used in both primary and salvage setting. The matched-pair analysis study used in the beginning of 
the study period the Ablatherm® Maxis device which is the predecessor of the current Ablatherm® 
device and the applied device generation might negatively affect occurrence of adverse events. 
Patients in the matched-pair analysis treated with the Maxis Ablatherm® (not commercially available 
anymore) had a higher number of complications than patients treated with the newer device 
(Ablatherm® Integrated Imaging) [19]. Nevertheless, the study did neither report on how many 
patients were treated with which HIFU-device, nor on the percentage of patients per sub-group with 
complications. Thus, a definitive conclusion cannot be drawn. Also, only one primary HIFU study 
described concomitant TURP which might not reflect how the intervention is done routinely and 
might affect the harms associated with the intervention.  
Comparators The only one comparative study compared HIFU with brachytherapy, which is only one of the 
standard treatment modalities. There were no other comparative studies. For salvage HIFU there 
was no comparative study available.  
Outcomes Most frequently reported outcomes were overall survival rate, urinary function, sexual function 
and complications/adverse events. The oncologic outcomes were reported on very different time 
spans. Overall survival rate was reported either at 1 year or at 5 years. Sexual function (IIEF-5 score) 
was reported at 12 months post-operatively and urinary function (IPSS score and usage of pads) 
was reported either at 12 months or at 3 months post-operatively. It was often not stated over 
what time period complications/adverse events were reported. The follow-up period for these 
outcomes is very short. Overall survival would require at least 5 year follow-up, but 10 year would 
be desirable. Functional outcomes would also need to be followed-up on a longer time period.  
Setting The studies represent a geographic spread across Western European countries. Clinical settings 
were not described in any of the studies. It was stated in some of the studies that experienced 
surgeon conducted the intervention which might have a relevance in the harms associated with 
the intervention, but as the prerequisite for the surgeon of receiving a certificate from the 
manufacturer is to complete a training and a certain number of treatments with a supervisor from 
the manufacturer, this is unlikely that unexperienced surgeons will perform the intervention. 
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List of ongoing controlled trials 
Table A-10: List of ongoing controlled trials of HIFU 
Study  
Identifier 
Estimated 
completion 
date 
Study  
type 
Number  
of 
patients Intervention Comparator Patient population Endpoints 
NCT00295802 September 
2014 (status 
unknown, no 
publication 
found) 
RCT (non-
inferiority) 
141 HIFU 
(device not 
stated) 
Cryotherapy  Diagnosis of prostate cancer confirmed  
by PSA and prostate biopsy, 
 Male, aged ≥ 50 years, 
 Organ-confined PCa, clinical stage T1a, b, 
or c or T2a, 
 ≥ 1 positive biopsy within the previous  
6 months, 
 PSA ≤ 10 ng/ml, 
 Gleason score ≤ 6, 
 Histological grading of 3+3, 3+2, 2+3, 2+4, 
or 2+2 based upon baseline TRUS-guided 
10 core biopsy, 
 Prostate volume ≤ 40 cc, 
 Prostate anteroposterior diameter ≤ 25 mm, 
 Normal rectal anatomy and rectal mucosa, 
 < 6mm rectal wall measurement , 
 The subject is willing and able to read, 
understand, and sign the study specific 
informed consent form, 
 The subject agrees to comply with study 
protocol requirements, including HIFU or 
cryotherapy treatment and all follow up 
visit requirements through 24 months of 
follow up. 
Primary: 
 Attainment achievement of PSA  
nadir < 0.5 ng/ml and stability of PSA 
according to ASTRO criteria through 
24 month follow up without a positive 
biopsy (timeframe: 24 month). 
Secondary: 
 Achievement of a nadir PSA within  
6 months < 0.5 ng/ml (timeframe:  
6 months), 
 Overall survival, defined as time to 
death due to any cause (timeframe: 
from date of treatment until the date 
of death due to any cause), 
 Disease specific survival, defined as 
the time to death due to the underlying 
disease (timeframe: from date of 
treatment until the date of death due 
to the underlying cause), 
 Change from baseline in the UCLA 
QOL (timeframe: 1 month, 6 months, 
12 months, 24 months), 
 Change from baseline in the IPSS 
(timeframe: 1 month, 6 months,  
12 months, 24 months). 
NCT00770822 December 
2017 
(terminated 
due to lack of 
inclusions)87 
Non-
randomized 
concurrently 
controlled 
study 
466 HIFU 
(Sonablate) 
Brachytherapy  T1c or T2a carcinoma of the prostate 
confirmed by biopsy, 
 Life expectancy ≥ 5 years, 
 Prostate biopsy with ≥ 10 core biopsies, 
 Gleason score ≤ 6, 
 Serum PSA ≤ 10 ng/ml, 
 Prostate volume ≤ 40cc, 
 Distance from the anterior capsule  
surface to the posterior capsule surface 
(AP Diameter) ≤ 40 cm, 
 Informed consent for the treatment study 
through 24 months post-treatment follow-up. 
Primary: 
 Absence of biochemical failure 
(timeframe: 24 months) 
                                                             
87 See: http://www.eu-focus.europeanurology.com/article/S2405-4569(15)00031-0/pdf  
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1 
Study  
Identifier 
Estimated 
completion 
date 
Study  
type 
Number  
of 
patients Intervention Comparator Patient population Endpoints 
NCT03348722 November 
2019 
Non-
randomised 
controlled 
study (cohort 
study)  
3,000 Active 
surveillance 
Radical 
prostatectomy, 
radiotherapy, 
Other radical 
treatments 
(HIFU, 
cryotherapy, 
others) 
 Newly diagnosed low risk PCa patients, 
defined according to the presence of all  
the following criteria: 
 Diagnosis of adenocarcinoma of the 
prostate, 
 PCa clinical stage T1c o T2a, 
 PSA ≤10ng/ml at diagnosis, 
 Adequate biopsy sampling according  
to prostate volume, 
 ≤ 2 positive cores for random sampling 
and ≤ 2 lesions for target biopsies (even 
if the number of positive samples if >2) 
 Gleason grade 3+3  
( in patients age>70 Gleason 3+4) 
 Residence in Piemonte or Valle D'Aosta 
regions, 
 Patients suitable for radical treatment 
(surgery or radiotherapy), 
 Age at diagnosis ≤ 75 years or >75 years  
if fragility assessment (measured with the 
G8 score) ≥14, 
 Patients suitability for expressing a valid 
consent to participate in the study. 
Primary:  
 Treatment-Free Survival  
Secondary: 
 Quality of life 
NCT00777452 October 2008 
(recruiting 
completed, no 
publication 
found) 
Non-
randomised 
controlled 
study (cohort 
study) 
93 Active 
surveillance 
Radical 
prostatectomy, 
radiotherapy, 
HIFU 
Patients diagnosed with clinically  
localised PCa. 
Primary: 
 HRQoL changes over time 
Secondary: 
 Urinary symptom score and erectile 
function over time 
DRKS00005179 NA 
(recruiting 
planned) 
RCT 60 HIFU 
(Ablatherm®) 
No intervention  Male, 
 18 – 80 years, 
 High risk patients (PSA<20 ng/ml,  
Gleason Score ≥8) 
 Life expectancy ≥10 years. 
Primary: 
 Biochemical disease free survival 
Secondary: 
 Recurrence 
 Necessity of additional therapy 
 QoL 
Abbreviations: ASTRO = American Society for Radiation Oncology, BCR = biochemical recurrence, BCRFS = biochemical recurrence free survival, HIFU = high-intensity focused ultrasound, 
HRQoL = health-related quality of life, IPSS = International Prostate Symptom Score, NA = not available, PCa = prostate cancer, PSA = prostate specific antigen,  
TRUS = trans-rectal ultrasound imaging, UCLA-QOL = University of California, Los Angeles Quality of Life, QoL = quality of life 
Sources: ClinicalTrials.gov; WHO ICTRP; EU Clinical Trail (EudraCT) Register 
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Table A-11: Overview of guidelines on HIFU 
Name of society/ 
organisation issuing guidance 
Date of 
issue 
Country/ies  
to which applicable 
Summary  
of recommendation 
Level of evidence (A,B,C)/class 
of recommendation (I, IIa, IIb, III) 
EAU-ESTRO-SIOG 2016 Europe Only offer HIFU within a clinical trial setting. The lack of long-term efficacy 
compared to standard modality has to be discussed with patients. 
Do not offer focal treatment outside clinical trials. 
Offer/discuss salvage HIFU to/with patients without evidence of metastasis 
and with histologically proven local recurrence. Inform them about the 
experimental nature of it. 
C 
 
A 
B/III 
NICE 2014 UK Do not offer HIFU to men with localised prostate cancer other than in the context 
of controlled clinical trials comparing its use with established interventions. 
“strong” recommendation 
S3 Leitlinie 2016 Germany HIFU is an experimental treatment and should be offered only in  
prospective studies. 
A/III 
AUA-ASTRO-SUO 2017 USA Clinicians should inform those localised prostate cancer patients  
considering focal therapy or HIFU that  
 these treatment options lack robust evidence of efficacy. 
 even though HIFU is approved by the FDA for the destruction of prostate 
tissue, it is not approved explicitly for the treatment of prostate cancer. 
 tumour location may influence oncologic outcome. Limiting apical 
treatment to minimize morbidity increases the risk of cancer persistence. 
 focal therapy may not be curative and that further treatment for prostate 
cancer may be necessary. (As prostate cancer is often multifocal). 
 
 
Expert opinion 
Expert opinion 
 
C/moderate recommendation 
 
Expert opinion 
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Literature search strategies 
Search strategy for Cochrane 
Search Date: 01/12/2017  
ID Search 
#1 MeSH descriptor: [Prostatic Neoplasms] explode all trees 
#2 (prostat* near (cancer* or neoplasm* or carcinoma* or tumo*r* or adenoma*)) (Word variations have been 
searched) 
#3 #1 or #2 
#4 MeSH descriptor: [High-Intensity Focused Ultrasound Ablation] explode all trees 
#5 MeSH descriptor: [Ultrasound, High-Intensity Focused, Transrectal] explode all trees 
#6 high-intens* focus*ed ultra*sound* (Word variations have been searched) 
#7 high-intens* focal* ultra*sound* (Word variations have been searched) 
#8 HIFU:ti,ab,kw (Word variations have been searched) 
#9 Magnetic resonance-guided focus*ed ultra*sound* (Word variations have been searched) 
#10 MR*-guided focus*ed ultra*sound* (Word variations have been searched) 
#11 Ablatherm:ti,ab,kw (Word variations have been searched) 
#12 EDAP:ti,ab,kw (Word variations have been searched) 
#13 Sonablate (Word variations have been searched) 
#14 Focus Surgery:ti,ab,kw (Word variations have been searched) 
#15 ExAblate:ti,ab,kw (Word variations have been searched) 
#16 Insightec:ti,ab,kw (Word variations have been searched) 
#17 #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 
#18 #3 and #17 Publication Year from 2010 to 2017 
Total: 106 Hits 
 
 
Search strategy for CRD 
Search Date: 01/12/2017  
ID Search 
1 MeSH DESCRIPTOR Prostatic Neoplasms EXPLODE ALL TREES 
2 MeSH DESCRIPTOR Prostatic Neoplasms, Castration-Resistant EXPLODE ALL TREES 
3 (prostat* NEAR (cancer* OR neoplasm* OR carcinoma* OR tumo*r* OR adenoma*)) 
4 #1 OR #2 OR #3 
5 MeSH DESCRIPTOR High-Intensity Focused Ultrasound Ablation EXPLODE ALL TREES 
6 MeSH DESCRIPTOR Ultrasound, High-Intensity Focused, Transrectal EXPLODE ALL TREES 
7 (high-intens* focus*ed ultra*sound*) 
8 (high-intens* focal ultra*sound*) 
9 (HIFU) 
10 (Magnetic resonance-guided focus*ed ultra*sound*) 
11 (MR*-guided focus*ed ultra*sound*) 
12 (Ablatherm) 
13 (EDAP) 
14 (Sonablate) 
15 (Focus Surgery) 
High-intensity focused ultrasound for the treatment of prostate cancer 
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16 (ExAblate) 
17 (Insightec) 
18 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 
19 #4 AND #18 
20 *WHERE LPD FROM 29/01/2010 TO 01/12/2017 
21 #19 AND #20 
Total: 13 Hits 
 
 
Search strategy for Embase 
Search Date: 01/12/2017 Results 
#27 #25 AND 'human'/de AND ([english]/lim OR [german]/lim) 580 
#26 #25 AND 'human'/de 601 
#25 #3 AND #23 AND [29-1-2010]/sd NOT [1-12-2017]/sd 711 
#24 #3 AND #23 972 
#23 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR 
#17 OR #18 OR #19 OR #20 OR #21 OR #22 
5,097 
#22 insightec:df 142 
#21 exablate:dn 134 
#20 'focus surgery':df 48 
#19 sonablate:dn 80 
#18 edap:df 110 
#17 ablatherm:dn 88 
#16 'magnetic resonance-guided focus*ed   343 
#15 insightec/df 139 
#14 exablate/dn 31 
#13 'focus surgery'/df 47 
#12 sonablate/dn 33 
#11 edap/df 100 
#10 ablatherm/dn 71 
#9 'mr*-guided focus*ed ultra*sound*':ti,ab   845
#8 'mr-guided focused ultrasound device'/exp 10 
#7 'mr-guided focused ultrasound'/exp 54 
#6 hifu:ti,ab 3,045 
#5 'high-intens* focus*ed ultra*sound*':ti,ab   3,398 
#4 'high intensity focused ultrasound'/mj/exp 2,593 
#3 #1 OR #2 137,630 
#2 ((recurrent OR relapsed OR 'locally advanced' OR 'clinically localised' OR 'clinically localized') 
NEAR/1 prostat* NEAR/1 (cancer* OR neoplasm* OR carcinoma* OR tumor* OR tumour* OR 
adenoma*)):ti,ab 
6,380 
#1 'prostate tumor'/mj/exp 136,717 
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Search strategy for Ovid MEDLINE(R) 
Search Date: 01/12/2017  
ID Search Results 
1 exp Prostatic Neoplasms/ 123,427 
2 (prostat* adj2 (cancer* or neoplasm* or carcinoma* or tumo?r* or adenoma*)).mp. 155,384 
3 1 or 2 1553,84 
4 exp High-Intensity Focused Ultrasound Ablation/ 1,788 
5 exp Ultrasound, High-Intensity Focused, Transrectal/ 486 
6 high-intens* focus?ed ultra?sound*.mp. 3,138 
7 high-intens* focal ultra?sound*.mp. 8 
8 HIFU.ti,ab. 2,072 
9 Magnetic resonance-guided focus*ed ultra*sound*.mp. 257 
10 MR?-guided focus?ed ultra?sound*.mp. 298 
11 Ablatherm.ti,ab. 58 
12 EDAP.ti,ab. 196 
13 Sonablate.ti,ab. 44 
14 Focus Surgery.ti,ab. 19 
15 ExAblate.ti,ab. 48 
16 Insightec.ti,ab. 45 
17 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 4,054 
18 3 and 17 860 
19 limit 18 to ed=20100129-20171201 513 
20 ("17034499" or "16831068" or "16834675" or "18704441" or "19021611" or "19268572" or "19513068" or 
"16287436" or "16829268" or "16011815" or "18651999" or "19084862" or "16971038" or "18718643" 
or "17921730" or "18409659" or "12756085" or "10671777" or "18025853" or "18025852" or "19388986" 
or "18313119" or "17997026" or "18829078" or "16850340" or "14972475" or "15161124" or "19337912" 
or "17339141" or "18508189" or "18852702" or "19220245" or "17006697" or "11062372" or "11394458" 
or "12756090" or "16474762" or "10795622" or "19455298" or "19334790" or "18491529" or "16237234" 
or "16467581" or "19098966" or "16285451" or "18164806" or "18949746" or "18476973" or "15452554" 
or "14977222" or "11885680" or "16286025" or "19856677" or "18508190" or "16225512" or "18544989" 
or "17432561" or "19163505" or "15675669" or "15000627" or "18094311" or "19764975" or "17573894" 
or "17699732" or "17218948" or "17997016" or "19997112" or "17936815" or "17125477" or "17997014" 
or "19091354" or "17662520" or "16425987" or "10954310" or "11528187" or "15072864" or "16430617" 
or "16536790" or "19084860" or "17482933" or "19406315" or "15933426" or "19499752" or "16861120" 
or "17356831" or "15963124" or "17956536" or "17382151" or "12909212" or "19357510" or "16278168" 
or "11212878" or "18507002" or "15245946" or "17578342" or "17280536" or "17125476" or "17960490" 
or "18521101" or "15162826" or "18533805" or "11221062" or "18025857" or "18430829" or "18561684" 
or "18223121" or "17936800" or "16107241" or "16362603" or "17434108" or "14716736" or "16894640" 
or "12796636" or "16847468" or "19412512" or "17495490" or "19298406" or "18831671" or "16197615" 
or "15592029" or "19391448" or "19326161" or "17430694" or "19047195" or "19260381" or "19095127" 
or "17414518" or "17437427" or "16813071" or "19081465" or "16344253" or "12827258" or "18581118" 
or "18024094" or "18419995" or "17615530" or "18508188" or "18281309" or "17155972" or "18502487" 
or "15963152" or "16225515" or "17225800" or "16430625" or "18258351" or "15877941" or "16857310" 
or "18382236" or "12600425" or "19084847" or "17378856" or "12096077" or "12096076" or "16053358" 
or "18325057" or "17121439" or "12532172" or "16144674" or "17459269" or "16013714" or "15264239" 
or "11684842" or "16439055" or "12243656" or "15182413" or "17414071" or "10765094" or "16281097" 
or "17880293" or "17557565" or "17482931" or "18070196" or "17549907" or "17682946" or "19451896" 
or "19098969" or "12878247" or "17482937" or "17688922" or "17919699" or "16145391" or "18355899" 
or "11425148" or "18070694" or "11337740" or "11062373" or "11405127" or "17593339" or "14622488" 
or "15816628" or "18211209" or "19386137" or "16285617" or "16879448" or "16925749" or "16336329" 
or "16643614" or "11880077" or "18242358" or "15126799" or "10889823" or "17958041" or "19220260" 
or "15027239" or "17659632" or "17365674" or "18699899" or "17499292" or "18564135").ui. 
229 
21 18 not 20 661 
22 19 or 21 661 
23 exp animals/not humans.sh. 4,743,197 
24 22 not 23 648 
25 limit 24 to (english or german) 577 
26 remove duplicates from 25 501 
Total: 501 Hits 
High-intensity focused ultrasound for the treatment of prostate cancer 
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Clinical trials registry search 
ClinicalTrials.gov  
Date: 29/12/2017 
(Advanced Search): ( prostate OR prostatic OR prostat* ) [DISEASE] AND ( High-Intensity Focused  
Ultrasound OR Magnetic resonance-guided focused ultrasound OR HIFU OR MRgFUS ) [TREATMENT] 
33 Hits 
 
WHO-ICTRP  
Date: 02/01/2017 
Basic Search mode: focused ultrasound AND prostat* 
32 (9 new) Hits 
 
EU Clinical Trials (EUdraCT) Register 
Date: 02/01/2017 
focused ultrasound 
4 (0 new) Hits 
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Regulatory and reimbursement status 
Table A-12: Regulatory status of HIFU devices 
 Country 
Institution 
issuing 
approval 
Authorisation 
status yes/no/ 
ongoing 
Verbatim wording of the 
(anticipated) indication(s) Specified contra-indications 
Date of approval  
(include expiry date for 
country of assessment) 
Launched yes/no 
If no include date 
of launch 
Sonablate®500 
Sonatherm® 
Europe CE mark 
(NB 0843) 
Yes Sonablate®: 
transrectal treatment of prostate 
cancer88 
Sonablate® 500: for treatment of 
primary and focal prostate cancer.89 
Sonatherm®: laparoscopic or 
intraoperative ablation of soft tissue 
from the ultrasound focal zone back 
to the surface of the targeted 
ablation area in general surgery.90 
Sonablate®: 
>10mm fluid-filled cavities, large 
reflective surfaces observed in the 
ablation zone. 
Metal implants or stents in the urethra. 
Brachytherapy seeds adjacent to the 
posterior prostate capsule, the Denon-
villiers’ fascia, or the rectal wall. 
Pre-existing inflammatory disease  
of the colon or rectum. 
Prior significant rectal surgery. 
Inability to insert or tolerate  
a transrectal ultrasound probe. 
Active urinary tract infection. 
Urethral stricture. 
Latex allergy.91 
Sonatherm® is not to be used to 
spare intervening tissue. 
Sonablate® 500: 
200192 
Sonatherm®:  
March, 201593 
Yes 
                                                             
88 http://sonacaremedical.com/index.php?option=com_content&view=article&id=38&Itemid=36  
89 https://www.fusfoundation.org/news/728-sonacares-devices-treat-prostate-cancer-other-urological-conditions  
90 http://sonacaremedical.com/index.php/surgeons/peer-reviewed-library  
91 http://sonacaremedical.com/index.php/surgeons/starting-my-hifu-practice  
92 http://drstevensukinurology.com/blog/hifu-high-intensity-focused-ultrasound-for-prostate-cancer/  
93 EC CERTIFICATE sent via email 
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 Country 
Institution 
issuing 
approval 
Authorisation 
status yes/no/ 
ongoing 
Verbatim wording of the 
(anticipated) indication(s) Specified contra-indications 
Date of approval  
(include expiry date for 
country of assessment) 
Launched yes/no 
If no include date 
of launch 
Sonablate®500 
Sonatherm® 
USA FDA Sonablate® 500: 
yes 
Sonatherm®: is 
510(k) cleared.94 
Sonablate® 500: transrectal high 
intensity focused ultrasound 
(HIFU) ablation of prostatic 
tissue95, 96 
- Sonablate®:  
Oct, 2015 
yes 
Ablatherm® Europe CE mark Yes Localised prostate cancer (T1, T2) as 
first choice therapy for non-
candidates to surgery and as salvage 
therapy for local recurrence after 
radiotherapy, brachytherapy, radical 
prostatectomy and HIFU97. 
- Ablatherm® Maxis: 
200098, 99 
Ablatherm® Integrated 
Imaging: 2005100 
yes 
Ablatherm® USA FDA Yes Ablation of the prostate tissue101 - Oct, 2015102 Yes 
Focal One® Europe CE mark Yes Focal therapy of prostate cancer103, 
non-invasive treatment of prostate 
cancer104 
 June, 2013105 Yes 
Focal One® USA FDA No106 - - - EDAP filed for new 
510(k) application107 
                                                             
94 http://sonacaremedical.com/index.php/blog/press-releases/62-us-hifu-announces-name-change-to-sonacare-medical  
95 http://sonacaremedical.com/index.php/surgeons/our-products/sonablate-ablation-tool  
96 https://www.accessdata.fda.gov/cdrh_docs/pdf16/K160942.pdf  
97 http://www.fusfoundation.org/images/pdf/Prostate_System_Comparison_Chart_Jan2016.pdf  
98 https://www.edap-tms.com/en/about-edap-tms/a-tradition-of-innovation  
99 http://www.fusfoundation.org/images/pdf/Prostate_System_Comparison_Chart_Jan2016.pdf  
100 http://www.fusfoundation.org/images/pdf/Prostate_System_Comparison_Chart_Jan2016.pdf  
101 https://www.accessdata.fda.gov/cdrh_docs/pdf15/k153023.pdf  
102 https://www.accessdata.fda.gov/cdrh_docs/pdf15/k153023.pdf  
103 https://globenewswire.com/news-release/2017/12/18/1263273/0/en/EDAP-s-Focal-One-Robotic-HIFU-Treatments-Performed-at-Acibadem-Hospital-Istanbul-Turkey.html  
104 https://www.medgadget.com/2013/06/focal%E2%80%A2one-robotic-high-intensity-focused-ultrasound-for-prostate-cancer-gets-green-light-in-eu.html  
105 https://www.edap-tms.com/en/about-edap-tms/a-tradition-of-innovation  
106 https://www.edap-tms.com/news/40/71/First-Focal-One-HIFU-Device-in-North-America-First-Focal-One-HIFU-Device-in-North-America  
107 https://www.edap-tms.com/news/98/151/EDAP-Announces-Filing-of-New-510K  
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 Country 
Institution 
issuing 
approval 
Authorisation 
status yes/no/ 
ongoing 
Verbatim wording of the 
(anticipated) indication(s) Specified contra-indications 
Date of approval  
(include expiry date for 
country of assessment) 
Launched yes/no 
If no include date 
of launch 
ExAblate® system Europe CE mark Yes Treating locally-confined prostate 
cancer108 
- December, 2016109 Yes 
ExAblate® system USA FDA No - - - No 
TULSA-PRO® Europe CE mark Yes110 Ablation of prostate tissue111 - April, 2016112 Yes 
TULSA-PRO® USA FDA No113 - - - No: TACT trial is 
expected to support 
Profound's FDA 
application.114 
Abbreviations: CE Conformité Européenne, FDA food and drug administration, NB notified body 
  
                                                             
108 https://www.massdevice.com/insightecs-exablate-wins-ce-mark-approval-prostate-treatment-japanese-approval-essential-tremor/  
109 https://www.insightec.com/news-events/press-releases/2016/insightec-receives-ce-mark-for-the-exablate-prostate-for-treating-locally-confined-prostate-cancer  
110 http://www.profoundmedical.com/new-tulsa/  
111 https://globenewswire.com/news-release/2017/06/30/1035465/0/en/Profound-Medical-Corp-Announces-Definitive-Agreement-with-Royal-Philips-to-Expand-Collaboration-and-
Acquire-Sonalleve-MR-HIFU-Business.html  
112 https://globenewswire.com/news-release/2016/05/19/841557/0/en/FDA-Grants-Profound-Medical-Corp-IDE-Approval-for-TULSA-PRO.html  
113 http://www.profoundmedical.com/new-tulsa/  
114 http://www.biotuesdays.com/features/2017/3/23/profound-medicals-tulsa-pro-pilot-ous-launch-paving-the-way-for-global-growth  
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Table A-13: Summary of (reimbursement) recommendations in European countries for HIFU  
Country and  
issuing organisation e.g. G-BA, NICE 
Summary of (reimbursement)  
recommendations and restrictions 
Source 
NICE, England Do not offer HIFU and cryotherapy to men with localised prostate 
cancer other than in the context of controlled clinical trials comparing 
their use with established interventions.  
311 inpatient episodes in England where the main procedure  
was ‘High intensity focused ultrasound of prostate’ 
https://www.nice.org.uk/guidance/cg175/chapter/1-
Recommendations#localised-and-locally-advanced-prostate-cancer-2  
ZIN, Netherlands No reimbursement due to insufficient evidence. There has been  
no request to re-evaluate since 2013.  
https://www.zorginstituutnederland.nl/publicaties/standpunten/2013/0
4/22/high-intensity-focused-ultrasound-hifu-bij-prostaatcarcinoom  
VASPVT, Lithuania Not reimbursed. When evidence will be available to support the use 
of the HIFU technology, VASPVT will recommend defining strategies 
to gather all the related costs to calculate proper HIFU specific 
reimbursement fees. 
http://www.vaspvt.gov.lt/files/SPTV/HIFU%20pilnas%20vertinimas%
202015.pdf  
Romania  HIFU is used for the treatment of prostate cancer in few private 
clinics and the treatment is not reimbursed by health insurance. 
- 
Germany  In line with the principle of "permission with the reservation of 
prohibition" HIFU is reimbursed within the inpatient sector. In the 
base case scenario, DRG reimbursement (M09-B) amounts to 3,467 €, 
which includes between 2 and 11 days of hospital stay. 
The exact number of procedures performed in Germany is not  
publicly available. According to a list prepared by a German patients’ 
association, about 50 hospitals currently offer HIFU in this indication. 
https://www.prostatakrebs-bps.de/medizinisches/spezialkliniken-und-
aerzte/159-kliniken-fuer-hifu-therapie  
RER, Italy Do not offer HIFU (in the Regione Emilia-Romagna region).  - 
LBI-HTA, Austria No reimbursement due to insufficient evidence to support  
the benefit of the technology. 
http://eprints.hta.lbg.ac.at/887/  
Abbreviations: HIFU = high-intensity focused ultrasound, LBI-HTA = Ludwig Boltzmann Institute for Health Technology Assessment, NICE = National Institute for Health and Care Excellence, 
RER = Regione Emilia-Romagna, VASPVT = State Health Care Accreditation Agency under the Ministry of Health, ZIN = Zorginstituut Netherland 
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1 
Definition of clinically significant disease 
 
Source: Fütterer [65] 
 
 
 
  
 
